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SUMMARY 
 
COPD is the second most common cause of pulmonary hypertension, and is a common 
complication of severe COPD with significant implications for both quality of life and 
mortality. Pulmonary arterial stiffening occurs early in the disease process before the 
development of overt pulmonary hypertension. Early detection would open this up as a 
potential therapeutic target before end stage arterial remodeling occurs.  Traditionally the 
assessment of the arterial stiffness required right heart catheterization, however recent 
advance in MRI are yielding new opportunities to undertake this assessment non-
invasively.  Pulse wave velocity is one of the most commonly used techniques in the 
systemic circulation but has been poorly explored in the pulmonary circulation.  This thesis 
was undertaken to test the hypothesis that pulmonary PWV would be elevated in COPD, 
and that this would correlate with right ventricular mass, and predict future adverse 
remodeling. 
 
Two commonly used techniques are available for measuring PWV with MRI: the transit 
time technique and the flow-area technique.  These techniques were applied in a cohort of 
young healthy volunteers (n=10) and older healthy volunteers (n=20).  These techniques 
were repeated using on-table repetition and repetition at 6 months.  These were also 
assessed during exercise in the young healthy volunteers.  PWV did not differ between the 
two age groups (YHV 2.4±0.3 ms-1, OHV 2.9±0.2 ms-1, p=0.1). Using a high temporal 
resolution sequence through the RPA using the flow-area technique accounting for wave 
reflections yielded consistently better within-scan, interscan, intraobserver and 
 21 
interobserver reproducibility. Exercise did not result in a change in PWV (mean (95% CI) 
of the differences: 0.10 (−0.5 to 0.9), p=0.49) despite a significant rise in heart rate (65±2 to 
87±3, p<0.0001), blood pressure (113/68 to 130/84, p<0.0001) and cardiac output 
(5.4±0.4 to 6.7±0.6 L/min, p=0.004). 
 
58 participants with COPD underwent pulmonary function tests, six-minute walk test, and 
cardiac MRI.  These were compared with a cohort of 20 healthy controls.  Cardiac MRI was 
used to quantify right and left ventricular mass and volumes, with phase contrast imaging 
of the main pulmonary artery in order to calculate pulmonary PWV and of the ascending 
and abdominal aorta in order to calculate the aortic pulse wave velocity.  Those with COPD 
demonstrated evidence of pulmonary arterial stiffening and pulmonary vascular 
remodeling with higher pulmonary artery area at end diastole (COPD: 2.36 ± 0.56 cm2/m1.7 
vs. HC: 2.14 ± 0.28 cm2/m1.7, p=0.027), reduced pulsatility (COPD: 24.88 ± 8.84 % vs. HC: 
30.55 ± 11.28 %, p=0.021), reduced PAT (COPD: 104.0 ± 22.9 ms vs. HC: 128.1 ± 32.2 ms, 
p<0.001) and higher PWV (COPD: 2.62 ± 1.29 ms-1 vs. HC: 1.78 ± 0.72 ms-1, p=0.001).  
Those with an elevated PWV did not demonstrate any difference in subjective 
breathlessness, exercise capacity, or any difference in right ventricular systolic function.  
Cardiac remodelling in COPD was instead that of a reduced preload with a lower RV end 
diastolic volume (COPD: 53.6±11.1 ml vs. HC: 59.9±13.0 ml,p=0.037) and RV stroke volume 
(COPD: 31.9±6.9 ml/m2 vs. HC: 37.1±6.2 m/m2l,p=0.003).  Those with COPD had a non-
significantly higher aortic PWV (COPD: 8.7 ± 2.7 ms-1 vs. HC: 7.4 ± 2.1 ms-1, p=0.06), with 
aortic PWV correlating with left ventricular remodeling (rho=0.34, p=0.01). 
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34 participants with COPD underwent repeat imaging at 1 year.  While there was a 
significant increase in pulmonary PWV (Baseline 2.30 ± 0.97, Follow-up: 3.39 ± 1.4 ms-1, 
p<0.001) there was no significant change in ventricular mass or volumes. 
 
This thesis has therefore proven its original hypothesis that pulmonary PWV is elevated in 
those with COPD.  However we have seen that this elevation in PWV has no significant 
association with right ventricular remodeling either at baseline or at one-year follow-up.  
Instead we observed a pattern of ventricular remodeling that was more consistent with an 
under filled condition rather than an overloaded condition.  Future work in COPD should 
thus be targeted at better understanding of the underpinning pathophysiological process 
behind this.   
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CHAPTER 1:  Background and Literature 
Review  
 
1 INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of morbidity and 
mortality in the UK, with this predicted to become the third most common cause of death 
by 2020, both in the UK and worldwide.(1,2)  It is the only leading cause of mortality that is 
increasing in prevalence, with approximately 30,000 people in the UK dying each year from 
COPD.(3)  Despite rapid advances in medicine over the past few decades and a fall in the 
general population mortality rate of 40%, no such improvement has been witnessed in 
patients with COPD, with static mortality rates in those with moderate and severe 
disease.(4)  Despite the high mortality associated with the primary disease, 25-50% of 
COPD patients will die from cardiovascular complications rather than their underlying lung 
disease.(1) It is not just cardiac mortality that patients with COPD are at increased risk of, 
they are also at increased risk of cardiac morbidity with unrecognised heart failure in 20%, 
ischaemic heart disease in 30% and atrial fibrillation in 13%.(5,6)  
 
Reduced FEV1 has been shown to be one of the strongest indicators for future cardiac 
death, second only to smoking and above that of blood pressure and cholesterol.(7) Poor 
FEV1 is also a strong predictor of ventricular arrhythmia, myocardial infarction, and heart 
failure, with the rate of decline in FEV1 independently predicting all cause and cardiac 
mortality.(7–11)  While shared aetiologies, in particular smoking, could be suggested as 
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confounding factors, the association between FEV1 and cardiac mortality persists even 
after accounting for smoking status.(7) 
 
A variety of models have been proposed for the interaction between COPD and 
cardiovascular disease which can be loosely grouped into 4 categories:(1) 
 Inflammation model 
 Lung hyperinflation model 
 Shared genetics model 
Pulmonary hypertension model 
 
The focus of this review will be on the pulmonary hypertension model, however, we will 
briefly review the merits of the other models prior to this. 
 
1.1 INFLAMMATION MODEL 
 
The inflammatory model is based on the premise that inflammatory mediators generated 
in the lung are carried in the circulation to the coronary arteries and systemic arteries 
where they promote atherosclerosis – itself a known inflammatory process.(12)  An 
excellent overview can be found on the topic by Sinden and Stockley.(13)  Circulating  
VEGF, hsCRP, TNFα and fibrinogen are all elevated in patients with COPD consistent with 
an inflammatory process,(14–18) and alveolar macrophages reacting to particulate 
inhalation have been shown to upregulate systemic inflammation.  The ability of proteins 
to move across from the lung surface to the systemic circulation has been documented in 
 25 
animals and humans, both in healthy lungs and in those with COPD, thereby providing 
evidence of the possibility of inflammatory mediator migration.(19–21)  Furthermore the 
discovery of circulating microparticles and microRNAs, known to modulate endothelial 
function, make this an attractive theory.(22)   
 
Indirect evidence of this is provided by evidence of arterial and endothelial dysfunction in 
patients with COPD.  Arterial stiffness is increased in patients with COPD compared with 
controls matched for age and smoking status.(23)  The degree of arterial stiffening 
correlates with the extent of emphysematous changes within the lungs, IL-6 levels and 
hsCRP levels.(23–25)  Furthermore a study by Dransfield et al. showed an improvement of 
PWV with inhaled fluticasone-salmetrol, although this was limited to those with elevated 
arterial stiffness at baseline.(26)  Arterial stiffness is important as increased stiffness is a 
known marker of future cardiovascular risk due to its effects of increasing afterload and 
impairing diastolic coronary blood flow.(27)  It also contributes to end organ damage by 
transmitting the high pressure fluctuations present in the central vessels to the less 
resilient microvasculature.(28)  This may explain the association between low FEV1 and 
microvascular damage.(29)  Endothelial function is also impaired in COPD compared with 
healthy volunteers and smokers without COPD.(30,31)  The importance of peripheral 
endothelial function has been ascribed to the correlation between the peripheral and 
coronary endothelial function(32,33), however this link has been called into doubt.(34,35) 
Despite the apparent lack of correlation, endothelial dysfunction remains a strong and 
independent predictor of future cardiovascular events.(36)  However, despite the apparent 
strong link between COPD and vascular function, Barr et al. found no correlation between 
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lung function or emphysema and coronary artery atherosclerosis as measure by CT calcium 
score in early COPD.(37) 
 
1.2 PULMONARY HYPERINFLATION MODEL 
 
Pulmonary hyperinflation occurs due to lung parenchymal destruction with loss of lung 
elasticity combined with expiratory airflow obstruction.(38) This in turn causes an 
increase in intrathoracic (and therefore intrapleural) pressures due to a high intrinsic 
positive end-expiratory pressure.(39)  Left ventricular hypertrophy has been noted in 
patients with COPD and hyperinflation(40,41), and has been posited to be due to these 
effects of raised intrapleural pressures increasing left ventricular transmural pressure 
thereby augmenting shear stress.(42)  The increase in left ventricular mass of 5% per SD 
rise in %emphysema within the lungs is comparable the per SD rise in systolic blood 
pressure.(41) This is of importance as a 5% rise in LV mass is associated with a 7% 
increased risk of cardiovascular death and a 20% increased risk of developing heart 
failure.(43) However, a study by Jorgensen et al. showed no evidence of increased diastolic 
stiffness in patients with severe COPD on invasive LV pressure measurements.(44)  Indeed 
several studies have shown that apparent diastolic dysfunction with low left ventricular 
end diastolic volumes in patients with hyperinflation is due to a low preload secondary to 
impaired filling rather than left ventricular stiffness causing impaired relaxation.(44–47)  
While early studies demonstrated a strong independent predictive value of hyperinflation 
on mortality,(48) more recent studies have shown this to be lost when the transfer co-
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efficient is taken into account weakening the prospect of a significant mechanistic 
link.(49,50) 
 
1.3 SHARED GENETICS MODEL 
 
The concept of shared genetics is similar to that of shared aetiologies, and stands on its 
own as well as feeding into the other models.  Despite smoking being a well acknowledged 
risk factor for emphysema, the extent of emphysema varies widely among smokers and 
response to smoke inhalation varies by genetic strain in mice models.(51,52)  Emphysema 
and arterial stiffening are both due to connective tissue degradation:  In the pulmonary 
parenchyma elastin degradation causes loss of alveolar attachments, decreased compliance 
and increased emphysema;(53) while in the arteries elastin degradation is associated with 
increased collagen deposition and arterial stiffening.(54)  The possibility of a genetic 
linkage is well demonstrated in Marfan syndrome where aortic root stiffening is a cardinal 
feature, and emphysema occurs even in the absence of a smoking history.(55,56) 
Furthermore, a decrease in skin elasticity is present in COPD independent of smoking or 
age,(57) a finding similar to that seen in the Klotho mouse model (a model of accelerated 
aging) where atherosclerosis, emphysema and decreased skin elasticity are all present.(58)  
The work of genetic studies is rapidly growing, with useful reviews on COPD and coronary 
artery disease readily available.(59,60)  In a recent review of GWAS in cardiovascular 
disease, out of 33 genetic risk variants identified, only 10 mediate their risk through known 
mechanisms, leaving a wide range of possible genetic linkages.(59)  Finally as mentioned in 
the inflammatory model chronic bronchitis and atherosclerosis are both inflammatory 
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conditions - itself a pathway with genetic influences.(61)  However, despite several 
promising avenues, at present the effects of the identified susceptibility loci are still 
dwarfed by the effects of smoking in COPD.(62) 
 
1.4 PULMONARY HYPERTENSION MODEL 
COPD is the second most common cause of pulmonary hypertension after left sided heart 
disease.(63) Pulmonary hypertension (Cor Pulmonale when associated with right heart 
failure in COPD) is relatively common in severe COPD and is present in >50% of patients 
awaiting lung transplantation.(64) The incidence increases with increasing severity of 
COPD, with pulmonary hypertension present in 5% of moderate (GOLD stage II), 27% of 
severe (GOLD stage III) and 53% of very severe (GOLD stage IV) COPD.(65)  The true 
incidence in mild to moderate COPD however is poorly appreciated due to the absence of 
large scale epidemiological studies.(66)  In comparison to other causes of pulmonary 
hypertension the pulmonary pressure elevations are modest, however survival is poor and 
correlates better with the pulmonary pressures and pulmonary vascular resistance than 
with the severity of airflow obstruction.(67–70)  
 
Pulmonary hypertension is defined as a mean pulmonary arterial pressure (mPAP) greater 
than or equal to 25mmHg at rest.(71)  The gold standard for the assessment of pulmonary 
pressures is through direct measurement of the pressures within the pulmonary arteries 
during right heart catheterization.  During this process pulmonary vascular resistance, 
right atrial pressure, pulmonary capillary wedge pressure, pulmonary saturations and 
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cardiac index can also be measured, with useful information both on the aetiology of the 
pulmonary hypertension and also on prognosis provided by these additional measures.(72) 
No other technique can currently conclusively diagnose pulmonary hypertension, however 
there are several options for assessing for its presence.  Both echocardiography and MRI 
can measure the pulmonary artery systolic pressure (PASP) through measurement of the 
velocity of the tricuspid regurgitant jet using the modified bournelli equation (∆P = 4v2) 
and combing this with the right atrial pressure (RAP) with PASP = ∆P + RAP.  RAP is 
estimated based on the diameter of the vena cava and its change in diameter during 
inspiration, although some groups have suggested it is more accurate to calculate PASP 
assuming a constant RAP of 10mmHg.(73) The crucial limitation of PASP is that it measures 
systolic pressure rather than mean pulmonary pressure which is what is used for the 
diagnosis of pulmonary hypertension, with PASP frequently inaccurate in those who are 
acutely unwell or with advanced lung disease.(72,74) One final technique is using CT with 
the ratio of the pulmonary artery diameter to the aortic diameter, with a ratio of >1 
demonstrating reasonable sensitivity and specificity for the presence of pulmonary 
hypertension in those with COPD and other lung conditions.(75,76) 
 
However: Pulmonary vascular changes occur in mild COPD before pulmonary hypertension 
occurs(77); Right ventricular dysfunction has been observed in normoxaemic COPD 
patients with normal pulmonary arterial pressures(78); and right ventricular hypertrophy 
is one of the earliest cardiac changes and is present even in mild COPD.(79–81)    
Additionally in both mice and guinea pig models, vascular remodeling occurs even before 
the onset of emphysema.(82–84) The notion of an elevated rest pressure as a cut-off is also 
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restrictive in evaluating the role of the pulmonary arteries and right heart as even minimal 
exertion causes marked elevations in mPAP and oxygen desaturation in COPD, with 
exercise induced pulmonary hypertension present in 35%-58% of patients with 
normoxaemia or mild hypoxia.(67,85–87) See Figure 1-1. 
 
Figure 1-1: Diagram of the gradually progressive changes in the right ventricle and 
pulmonary arteries that precede the development of outright pulmonary hypertension 
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Therefore the pulmonary hypertension model, whereby right ventricular failure occurs 
once pulmonary hypertension exists, is a misnomer, and an alternate should be considered 
- the right ventriculo-arterial model.   
 
1.4.1 Vascular changes 
Vascular remodeling within COPD develops secondary to intimal hyperplasia, with 
muscularisation of the arterioles and with rather little change in the tunica media.(88,89) 
This hyperplasia is induced by proliferation of smooth muscle cells and the deposition of 
elastic and collagen fibers.(90,91) Originally hypoxia was held to be the driving force 
behind this remodeling, however similar arterial changes are present in smokers with and 
without COPD, and arterial changes can be observed in mild COPD when hypoxia is yet to 
develop.(77,90,92) The vascular remodeling in COPD is most likely due to endothelial 
dysfunction and apoptosis which in turn causes remodeling, capillary loss and small vessel 
thrombosis.(12) This is likely due to a combination of local inflammatory mediators 
released from the endothelial dysfunction in the adjacent pulmonary parenchyma, and 
direct effects from the inhaled cigarette smoke on the vascular endothelium.(12,91) 
However an experimental study by Ferrer et al. in guinea pig models shows hypoxia still 
plays a contributory role, as a hypoxic environment after cigarette exposure induced 
significantly greater changes in pulmonary arterial pressures and pulmonary vascular 
remodeling than cigarette smoking or hypoxia alone.(84) More recently the pulmonary 
vascular sympathetic nerves which control the pulmopulmonary baroreceptor reflex 
originating at the pulmonary trunk has been proposed to be of significant importance in 
the development of pulmonary arterial hypertension.(93) This is evidenced by a rise in 
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pulmonary arterial pressures and pulmonary vascular resistance (PVR) induced by 
stretching the branch pulmonary arteries.(93–96)  In a single study by Chen et al.(97) on 
21 patients with significant pulmonary hypertension despite maximum medical therapy, 
intravascular pulmonary artery denervation with cessation of medical therapy resulted in 
significant improvement in pulmonary pressures and exercise capacity.  However the role 
of this reflex in humans is still controversial and has also yet to be evaluated in COPD 
induced pulmonary hypertension.(98) 
 
1.4.2 The right ventriculo-arterial model 
1.4.2.1 Right ventricle 
The right ventricle (RV) got off to an inauspicious start in the 1940s and 50s when a series 
of papers showed no significant alterations in the pulmonary arterial or systemic pressures 
following open ablation of the right heart in a dog model (see Figure 1-2), leading one of 
the authors to conclude that “a normal, contractile right ventricular wall is not necessary 
for the maintenance of a normal circulation”.(99–101) 
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Figure 1-2: Example of the ventricular charring and lack of change in systolic systemic and 
venous pressures 
 
Adapted from Bakos ACP, Circulation and Kagan A, Circulation.(100,101) 
 
Despite this apparent swan song for a significant role of the right ventricle, a paper in 1982 
demonstrated that the open pericardial model did not accurately represent the functional 
haemodynamics of the heart.(102)  Goldstein et al. demonstrated that when the right 
coronary artery was infarcted within an intact pericardium there was a profound and rapid 
fall in left ventricular pressures due to a fall in left ventricular (LV) preload, equalisation of 
RV and LV pressures and elevated intrapericardial pressures which did not occur when 
they repeated their experiment after pericardiectomy.  Thus there is a marked ventricular 
interdependence due to the shared pericardial compartment, shared interventricular 
septum and the dependence of the left heart preload on the output of the right.(46,103–
108)  
 
Recent work has shown the importance of the right heart in health and disease.  In health 
the right ventricle responds to exercise, obesity and traditional cardiovascular risk factors 
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in a manner similar to, but independent of, the left ventricle.(109–111)  A decreased RV 
mass is associated with an increased risk of developing dyspnoea, and an increased RV 
mass is associated with an increased risk of future congestive cardiac failure and 
cardiovascular mortality in a healthy population.(112,113) In patients with COPD, right 
ventricular remodeling is apparent even early in the disease with right ventricular 
hypertrophy and diastolic dysfunction present in mild and moderate COPD with systolic 
impairment occurring in severe COPD.(79,80) This has significant implications with right 
ventricular dysfunction associated with poorer exercise capabilities and increased 
mortality independent of pulmonary function tests.(114,115) 
 
1.4.2.2 Pulmonary artery 
There has been a great deal of recent interest in systemic arterial stiffening in COPD due to 
the mechanistically plausible link this provides between COPD and the excess 
cardiovascular mortality associated with this condition.(116)  In comparison to the 
systemic arterial circulation there are several key differences in the nature of the vascular 
tree between that of the pulmonary and systemic circulation.  The pulmonary artery is a 
low pressure, high distensibility system which acts to transform the highly pulsatile right 
ventricular output into the near steady flow at the capillary level.(117) The distal 
pulmonary vascular bed is also comprised of highly distensible vessels that, through 
distension and recruitment of the microvascular bed, are able to accommodate large 
increases in volume such as during exercise.  This response is the opposite of that 
experienced in the systemic circulation where exercise induces vasoconstriction in the 
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majority of the vascular tree other than the vessels supplying the muscles.  This inbuilt 
reserve means that resting pulmonary arterial pressures will only rise relatively late in a 
disease process when 60-70% of the bed is obstructed.(118) The peripheral distensibility 
of the vessels also differs from the systemic circulation where only the proximal arteries 
act as capacitance vessels, expanding and contracting with each beat of the heart, while the 
peripheral vessels are responsible for resistance.  Due to the dual function of the vessels, 
there is an inverse relationship between the resistance and capacitance of the pulmonary 
circulation, with the product of the two (the resistance-compliance time constant) 
remaining the same in both health and disease.(119) 
 
The pulmonary arteries and microcirculation have distinct effects on the right ventricular 
afterload which can be split into two key components – the steady component required to 
drive and maintain forward flow and the oscillatory component required to overcome the 
pulsatile component of flow (see Figure 1-3).  The steady component is a function of 
peripheral vascular resistance whereas the oscillatory component is a function of both 
proximal and distal pulmonary arterial stiffness.(120) Even in the healthy adult, 30% of the 
right ventricular output is spent on generating pulsations (compared with only 10% in the 
systemic circulation).(121)  This energy is considered wasted in terms of ventricular power 
output, but is crucial in acting as a blood reservoir and maintaining steady flow through the 
pulmonary tree.(122)  As the pulmonary artery stiffens the oscillatory component of the 
workload increases, although remains as a constant of the total energy expenditure of the 
right ventricle.(123,124) As the artery stiffens it also starts to dilate and become less 
compliant, and the dilation of this in relation to the aorta has been shown to be a useful 
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clinical marker in COPD, with a PA:Aortic ratio>1 an independent predictor of future acute 
exacerbations, exercise capacity, pulmonary hypertension and mortality.(125–128) 
 
Figure 1-3: The role of pulmonary arterial stiffening  in peripheral and proximal vascular 
remodeling and impact on tight ventricular function.  From Tan et al, Pulm Circ 2014.(129) 
 
 
The compliance of the pulmonary artery is a key component in decoupling the right 
ventricle from the pulmonary bed, allowing the right ventricle to work at maximum 
efficiency and protecting the microcirculation from large pressure gradients.(117,130)   
Indeed the stiffness of the pulmonary artery is a strong determinant of right ventricular 
function,(131) and increased stiffness causes distal pulmonary arterial endothelial 
dysfunction and inflammation.(132,133)  Increased stiffness is independently associated 
with reduced functional capacity,(134) and higher mortality than the pulmonary artery 
pressures or pulmonary vascular resistance.(135–139)  While vascular distensibility is 
partly dependent on underlying distending pressures,(119,140)  multiple studies have 
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shown the intrinsic stiffness of the arterial walls to be increased in pulmonary 
hypertension independently of these.(141–145)   
 
1.4.2.3 Right ventriculo-arterial model 
Optimal ventriculo-arterial coupling occurs when there is maximal transference of 
potential energy from one elastic chamber to another, e.g. from the ventricle to the artery.  
This is dependent on the elastance – the change in pressure for a given change in volume – 
of the two chambers.(146) The ventricular elastance (EES) is a load independent measure of 
the ventricular contractility combined with the modulating effects of the geometric and 
structural properties of the ventricle.(147) It relies on measuring the response of the 
ventricular pressure to increasing volumes (see Figure 1-4).  The arterial elastance (EA) is 
an index incorporating the elements affecting arterial load including pulmonary vascular 
resistance, arterial compliance, characteristic impedance, and systolic and diastolic time 
interval.(148,149) The EA/ EES calculates the extent of ventriculo-arterial coupling.  
 
At rest the ventricle and pulmonary artery are coupled so that the right ventricle is 
working at optimal efficiency which occurs when the stroke work is maximal with minimal 
oxygen consumption.(120,150–152)  This has been shown to occur when EA is half 
EES.(152–154) In exercise this moves towards optimal coupling when there is maximal 
cardiac efficiency which is where there is maximum flow generation with minimal energy 
loss (EA=EES).(155–157) Interestingly the optimal values for energy efficiency and cardiac 
efficiency are similar throughout a variety of studied mammals suggesting it has been 
conserved throughout mammalian evolution.(158,159) During exercise, arterial stiffness 
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has a progressively and intensity-dependent greater impact on EA than PVR with the result 
that EA increases on exercise despite a fall in PVR in a manner paralleling the rise in arterial 
stiffness.(160–162)  A similar relationship is present in pulmonary hypertension whereby 
pulmonary stiffness has a 1.2-18 fold greater contribution to right ventricular workload 
than PVR.(119,141,163)  In the systemic circulation, age and hypertension (two known 
factors associated with increased arterial stiffness) result in an exaggerated increase in EA 
during exercise increasing the pulsatile load on the heart and in turn decreasing left 
ventricular efficiency.(155,164)  This exaggerated response secondary to arterial stiffening 
may explain the rapid rise in mPAP observed in COPD during exercise despite a stable or 
minimal rise in PVR.(85)  Indeed in a study by Hilde et al., an increase in pulmonary arterial 
stiffness was observed during exercise with a greater contribution from this to changes in 
mPAP than PVR.(65)  Further indirect evidence comes from a study by Kubo et al. which 
showed the pulmonary arterial wall thickness to be related to exercise pulmonary 
pressures rather than resting pulmonary pressures, and to correlate highly with change in 
pressure from rest to exercise.(165)   
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Figure 1-4: Calculation of EA:EES in the right ventricle and pulmonary artery. Ventricular 
end systolic pressure-volume is linear and characterised by the slope Ees and is generated 
by measuring pressure-volume loops under gradated preload and afterload conditions 
 
Reproduced from Wang et al. 2011.(166). Ea = Arterial elastance; Ees = Ventricular elastance. 
 
When the EA increases so that the EA:EES is consistently above 0.5 the ventricle adapts to 
the increased workload by inducing hypertrophy.(167) This increases the EES thereby 
returning the ventriculo-arterial system to its most energy efficient state, albeit at a slightly 
higher energy consumption than previously.(168–170)  As EA continues to rise the right 
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ventricle eventually fails to adapt with a resultant decrease in the EES and thereby a rapid 
increase in EA/ EES indicating uncoupling and reduced myocardial efficiency.(152,171) 
 
Fourie et al. demonstrated that myocardial efficiency reached a maximum when the EA 
reached 1mmHgml-1 (corresponding to an mPAP of 20mmHg), while maximum stroke 
work corresponded to an EA of 2 mmHgml-1 (corresponding to a MPAP of 30-
40mmHg).(117) This corresponds with observations that at approximately 40mmHg the 
pulmonary artery reaches it maximum dimension and minimal distensibility.(143,171,172) 
Consistent with this, Stevens et al. demonstrated that in patients with pulmonary 
hypertension there was a curvilinear relationship between RV function and PA 
distensibility with marked loss of pulmonary artery distensibility without commensurate 
loss of ventricular function until only minimal distensibility remained when a rapid 
decompensation of the right ventricle occurred.(141) A similar curvilinear relationship has 
also been observed in COPD between pulmonary arterial stiffness and peripheral vascular 
resistance, with a rapid rise in PVR only occurring after significant stiffening of the 
pulmonary arteries has occurred.(78)   Pulmonary stiffness is increased early in pulmonary 
hypertension development, and is increased even in those with exercise induced 
pulmonary hypertension, both in mixed pulmonary arterial hypertension studies and in 
COPD.(65,78,143,172) This combination of features suggest pulmonary arterial stiffness as 
a promising biomarker for detection of early disease and as a potential therapeutic target 
before end stage arterial remodeling occurs with dire consequences for the right ventricle. 
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1.5 MEASURING PULMONARY ARTERY STIFFNESS. 
The stiffness of the pulmonary artery can be quantified using a variety of metrics, with 
these measuring stiffness locally, regionally or systemically. Table 1-1 summarises the 
various methods of measuring arterial stiffness and the common methods for acquiring 
these.  As can be seen from the table the majority of these require knowledge of the arterial 
pressures to calculate the stiffness.  In the arterial circulation this is not a significant issue 
as the brachial arterial pressures are readily obtained with a sphygmomanometer, as mean 
BP and diastolic BP are relatively constant throughout the large arteries.(173) However in 
the pulmonary arteries this provides a significant hurdle as an external measurement of 
the pressures is not readily available.  Despite numerous attempts to quantify pulmonary 
arterial pressures and vascular resistance using echocardiography, CT and MRI, none of 
these have yet proven accurate enough to negate the need for invasive measurement with 
right heart catheterisation.(73,174–180)   
 
1.5.1 Right heart catheterisation 
Right heart catheterisation can be used to calculate several metrics of arterial stiffness, 
including capacitance, PWV and elastance, although the latter two require dedicated 
catheters and equipment not routinely available in the catheter laboratory.  In addition, it 
can be combined with techniques for the visualisation of the pulmonary artery cross 
sectional area such as MRI or intravascular ultrasound, to derive a wide range of metrics of 
arterial stiffness and ventriculo-arterial coupling.  Table 1-2 summarises the studies 
looking at invasive assessment of pulmonary arterial stiffness.  Despite its utility, RHC has 
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numerous disincentives including its invasive nature, cost, and exposure to ionising 
radiation.  While the combination of MRI and right heart catheterisation allows catheter 
guidance without exposure to ionising radiation and simultaneous acquisition of 
anatomical and pressure measurements, it does not negate the invasive or costly nature of 
the study.(181,182) Of the measures of arterial stiffness, only pulsatility and pulse wave 
velocity can be derived entirely non-invasively.   
  
1.5.2 Pulsatility 
Multiple studies have shown reduced pulsatility in pulmonary 
hypertension.(134,135,145,172,183–185)  A single echocardiography study has shown 
reduced pulmonary artery pulsatility in COPD, which correlated with right ventricular 
functional parameters.(186)  A single abstract using cardiac MR has also described 
decreasing pulsatility with increasing severity of COPD.(187)(Table 1-3) However, as 
discussed above, the pulmonary stiffness is dependent not only upon distending pressures, 
but also upon the intrinsic elasticity of the pulmonary vessel wall, thus a fall in pulmonary 
pulsatility does not differentiate a fall in pulsatility due to a fall in stroke volume or in 
distending pressures from that of a rise in arterial stiffness. 
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Table 1-1: Measures of arterial stiffness - Calculations, definitions and alternate means of 
assessment. 
 Calculation Definition Method of 
assessment 
 
Local 
Pulsatility 
(%) 
(maxA – minA)/minA X 100 Relative change in lumen area during the 
cardiac cycle 
MRI 
Echocardiography 
IVUS 
Compliance 
(mm2/mmHg) 
(maxA – minA) / PP Absolute change in lumen area for a given 
change in pressure 
RHC plus 
MRI/Echo/IVUS 
Distensibility 
(%/mmHg) 
[(maxA – minA)/PP X minA] X 
100 
Relative change in lumen area for a given 
change in pressure 
RHC plus 
MRI/Echo/IVUS 
Elastic 
modulus 
(mmHg) 
PP X minA/(maxA – minA) Pressure change driving a relative increase in 
lumen area 
RHC plus 
MRI/Echo/IVUS 
Stiffness 
index 
(N/A) 
Ln(sPAP/dPAP) / [(maxA – 
minA)/minA] 
Slope of the function between distending 
arterial pressure and arterial distension 
RHC plus 
MRI/Echo/IVUS 
Young’s 
elastic 
modulus 
[3(1+minA/WCSA)]/Distensibility Wall thickness for a given distensibility RHC plus IVUS 
 
Regional 
Capacitance 
(mm3/mmHg) 
SV/PP Change in volume associated with a given 
change in pressure 
RHC 
PWV 
(ms-1)  
∆d/∆t (TT technique) 
∆Q/∆A (Flow-area technique) 
Speed of transmission of pressure wave  RHC 
MRI 
 
Systemic 
Elastance 
(mmHgml-1) 
EA/ EES =  
(ESP/SV) / (ESP/ESV-V0) 
Change in pressure for a given change in 
volume 
RHC with flow-
volume loops 
 
A= area; d = distance; dPAP = diastolic pulmonary artery pressure; EA = Arterial elastance; Echo = echocardiography; EES = Ventricular 
elastance; IVUS = intravascular ultrasound; maxA = maximum cross sectional area; mina = minimum cross sectional area; MRI = magnetic 
resonance imaging; PP = pulse pressure; PWV = pulse wave velocity; Q=Flow over a single heart beat; RHC = right heart catheter; sPAP = 
systolic pulmonary artery pressure; SV = stroke volume; t = time; WCSA = Wall cross sectional area.  
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Table 1-2: Summary of studies looking at invasive measurement of pulmonary arterial 
stiffness. 
Study Populat
ion 
No Method Finding 
Milnor et al(188) 
 
Mixed PH 7 RHC Increased impedance in PH 
Nakayama et 
al(189) 
 
Mixed PH 62 RHC Increased augmentation index and earlier inflection time in PH 
Castelain et 
al(142) 
 
Mixed PH 14 RHC Increased augmentation index and earlier inflection time in PH 
Mahapatra et 
al(136) 
Mixed PH 104 RHC Capacitance strongest predictor of mortality in PH.  On multivariate analysis, 
capacitance was the only statistically significant predictor of mortality. 
Hilde et al(78)* COPD 98 RHC PA compliance greatly reduced in COPD Gold 2,3 and 4 
Hilde at al(65)* COPD 98 RHC PA compliance fell with exercise in patients with and without PH, with similar 
elevations in mPAP during exercise between the two groups. 
Muthurangu et 
al(190) 
IPAH 17 RHC with MRI Inverse relationship between compliance and PVRI and mPAP.  A fall in 
compliance was evident in 7/17 following nitric oxide inhalation 
Kuehne et 
al(152) 
Mixed 12 RHC with MRI Increased elastance in PH, with resultant ventriculo-arterial uncoupling  
Kopec et al(191) IPAH 26 RHC with IVUS PWV high in IPAH (mean PWV 10ms-1) with excellent correlation with 
compliance (β= -0.81) and reasonable correlation with mPAP (β =0.48) 
Lau et al 
2012(144) 
IPAH 8 RHC with IVUS Increase in all measure of pulmonary arterial stiffness.  Inverse curvilinear 
relationship between mPAP and compliance and distensibility.  No change in 
PA stiffness following 6 months of bosentan therapy. 
Rodes-Cabau et 
al(138) 
IPAH 20 RHC with IVUS Reduced pulsatility in PH, with reduced pulsatility predictive of future 
mortality.  Epoprostenol infusion increased pulsatility by 53%. 
Lau et al 
2014(192) 
IPAH 5 RHC with IVUS High PWV in IPAH (mean PWV 10.6ms-1) with the reflected backward 
compression wave carrying 31% of the energy of the forward compression 
wave 
 
*Drawn from the same population 
ǂ Different calculation for %pulsatility so not directly comparable 
COPD = chronic obstructive pulmonary disease; CoV = Coefficient of variation; EIPH = Exercise induced pulmonary 
hypertension; FEV1 = Forced expiratory volume in one second; HV = Healthy volunteers; IPAH = Idiopathic pulmonary 
arterial hypertension; NYHA = New York heart association; PASP = Pulmonary artery systolic pressure; PH = Pulmonary 
hypertension; PWV = pulse wave velocity; QA= flow by area; TT = transition time; 6MWT = six minute walking test. 
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1.5.3 Pulse wave velocity 
Pulse wave velocity (PWV) is the speed at which the pressure wave, generated by 
ventricular contraction, is transmitted through the arterial tree.  This is directly related to 
vessel wall elasticity, with increased stiffness leading to increased PWV.(193) A reflected 
pressure wave is present which is generated when the pressure wave is reflected from the 
termination of the arteries, with alterations in the smallest arteries increasing the size of 
the reflected wave while large artery stiffening increases the PWV.(188) In health this 
reflected wave only represents a tiny fraction of the total output energy, and arrives in 
diastole and reduces preload of the subsequent ventricular contraction.(157,188,194,195) 
However in pulmonary hypertension this can reach 30% of the forward wave energy. With 
an increased PWV resulting in the earlier arrival of the reflected wave during systole 
thereby increasing the afterload of the heart and thus cardiac workload.(142,189,192,196–
198) 
 
PWV is an established marker of arterial stiffness in the systemic circulation with aortic 
pulse wave velocity shown to be associated with future cardiovascular events, and to 
improve risk stratification.(199) Transcutaneous waveform analysis methods are the gold 
standard for aortic PWV measurement including pressure,(200) distension,(201) and flow 
waveform.(202) However a transcutaneous approach is not possible for the pulmonary 
arteries.  While PWV can be measured invasively on right heart catheterisation,(188) 
magnetic resonance imaging is a possible alternative for non-invasive assessment of the 
pulmonary arteries using flow waveforms.(203) It is performed by the acquisition of ECG 
gated phase contrast sequences which measure flow the in proximal main pulmonary 
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artery and in the mid right or left pulmonary arteries.  A distance can be calculated 
between the two imaging planes (Figure 1-5), and the pulse wave timed from when it 
leaves the main pulmonary artery until it arrives in branch pulmonary arteries thus 
allowing a speed between the two points to be generated.(203) 
 
Figure 1-5: Measurement of PWV using MRI 
 
The locations of the two-phase contrast planes are delineated on the left image (a) with the distance between them 
measured.  The two separate waveforms are traced on the right (b) relative to the triggering R-wave used to start image 
acquisition.  The time between the waves arriving at the two consecutive locations can then be measured allowing 
calculation of the speed of the pulse wave.  
 
 
MRI derived pulse wave velocity has been previously validated against both invasive and 
non-invasive techniques in the aorta.(204–206)  Several studies have shown this to be a 
feasible and reproducible technique in the pulmonary arteries in healthy 
volunteers,(203,207) with the observed pulse wave velocity of 1.96-2.3ms-1  similar to that 
obtained invasively.(188,194) Pulse wave velocity is raised in pulmonary hypertension 
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using both invasive RHC and MRI assessment (See Table 1-2).(191,208) To date there have 
been no studies assessing pulmonary PWV in COPD. 
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Table 1-3: Summary of studies looking at non-invasive measurement of pulmonary arterial 
stiffness. 
Study Popula
tion 
No Met
hod 
Finding 
Pulsatility 
Bogren et al 
(209) ǂ 
Mixed 
PH 
4 MRI Pulsatility 23% in HV and 8% in PH 
Paz et al (210) HV 9 MRI No difference in pulsatility between the main pulmonary artery, right pulmonary artery 
and left pulmonary arteries. 
Gan et al 
(135) 
Suspecte
d PH 
70 MRI Right pulmonary artery pulsatility showed a curvilinear relationship with mortality.  
Pulsatility <16%  
Jardim et al 
(185)ǂ 
IPAH 19 MRI <10% pulsatility predicts non-responders to acute vasodilator testing with 100% sens 
and 56% spec. 
Sanz et al 
(184)* 
Suspecte
d PH 
59 MRI Pulsatility 41% in non-PH and 17.4% in PH.  No difference in pulsatility between different 
causes of PH. 
Sanz et al 
(143)* 
Suspecte
d PH 
94 MRI No difference in pulsatility between group without PH and EIPH. Pulsatility <40% 
predicted PH with 93% sens. and 63% spec.  
Kang et al 
(134) 
Mixed 
PH 
35 MRI Pulsatility correlated with 6MWT (R2=0.61, p<0.001).  <20% pulsatility predicted poor 
function (6MWT <400m) with 82% sens. and 94% spec. 
Stevens et al 
(141)* 
Suspecte
d PH 
12
4 
MRI Pulsatility correlates with right ventricular function 
Stevens et 
al(211) 
Suspecte
d PH 
43 MRI Pulsatility correlated with exercise capacity while RHC pressures did not. 
Swift et al 
(172) 
Suspecte
d PH 
13
4 
MRI Pulsatility elevated even in very mild elevations in PVR.  Pulsatility predicted mortality. 
Revel et al 
(212)ǂ 
Suspecte
d PH 
45 CT Pulsatility of 16.5% predicted PH with sens 86% and spec 96%. 
Pasierski et al 
(145) 
Suspecte
d PH 
19 Echo Pulsatility reduced in pulmonary hypertension with a linear relationship between 
pulsatility and PASP 
Mahapatra et 
al (137) 
Suspecte
d PH 
54 Echo Capacitance was the strongest predictor of mortality including invasive pressure 
measurements 
Ertan et al  
(186) 
COPD 54 Echo Right pulmonary artery pulsatility reduced in COPD patients, with significant differences 
between NYHA functional classes. 
Liu et al (187) COPD 13
5 
MRI Pulsatility falls with increasing severity of COPD, with a positive association with 
%predicted FEV1 and inversely correlated with  %emphysema 
PWV 
Peng et al 
(207) 
HV 17 MRI PWV 1.96±0.27 with high intra-scan and inter-scan reproducibility (5.5% and -10.9%  
respectively) 
Bradlow et al 
(203) 
HV 10 MRI No significant difference in PWV using the left or right pulmonary arteries.  CoV 12% for 
both intra and inter-observer assessment. 
Ibrahim et al 
(208) 
Heteroge
neous 
33 MRI PWV raised in pulmonary hypertension.  Comparable measurements between TT and QA 
methods. 
 
*Drawn from the same population, ǂ Different calculation for % pulsatility so not directly comparable to other studies.  
COPD = chronic obstructive pulmonary disease; CoV = Coefficient of variation; EIPH = Exercise induced pulmonary 
hypertension; FEV1 = Forced expiratory volume in one second; HV = Healthy volunteers; IPAH = Idiopathic pulmonary 
arterial hypertension; NYHA = New York heart association; PASP = Pulmonary artery systolic pressure; PH = Pulmonary 
hypertension; PWV = pulse wave velocity; QA= flow by area; TT = transition time; 6MWT = six minute walking test. 
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1.6 PULMONARY ARTERIAL STIFFNESS AS A TREATMENT TARGET 
Traditional treatments of pulmonary hypertension such as phosphodiesterase inhibitors 
and endothelin-1 receptor antagonists have yielded disappointing results, despite their 
success in treating the underlying pulmonary hypertension in the COPD cohorts with 
significant reductions in mPAP and PVR with therapy with sildenafil and bosentan.(213–
216)  However by counteracting the natural vasoconstrictive response of the blood vessels 
to the hypoxic state of severely damaged lung tissue, these medications simply divert blood 
away from the best oxygenated segments of the lung to those that are most severely 
disease, thereby worsening the ventilatory-perfusion mismatch,failing to improve the 
hypoxic and hypercapnic driven symptoms in severe COPD cohort.(217) However these 
treatments have all focused on altering the peripheral vasculature.  Given the greater 
impact of pulmonary stiffness on remodeling, drugs to target and ameliorate this process 
may be a novel route to target.  Due to the relatively recent identification of the importance 
of pulmonary arterial stiffness in right ventricular remodeling, there have been relatively 
few studies targeted at its treatment.  Despite this there are several studies suggestive of 
promising avenues for further exploration. 
 
Statins have been proposed as a route to reduce systemic arterial stiffness,(218) although a 
meta-analysis showed mixed response with two studies showing improvement, one 
showing no change and another showing progression of stiffening.(219) Statins in guinea 
pigs and mice with emphysema have been shown to reverse arterial remodeling and halt 
the formation of emphysema.(220,221)  Indirect evidence of the benefits from statins in 
COPD related pulmonary hypertension come from observational studies showing lower 
 50 
pulmonary arterial pressures in patients on statins prior to right heart 
catheterisation.(222)  Furthermore a study on pulmonary arterial stiffness showed that 
other than mPAP, the only other factors independently associated with pulmonary arterial 
stiffness was LDL cholesterol and BMI.(191) Statins are also associated with increased 
exercise capacity and reduced mortality in COPD,(223–225) however due to the 
observational nature of these studies the underpinning mechanisms are still in 
debate.(226,227)  
 
Xanthine oxidase inhibitors have been shown to improve endothelial function and arterial 
stiffness in the systemic circulation.(228–232) They have also been shown to reduce 
endothelial dysfunction induced by smoking and obstructive sleep apnoea (233–235) – a 
condition similar to COPD in its effects of intermittent hypoxia.(236) Additionally 
allopurinol inhibits hypoxia induced pulmonary vasoconstriction, pulmonary hypertension, 
endothelial dysfunction and vascular remodeling in hypoxic animal models of pulmonary 
hypertension.(237–241) It has been shown to reduce airway reactive nitrogen species 
production in COPD, however its effects on smoking induced pulmonary vascular damage 
has not been assessed.(242) 
 
As with xanthine oxidase inhibitors, mineralocorticoid receptor antagonists have been 
shown to improve systemic endothelial function and arterial stiffness.(243–245)  In 2 
separate mouse models of pulmonary hypertension, mineralocorticoid receptor 
antagonists prevented or reversed adverse pulmonary vascular remodeling with improved 
pulmonary vascular resistance, pulmonary artery pressure, and remodeling of the right 
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ventricle.(246)  A group in Bethesda, USA are currently recruiting patients with pulmonary 
hypertension without right heart failure to evaluate its efficacy in humans in modulating 
pulmonary vascular remodeling.(247) Its use in COPD has not currently been assessed. 
 
Long term oxygen therapy improves survival in severe COPD and reduces pulmonary 
arterial pressures and vascular resistance while improving cardiac output.(68,248)  It has 
also been shown to reduce peripheral arterial stiffness in COPD, however its effects on the 
pulmonary arterial stiffness has not been evaluated.(249) 
 
There are also several new classes of pharmaceutical agents currently being designed that 
specifically target the processes causing arterial stiffening.  Currently these are all being 
targeted at systemic vascular remodeling and are in the pre-clinical stages, however should 
they prove successful at preventing or reversing systemic arterial remodeling they would 
be promising agents for evaluation in pulmonary remodeling.  The most promising of these 
are TGF-B1 antagonists, and drugs targeting the advanced glycation end products 
(AGEs).(54)   TGF-B1 is responsible for extracellular matrix remodeling and vascular 
fibrosis in chronic inflammatory conditions, whilst AGE form irreversible cross-links with 
collagen and elastin, reducing the elasticity of the arterial wall.(54) 
 
1.7 CONCLUSIONS 
Given the poor mortality in COPD, which has been largely static over the past few decades 
despite leaps forward in the understanding of the underlying pathophysiology, a new 
avenue of exploration is warranted.  Pulmonary arterial stiffness holds a crucial role in 
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right ventricular dysfunction in pulmonary hypertension, and demonstrates promise as a 
useful biomarker in the development of this disease.  While little is understood about the 
role of pulmonary arterial stiffness in COPD, the findings to date agree with the 
observations made in pulmonary hypertension.  Further work is needed to explore this 
promising new path. 
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CHAPTER 2:  Physics of Cardiac MRI  
 
 
2 INTRODUCTION 
Nuclear induction (the act of deposition of radiofrequency energy in the nuclei of matter 
which is then re-emitted) was first described by Bloch and Purcell in the 1940s. This was 
readily taken up in the field of chemistry where it was used to determine structural and 
chemical properties of molecules.(250) Indeed Paul Lauterbur (who was later awarded the 
Nobel prize in conjunction with Peter Mansfield for the translation of this technique into 
biomedical imaging), was himself a chemist.  The underlying principle of the use of 
radiofrequency energy and magnetic gradients to produce an MRI image remain central to 
magnetic resonance imaging (MRI) to this day, albeit with significant subsequent advances 
and adaptations to this since.  This chapter will look at the central principles of MRI 
imaging, and their current use and application within imaging of the cardiovascular system. 
 
2.1 MRI SYSTEM COMPONENTS 
In its most basic guise a magnetic resonance imaging scanner can be broken down into 3 
key electromagnetic constituent elements: the main magnet, the gradient coils and the 
radiofrequency (RF) transmitter coil (see Figure 2-1).  The main magnet is responsible for 
generating a constant background magnetic field (B0).  The strength of this magnetic field 
describes the operating strength of the magnet, and in modern clinical scanners this is 
typically in the order of 1.5 Tesla (symbol T, with 1T equating to approximately 20,000  
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Figure 2-1: Diagrammatic representation of the electromagnetic constituents 
 
Diagrammatic representation of the electromagnetic components and their spatial distribution 
within an MRI system (a) and the alignment of the reference co-ordinate axis in relation to B0 which 
is generated by the main magnet coils (b).  Adapted from Ridgway(251). 
 
times the strength of the earths magnetic field) and 3T.  Although, 7T scanners are rapidly 
becoming more commonplace in a research environment, and 11T pre-clinical scanners are 
also in development, these are still some way off becoming routinely used in the clinical 
environment.  The gradient coils each generate much weaker (being measured in the order 
of milli-Tesla) transient magnetic gradients, with 3 gradient coils used in order to generate 
gradients in the x, y and z planes. The final component – the RF transmitter coil – generates 
the weakest magnetic field, and is located closest to the patient.  Using a combination of 
these three elements, magnetic gradients can be generated in a specific pattern and order 
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that allow the production of a magnetic resonance signal within the body that can be 
spatially localized and used to build up the MR image. 
 
2.2 MRI SIGNAL GENERATION 
2.2.1 The nuclei 
The entirety of MRI is built on the premise that the components of the atomic nuclei 
(protons and neutrons) each exhibit an intrinsic property known as spin. The ability to 
produce signal from this spin requires for the nucleus of the atom to have a net spin, which 
therefore requires an odd number of protons and neutrons so that the spin of each of these 
do not cancel each other out.  Several elements within the body exhibit just such a property 
including, but not limited to, hydrogen (1H), carbon (13C), sodium (23Na), fluorine (19F) 
and phosphate (31P).  As hydrogen is one of the most abundant elements within the body, 
being incorporated into water, fat and protein it is a natural choice to use for magnetic 
induction.   
 
The nuclear spin gives rise to a small magnetic field (or magnetic moment).  In the natural 
environment these are all directed in random directions, however when these are then 
exposed to the external magnetic field of the main magnet (with field strength B0) they 
align towards or away from the magnetic field, reaching an equilibrium whereby there is a 
small net direction of the protons in the direction of the main field, although this is typically 
in the magnitude of only a few protons excess per million.  This net magnetization is along 
the z-axis in parallel to B0, and is known as M0.  The stronger the main magnet (and thus 
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B0), the greater the excess of protons aligned in parallel to the main field (and as a 
consequence an increase in M0).  As M0 increases so does the maximum signal intensity that 
can be generated in order to produce images thus improving the signal to noise ratio of the 
resultant image. 
 
In order to use this net magnetization to produce a MR signal, the RF transmitter coil must 
be used to deliver energy to this group of protons.  To allow for the transmission of energy 
that will be absorbed by the protons, a resonant frequency must be used.  This resonant 
frequency is known as the Larmor frequency (ω0), and can be calculated using the Larmor 
equation: 
 
ω0 =  ϒ x B0 
 
where ϒ is a gyromagnetic constant specific to each particle dependent on its mass, size 
and spin. For hydrogen protons this is 45.27MHz/T, therefore the Larmor frequency of 
hydrogen for 1.5T imaging is 67.91MHz, while at 3T this is 135.81MHz.(252) 
 
2.2.2 Flip angles, repetition time and echo time 
Prior to magnetic induction by the RF pulse the net magnetization, M0, is aligned in parallel 
with B0. By using knowledge of the Larmor equation and the magnet being used, the RF 
coils can be used to emit RF waves at the Larmor frequency.  This induces the 
magnetization of the spinning protons to move from their thermal equilibrium into the 
transverse plane (Figure 2-2).  The longer the pulse is applied for or the greater the 
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amplitude of the RF pulse, the further into the transverse plane the magnetization will be 
moved.  The degree of this movement from the z-axis into the x-y plane is known as the flip 
angle (FA), which determines the amount of energy the precessing protons contain in both 
the z-axis and in the x-y axis.  At a FA of 90˚ all the longitudinal energy has been transferred 
into transverse energy while at FAs of <90˚ the protons contain some energy in the z axis 
and some in the xy plane.  As soon as the RF pulse is turned off the protons once again 
resume their precession around the z-axis, inducing a current in the same RF coils that 
emitted the RF pulse, which can be detected and used to generate the signal from which the 
MRI image is generated.   
 
Figure 2-2: Spin magnetization 
 
Figure 2-2: Spin magnetization: (a) during thermal equilibrium (M0);  (b) after excitation by radiofrequency 
induction to flip the magnetization into the horizontal plane; and (when the RF pulse is removed) (c) 
dephasing of the transverse magnetization Mxy occurs. 
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2.2.3 Relaxation 
As the precessing protons emit this detectable signal they lose their energy relaxing back to 
their native equilibrium where they once again align along B0.  Just as the flipped 
magnetization has both a horizontal and transverse component, the relaxation phase has 
both a horizontal and transverse component.   
 
The horizontal relaxation is an exponential process and is referred to as T1 and is affected 
by the molecular structure in which the hydrogen protons are bound and deposit their 
energy.  Medium sized molecules, such as fat, ‘tumble’ in such a way that this rate coincides 
with the Larmor frequency resulting is an incredibly rapid release of energy from the 
spinning hydrogen protons into the adjacent lattice in which they are held.  Both small 
molecules (such as water) and large molecules (such as proteins) tumble much faster or 
slower than the Larmor frequency hindering efficient energy transfer thus resulting in a 
slow T1 relaxation.  It is due to this process of transfer of energy from the spinning protons 
to the tumbling lattice in which they are held that T1 relaxation can be considered as spin-
lattice relaxation.   
 
In comparison, the transverse relaxation occurs due to the loss of coherence of the 
precessing protons.  When the RF pulse is first stopped, all the hydrogen protons are 
precessing in coherence with one another, generating a large amplitude signal.  However 
every atom and molecule containing the hydrogen protons are moving at random, each 
with their own magnetic field.  As the magnetic fields of the spinning protons within these 
atoms interact with one another they cause tiny shifts in the Larmor frequency, resulting in 
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an exponential loss of coherence of the precessing protons.  This can be seen as an 
exponential decay in the signal detected by the RF coils, known as free induction decay 
(FID).  The rate of this decay is the T2 relaxation value and, as it is caused by the 
interactions of individually spinning protons with one another, it is also known as spin-spin 
relaxation.  Molecular structures such as proteins, which hold a large number of protons in 
relatively close proximity to each other, facilitate a more rapid and consistent interaction 
between the spinning protons thus accelerating this spin-spin relaxation.  In comparison, 
water molecules are small and widely spaced meaning they interact relatively infrequently, 
as a result of which spin-spin relaxation is much slower.  This results in water having a long 
T2 relaxation time and thus a high T2 signal.  One added complexity when considering T2 
relaxation is that it is not just changes in the magnetic field induced by adjacent spinning 
protons that alter T2 relaxation rates.  Inhomogeneities in the magnetic field itself (a major 
problem in older solid state MRI scanners but less of an issue in modern superconducting 
magnets) will cause more rapid relaxation, as will interfaces between tissues which have 
very different magnetic susceptibilities (such as seen between the lungs and adjacent heart, 
or between the iron in haemosiderin and tissue parenchyma).  These two factors cause 
more rapid dephasing of the protons leading to a steeper relaxation curve which is referred 
to as T2*. 
 
2.3 MR IMAGE GENERATION 
So far we have discussed how it is possible to generate an MR signal, however in order to 
generate an image this signal must be localized.  This is done through the sequential 
application of three magnetic gradients – the slice selection gradient, the phase encoding 
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gradient and the frequency-encoding gradient.  Each of these is generated by the 3 
directional gradient coils, and applied at right angles to each other to determine the x, y and 
z planes of the image stack.  Through the use of these three gradients, specific tissue planes 
can be excited, with the resultant frequency and phase of the returned MR signal affected in 
such a way that spatial localization  of the signal origin can be determined. 
2.3.1 Slice selection 
The slice selection gradient applies a magnetic gradient across the body, which adds to or 
detracts from the strength of B0.  Since the Larmor frequency is determined by B0, changing 
this across the body will increase or decrease the Larmor frequency as the distance from 
the center point of the gradient increases.  Thus when the radiofrequency pulse is 
generated it will only excite the protons at the level of the null point of the gradient, which 
retain the original Larmor frequency.  By choosing the location of this null point, the slice of 
tissue to be imaged is selected. 
2.3.2 Phase encoding 
Once the slice selection gradient has been applied and the RF pulse has excited the slice of 
interest, the phase encoding gradient is applied.  This causes an increase or decrease in the 
frequency of precession of the protons with the magnitude of this change determined by 
their location on the gradient and the length of time the gradient is applied for.  When the 
gradient is turned off, the protons will return to their normal frequency of precession, 
however they will now be out of phase with each other with the phase of their current 
frequency determined by their location in the phase encoding direction.    
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2.3.3 Frequency encoding 
The frequency-encoding gradient is subsequently applied at right angles to the phase 
encoding gradient and works on the same principles that the gradient changes the 
frequency of precession across the gradient, with the magnitude in change of the frequency 
determined by the protons location along the frequency-encoding axis.  The frequency-
encoding gradient is applied during the process of signal readout meaning the received RF 
signal will be composed of a range of frequencies, each of which describes the location of 
the signal within the frequency encoding direction.   
2.3.4 Image reconstruction 
The generated MR signal detected by the RF coils will now be composed of a range of 
frequencies, describing phase and frequency data from the emitting protons.  Standard 
Fourier transform can only extract the frequency data from this, thus the above three 
gradients have to be repeatedly applied, with the slice selection and frequency encoding 
gradient kept constant while slight incremental changes in the strength and duration of the 
phase encoding gradient are applied.  Once multiple readouts have been performed using 
this technique, a 2D Fourier transform can be applied to extricate both the phase and 
frequency data from the signal to generate the image.  The greater the number of times this 
is repeated, the greater the spatial resolution that can be achieved, but at the cost of the 
added time required to repeat the necessary gradients and obtain the extra readouts.   
2.3.5 K-space 
The fact that every readout from the RF coils contains both frequency and phase data 
(which in turn represents x- and y- co-ordinates of the location of the origin of the signal) 
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leads to the need for the concept of k-space.  Each line of k-space represents a single 
readout from the end of the pulse sequence.  As the number of lines of k-space is built up 
the spatial data is pulled from all lines of k-space simultaneously through the 
aforementioned 2D Fourier transform.  The parts of k-space that are filled by the signal 
produced following the shortest and weakest phase encoding gradients generate the 
highest amplitude signal due to the minimal loss of cohesion of the preceding protons, and 
thus generate the contrast of the tissues.  In comparison the parts of k-space filled by the 
signal produced following the greatest strength and length of phase encoding gradients 
experience the greatest loss of cohesion of the protons generating the MR signal producing 
a low amplitude signal with very little contrast information but instead containing the edge 
definition and fine spatial detail. 
 
2.4 MRI SEQUENCES 
There are only two fundamental types of MR pulse sequences, with all other sequences 
being variations of these.  These two building blocks are Spin Echo (SE) and Gradient Echo 
(GRE) sequences. 
2.4.1.1 Spin echo 
When the 90º RF pulse is applied and turned off the protons immediately start dephasing 
with loss of signal according to their spin-spin relaxation rate and the inhomogeneities of 
the field they are in.  Through the application of a 180˚ transverse RF pulse the dephasing 
protons are refocused so that the field inhomogeneities are reversed and therefore nullified 
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(see Figure 2-3).  This allows the larger T2 signal to be measured rather than the smaller 
T2* signal.    
2.4.1.2 Gradient echo 
In comparison to spin echo which are refocused by a transverse 180˚ RF pulse, gradient 
echoes are refocused through the use of an applied gradient.  As this does not reverse the 
effects of magnetic field inhomogeneities, the produced signal is T2* dependent.  This 
means the signal decays much quicker in GRE sequences than SE sequences.  However the 
hindrance of this loss of signal is counterbalanced by the fact that a spin echo does not have 
to be waited for and thus this imaging is much quicker than SE sequences - a fact 
capitalized on by the majority of cardiac imaging sequences. 
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Figure 2-3: Signal formation for spin echo (top) and gradient echo (bottom) imaging. 
 
Top: The 180˚ refocusing pulse for spin echo imaging flips over magnetization and reverses the rotation 
direction of the transverse magnetization resulting in a compensation of dephasing caused by the T2’ effect 
meaning the magnetization is rephased at echo time TE. 
Bottom: For gradient echo imaging, the dephasing is not reversed. Signal and contrast are determined by both 
T2’ and T2* effects. As a result shorter echo times are necessary for detectable gradient echo signal intensity 
 
2.4.1.3 Tissue signal 
All MRI signal is composed of a combination of T1 and T2 signal.  The weighting of these 
two components is dependent on the sequence acquisition parameters, in particular the 
time to recovery (TR) between pulse sequences, and the time to echo (TE). A rapid TR with 
a rapid TE combines to produce a signal which is predominantly T1 weighted, while a pulse 
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sequence with a long TR and long TE will produce a predominantly T2 weighted image.  
Combining a long TR with a short TE produces a signal neither T1 or T2 weighted, and is 
instead predominantly affected by the number of excited protons producing any signal, and 
is therefore known as ‘proton-density’ weighting.  
 
2.5 CARDIAC MRI 
Cardiac MRI produces numerous challenges in MRI acquisition.  The heart is in constant 
motion, not just due to the regular contraction of the atria and ventricles, but also due to 
the movement of the diaphragm, on which it sits, during respiration.  Thus standard 
sequences, which take several minutes to acquire, cannot be used.  Secondly, blood itself 
produces numerous artifacts.  Fast blood flow, as seen through stenotic valves and vessels, 
causes dephasing of protons leading to signal drop out, while slow flowing blood (typically 
seen between the trabeculae of the ventricular apex) produces a signal not dissimilar from 
that of the ventricular wall itself. Finally the flow of blood generates its own magnetic field 
inhomogeneity causing artifacts, a problem exacerbated by the requirement to use fast 
gradient echo sequences in order to capture the heart in motion.  Each of these problems 
can be overcome, but explain the need for higher specification scanners compared to 
conventional anatomical imaging, and the relatively delayed uptake of cardiac MRI 
compared to imaging of other regions of the body. 
2.5.1 Commonly used sequences 
Numerous cardiac sequences exist which allow for a detailed and thorough interrogation of 
the anatomical structure and function of the heart.  For anatomical imaging these range 
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from black blood T1 and T2 weighted images, which most closely resemble conventional 
MRI imaging elsewhere in the body, through to tissue mapping which is revolutionizing our 
ability to perform a ‘virtual biopsy’ of the myocardium.  On a functional front cine imaging 
provides visualization of the heart throughout the cardiac cycle allowing assessment of 
motion abnormalities, while perfusion sequences provides functional information on the 
haemodynamic flow of blood to the myocardium.  However for the purpose of this thesis 
this chapter will focus on two of the most useful sequences for the quantification of 
myocardial function and blood flow: cine imaging and flow quantification  
2.5.1.1 Cine sequences 
As with almost all cardiac imaging, cine imaging requires the use of ECG gating in order to 
time the data acquisition to specific phases of the cardiac cycle.  To compensate for 
respiratory motion, the easiest way to do this is through breath-hold acquisition.  Given 
that a breath-hold beyond 20s is unfeasible for most patients with cardiovascular disease 
and that the cardiac cycle is typically in the order of 800-1000ms, image acquisition has to 
be fast.  To achieve this gradient echo sequences must be used.  These are acquired using 
either a spoiled gradient echo sequence or a balanced steady state free precessional 
(bSSFP) sequence.  Both sequences use extremely rapid TRs typically in the order of 
magnitude of <10ms to achieve the temporal resolution and speed of image acquisition 
required to perform cardiac imaging.  In spoiled gradient echo imaging, a low flip angle is 
combined with a rapid TE to provide a preserved signal while allowing rapid imaging.  As 
the TR is smaller than the T2* relaxation of the excited tissue this means some transverse 
magnetization remains at the end of the sequence requiring a final gradient to be applied to 
remove this.  This final gradient is known as the spoiling gradient which gives rise to the 
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name of the sequence.  bSSFP on the other hand capitalizes on the residual transverse 
magnetisation.  It instead applies a balanced gradient echo so that at the time of application 
of the next RF pulse the transverse magnetisation is in phase and preserved albeit with 
some T2* decay.  This means the next RF pulse has a larger transverse magnetisation than 
the former with this building with each RF pulse.  This results in a much larger returned 
signal improving image quality, albeit with a slightly unique tissue weighting which is 
neither T1 or T2 weighted but dependent on the square root of the ratio between the two.  
This incremental gain in signal and resultant improvement in signal is less susceptible to 
slow flowing blood providing better visualization of the blood-myocardium interface and 
thus more accurate myocardial delineation and quantification.(253)  However this 
improved signal and efficiency of imaging comes at a cost.  Any inhomogeneities in the 
magnetic field will be compounded as the transverse magnetization is amplified resulting 
in a significant band like signal drop out artifact in the images at the sites of these 
inhomogeneities.  It is for this reason that bSSFP has only recently become widely used in 
3T imaging as the effect of these inhomogeneities is amplified by the higher field strength 
and thus requires higher quality magnets with less variation in the magnetic field or more 
advanced shimming techniques to account for any magnetic field variation. 
2.5.1.2 Flow sequences 
Flow quantification can be achieved through the use of phase contrast sequences.  A phase 
contrast sequence utilizes two bipolar gradient echo pulses, which are identical in length 
and amplitude varying only by their direction.  As the phase shift a proton undergoes is 
dependent upon its location within the magnetic gradient, all stationary tissues will 
experience the same two opposed phase gradients, which will cancel each other out.  
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However any tissue moving in parallel with the opposed gradients will experience different 
degrees of dephasing then rephasing so will thus retain signal (see Figure 2-4).  The 
magnitude of this phase shift is proportional to how far the proton has moved between the 
two gradient pulses.  By varying the length of the pulses and the timing between these a 
direct correlation between velocity and signal can be obtained thus allowing quantification 
of the velocity within each voxel within the image.  By combining the velocity data of each 
voxel with the number of voxels within a specified region of interest, such as a blood vessel, 
the total flow can be calculated.   
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Figure 2-4: Diagrammatic representation of the gradients applied in order to produce a 
phase contrast sequence – from Nayak et al.(254) 
 
MR images are sensitized to measure the through-plane component of velocity by applying a flow-encoding 
gradient to the slice-selection axis of the pulse sequence. The flow encoding gradient can be added as (top) a 
bipolar pair to a flow-compensated slice selection waveform, or (bottom) to reduce minimum TE, combined 
with other gradient lobes 
 
2.6 CONCLUSION 
We have seen in this chapter that using a series of magnetic gradients applied in specific 
pulse sequences allows: selective excitation of a slice of tissue of interest; localization of the 
signal within the tissue; and weighting of the signal produced according to the type of 
tissue we best wish to detail.  By varying and tweaking these gradients in a myriad of ways 
we can produce the wide range of sequences that are a daily feature within modern 
medical practice.  
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CHAPTER 3:  Materials and Methods  
 
3 INTRODUCTION 
In this Chapter we will discuss the study design, the conductance of the study procedures 
and the acquisition of the MRI scans 
 
3.1 STUDY DESIGN 
3.1.1 Study Description 
• The main body of work for the PhD (Chapters 5-7) comprises a single centre 
prospective observational cohort study of patients aged 40-85 years with stable 
COPD, with 1 year follow up. 
 
Patients with COPD were recruited between June 2013 and May 2016.  They were recruited 
from a combination of local COPD clinics, participants identified in screening for other 
studies, previous study participants and the Tayside Allergy & Respiratory disease 
Information System (TARDIS) database.   
 
As well as a cohort of COPD patients a cohort of healthy volunteers was also recruited, the 
purpose of which was two fold.  The first was to act as a comparator group to those with 
COPD using an approximately age and sex matched cohort.  The second was to examine 
variables which might affect the measurement of PWV such as age, technique and cardiac 
outputs.  These healthy volunteers had no history of cardiovascular or respiratory disease 
and were recruited via local recruitment process involving advertising in University of 
Dundee pay slips and the weekly University electronic newsletters.   
 
Potential participants received an invite letter, a written ‘Participant Information Sheet’ 
(PIS) detailing the requirements of the study and the extent of their participation.  An opt-
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in form and pre-paid addressed envelope were included in the letter sent out.  Participants 
were given at least 24 hours to read the PIS.  Participants opting into the study were then 
contacted with details for their screening visit. 
 
All study visits were held at Ninewells Hospital and Medical School. 
 
3.1.1.1 Screening Visit 
A member of the research team discussed the PIS with the participant, answered any 
questions posed and then obtained written informed consent.  A detailed medical history 
was taken including and documented in a written case report form.   Heart rate, blood 
pressure and oxygen saturations were all obtained and where a recent eGFR was not 
available, blood was also taken to assess renal function for safety of contrast injection.  An 
echocardiogram was performed during the screening visit on all potential COPD recruits, 
with a practice six minute walk test (6MWT) also undertaken to familiarize the patient with 
the procedure. 
 
3.1.1.2 Visit 1 (Baseline) 
This occurred over a half day visit to the Clinical Research Centre at Ninewells hospital.   
 
COPD cohort: 
• Pulmonary function tests: Spirometry including forced and relaxed vital capacity, 
gas transfer co-efficient, and impulse oscillometry on air was performed as per ATS 
guidelines.(255)  
• MRI scan (see below for a description of acquisition and analysis and the Appendix 
for the MRI study SOP).   
• Bloods were taken at the same time as cannulation and saved for future biomarker 
and genomic analysis. 
• 6MWT as per ATS guidelines.(256) 
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Healthy volunteers 
• MRI scan (as above).   
• Bloods were taken at the same time as cannulation and saved for future biomarker 
and genomic analysis. 
 
3.1.1.3 Visit 2 (Follow-up) 
This involved a half day visit to the Clinical Research Centre at Ninewells hospital.   
 
COPD cohort: 
• Pulmonary function tests: Spirometry including forced and relaxed vital capacity, 
gas transfer co-efficient, and impulse oscillometry on air will be performed.   
• MRI scan (see appendix A).  Bloods will be taken at the same time as cannulation. 
o Bloods will be saved for future biomarker and genomic analysis. 
• 6MWT  
 
Healthy volunteers were not required to re-attend. 
 
Figure 3-1 and Table 3-1 demonstrate the study visits and study flow plan.  
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Figure 3-1: Study flow chart for the COPD cohort 
 
 
 
 
 
Table 3-1: Study matrix of the three study visits as undergone by the COPD cohort 
 
 
Time 
 
Sc
re
en
in
g 
 
Ba
se
lin
e 
 
1 
ye
ar
 
Inclusion/Exclusion criteria X   
Consent X   
History X  X 
HR/BP/Oxygen saturations X X X 
Echocardiogram X   
PFTs  X X 
6MWT  X X 
MRI  X X 
Bloods  X X 
Participant identification 
Screening 
Baseline 
1 year follow up 
No interest in taking part:  
No data saved no further contact 
Failed screening:  Anonymised data will be saved.   Patient will be 
invited to have details retained for future potential studies. 
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3.2 STUDY POPULATION 
3.2.1 Patient Inclusion Criteria 
• Male and female volunteers aged 40-85 years with stable COPD  
• Previous spirometry/PFTs documenting FEV1/FVC ratio <70% 
• Smoking history ≥10 pack-years. 
• GOLD 1 criteria: FEV1 >80% predicted 
• GOLD 2 criteria: 50% < FEV1 <80% predicted 
• GOLD 3 criteria: 30% < FEV1 <50% predicted  
• GOLD 4 criteria: FEV1 <30% or FEV1<50% plus chronic respiratory failure 
predicted  
• Stable defined as no exacerbation in previous 2 months. 
 
3.2.2 Patient Exclusion Criteria 
• History of cardiac condition, including but not limited to ischaemic heart disease, 
valvular disease(mild functional regurgitation allowed), arrhythmia, 
cardiomyopathy, congestive cardiac failure or congenital cardiac disease 
• Previous cardiac or thoracic operation 
• Other co-existent lung condition 
• Connective tissue disease or systemic vasculitis. 
• Severe renal impairment: eGFR ,30ml/min 
• Moderate or severe LV systolic dysfunction (EF <40%) 
• Any absolute contra-indication to MRI 
• Participation in an interventional clinical trial 
• Pregnancy 
• Inability to provide informed consent 
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3.2.3 Healthy Participant Inclusion Criteria 
• Asymptomatic 
• Able to provide informed consent 
 
3.2.4 Healthy Participant Exclusion Criteria 
• History of cardiac condition, including but not limited to ischaemic heart disease, 
valvular disease (mild functional regurgitation allowed) , arrhythmia, 
cardiomyopathy, congestive cardiac failure or congenital cardiac disease 
• Previous cardiac or thoracic operation 
• Lung condition including but not limited to COPD 
• Connective tissue disease or systemic vasculitis. 
• Severe renal impairment: eGFR ,30ml/min 
• Moderate or severe LV systolic dysfunction (EF <40%) 
• Any absolute contra-indication to MRI 
• Participation in an interventional clinical trial 
• Pregnancy 
 
3.2.5 Ethical approval 
Ethical approval was sought and approved by the East of Scotland Research Ethics 
Committee 2 (reference 14/ES/0034, granted 14/04/2014 - see appendix) prior to the 
start of patient identification and recruitment.  All research was conducted in accordance 
with the declaration of Helsinki.   
 
3.2.6 Screening For Eligibility 
As described above a screening visit was undertaken to assess eligibility.  This was both to 
consent patients as well as to perform an echocardiogram to ensure there was no 
significant left ventricular systolic impairment (ejection fraction <45%) or the presence of 
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significant valvular pathology prior to progression with the rest of the study (see Table 
3-2). 
Table 3-2: Echocardiographic results obtained during screening visit 
Parameter Mean (SD) 
LVIDd (mm) 46.4 ± 6.6 
LVIDs (mm) 32.1 ± 7.6 
LVEF* (%) 62.5 ± 8.2 
PASP (mmHg) 12.8 ± 9.9 
PAT (ms) 117.0 ± 28.9 
 
*based on biplanar modified simpsons technique 
 
 
3.2.7 Ineligible and non-recruited participants 
All participants who failed screening did not progress any further with the study.  
Anonymised details were retained for future comparison with the study group to assess for 
the presence of potential skewing in the study.  This was included in the consent 
documentation  during the screening visit. 
 
3.2.8 Withdrawal procedures 
All participants were free to withdraw from the study at any time.  If they withdrew prior 
to the baseline visit, all data pertaining to that patient was removed.  If they withdraw after 
the baseline visit then their data was saved unless they requested otherwise. 
 
Data collected from study visits up to the point of withdrawal and any safety visit was 
available for analysis.  If a participant withdrew consent for use and retention of data 
and/or samples collected, this was complied with and documented.   
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3.3 STUDY VISIT PROCEDURES 
All study procedures were performed on the same visit.  For the COPD participants this 
included pulmonary function testing, a six minute walk test (6MWT) and a cardiac MRI. 
 
3.3.1 Pulmonary Function Testing 
All pulmonary function tests were performed using a VMax Encore V22 bodybox 
(CareFusion, Basingstoke, UK).  Spirometry, lung diffusion and body plethysmography were 
all performed at the same time during the study visit prior to the six-minute walk test.  
Patients were instructed to abstain from using their inhalers for the day of, and the day 
before, their study visit.  All measures were performed by one of three experienced 
pulmonary physiologists.  Measurements were performed as per ERS/ATS guidelines.(255) 
 
3.3.2 Six-Minute Walk Test 
The six minute walk test was performed as per ATS guidelines.(256)  The only deviation 
from these guidelines was the use of a 25m straight line course as opposed to a 30m 
course.  While in theory this has the potential to reduce the observed distance walked by 
the individuals due to a greater frequency of having to alternate direction, in practice 
variations in course length between 15 and 50m have been shown to not significantly affect 
the total distance walked.(257)  All 6MWT were performed by myself.  Pre and post test 
oxygen saturations, heart rate and blood pressure were all obtained.  The course and route 
were demonstrated before the test started.  Predefined phrases of encouragement were 
used every minute in conjunction with informing the participant of the time remaining. The 
6MWT was always performed after the pulmonary function tests to ensure that these 
measures were not influenced by tiredness from the exercise.       
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3.4 MRI IMAGE ACQUISITION 
3.4.1 Patient preparation 
All patients were informed about the MRI using both the PIS and a detailed explanation 
during the screening visit.  A safety questionnaire was performed during screening, and 
again by a radiology department assistant on the day of attendance for their MRI.  Details of 
this were confirmed by the MRI radiographer prior to progression for their MRI scan.  
Patients were changed into hospital gowns on their upper body and all external metal work 
removed as per standard safety procedures.  A cannula was then inserted into the 
antecubital fossa before the patient was taken through to the MRI scanner. 
 
All MRI scans performed in this thesis were acquired with a 32 RF cardiac receiver channel 
coil, on a 3 Tesla MRI scanner (Magnetom Trio, Siemens, Erlangen, Germany).  Patients 
were positioned supine on the bed with their head positioned towards the bore of the 
magnet.  Pillows and foam leg supports were used as appropriate to ensure the patient was 
comfortable during the examination.  An MRI compatible blood pressure cuff was applied 
around the upper arm of the upper limb contralateral to the site of the cannula.  A 
spirometric probe was placed on the index finger of the same arm.   
 
3.4.2 Ventricular image acquisition 
A three-plane localiser was obtained, following which 4 chamber, 2 chamber and short axis 
localisers of the heart were obtained. An axial half-Fourier acquisition turbo spin echo 
(HASTE) stack was acquired of the chest.    
 
Using these sequences a 4 chamber, and 2 chamber long axis cine sequences were 
obtained.  From these a short axis stack was planned aligned to the atrioventricular groove.  
A balanced steady state free precession (bSSFP) stack was acquired in breathold from the 
atrioventricular ring to the apex (Slice thickness=6 mm, interslice gap 4mm, 
TR/TE=47.6/1.49 ms, no. averages=1, phases=25, bandwidth/pixel=446 Hz, flip angle=53°, 
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field of view (FOV) = 360 × 360mm2, FOV phase = 84.4%, matrix=256 × 256), parallel 
acceleration factor = 2).  
 
3.4.3 Pulmonary PWV image acquisition: 
Using the short axis bSSFP and HASTE stack, a bSSFP view of the right ventricular outflow 
tract was planned following which an orthogonal plane was acquired to optimally visualise 
the main pulmonary artery and valve.  Localisers along the length of the right and left 
pulmonary artery were then obtained.  From these phase contrast imaging was acquired in 
three planes - through the main pulmonary artery (MPA), right pulmonary artery (RPA), 
and left pulmonary artery (LPA) to provide a true cross section through each of the three 
arteries.  The MPA slice was located in the proximal main pulmonary artery as close to the 
valve as possible in order to maximise the distance for the TT technique while also avoiding 
the valve throughout the cardiac cycle. The RPA and LPA were placed as close to the hila as 
possible while remaining proximal to the origins of the first visualised branch (See Figure 
3-2).  
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Figure 3-2:  Planning of the short axis views of the pulmonary arteries. 
 
Planning of the main (A-C), right (D-F) and left (G-I) pulmonary arteries using a combination of right 
ventricular outflow views (A-B), the HASTE axial stack (D and G) and dedicated scout views of the branch 
pulmonary arteries (E and H).  The linear lines represent the planes planned for the final short axis view as 
demonstrated in C, F and I. 
 
 
3.4.3.1 High temporal resolution sequences 
For the high temporal resolution scan the acquisition parameters of the phase contrast 
sequence were as follows: Slice thickness=6 mm, TR/TE=7/4 ms, no. averages=1, 
phases=128, velocity encoding=150 cm/s, bandwidth/pixel=340 Hz, flip angle=15°, field of 
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view (FOV) =320 × 320mm2, matrix=256 × 256. This provided a temporal resolution of 
7ms (based on a TR of 7ms with a single read out and no view sharing) and a spatial 
resolution of 1.25 x 1.25 x 6mm.   
 
3.4.3.2 High spatial resolution sequences 
For the high spatial resolution scan, the acquisition parameters were: Slice thickness=6 
mm, TR/TE=12/4 ms, no. averages=1, phases=80, velocity encoding=150 cm/s, 
bandwidth/pixel=340 Hz, flip angle=15°, field of view (FOV) = 320 × 320mm2, matrix=512 
× 512. This provided a temporal resolution of 12ms, spatial resolution of 0.625 x 0.625 x 
6mm.  Both sequences were free breathing, with an acquisition time of approximately 4 
minutes depending on heart rate. 
 
 
3.5 IMAGE ANALYSIS 
All images were anonymised and allocated a randomized study number before being 
exported to a dedicated workstation with image analysis performed using CVI 42 (Circle 
Cardiovascular Imaging Inc., Calgary, Alberta, Canada) with all analysis being performed by 
myself. 
 
3.5.1 Ventricular quantification: 
Epicardial and endocardial contours were drawn around the right and left ventricles at end 
systole and end diastole (see Figure 3-3) as per SCMR guidelines.(258) The only deviation 
from these guidelines was that the right ventricular trabeculae were included in the mass 
measurement and excluded from the volume calculation.  The rationale for this is two-fold:  
Firstly, the SCMR guideline do not provide guidance on right ventricular mass 
measurement with their guidelines centered on the optimization of the volume 
reproducibility rather than mass quantification; and secondly, previous work has shown 
that right ventricular papillary and trabecular mass comprises a greater percentage of the 
right ventricular mass in those with pulmonary hypertension than in healthy controls, and 
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that changes in papillary and trabecular mass better reflect changes in pulmonary 
haemodynamics than right ventricular free wall mass alone.(259) The septum was treated 
as belonging to the left ventricle and was excluded from the right ventricular mass.  Mass 
and volumes were normalised to height^1.7. 
Figure 3-3: Short axis image of the right and left ventricles with epicardial, endocardial, and 
trabecular borders drawn. 
 
 
Pale blue line – Right ventricular epicardial border; Yellow line – right ventricular endocardial border; Green 
line – Left ventricular epicardial border; Red line – Left ventricular endocardial border; Dark blue line – Right 
ventricular trabecular outlines. 
 
Intra-observer repeatability was tested in n=20 COPD participants randomly selected from 
the main study.  Agreement was excellent for all volumetric measures (See Table 3-3) 
although the limits of agreement were consistently wider for the right ventricle measures 
than for the left.  No significant difference was observed between the two measures when 
compared using a paired sample t-test (p>0.05 for all). Bland-Altman plots are provided in 
Figure 3-4 and Figure 3-5. 
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Table 3-3: Absolute agreement average measure intraclass correlation coefficients for 
repeated measures of right and left ventricular volumes and function. 
Ventricular metric ICC 95% CI p 
LVEDV 0.99 0.99-1.0 <0.001 
LVESV 0.99 0.96-0.99 <0.001 
LVSV 0.97 0.93-0.99 <0.001 
LVEF 0.94 0.85-0.98 <0.001 
LVM 0.97 0.93-0.99 <0.001 
RVEDV 0.99 0.96-0.99 <0.001 
RVESV 0.94 0.87-0.98 <0.001 
RVSV 0.96 0.91-0.99 <0.001 
RVEF 0.84 0.64-0.93 <0.001 
RVM 0.86 0.69-0.94 <0.001 
 
Figure 3-4:  Bland-Altman plots of intra-observer differences between left ventricular 
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Figure 3-5:  Bland-Altman plots of intra-observer differences between right ventricular 
measures. 
 
 
 
3.5.2 Pulmonary PWV Image analysis 
3.5.2.1 Transit time technique 
For the transit time (TT) method both distance and time data need to be measured.  For the 
distance, the HASTE axial images were used to measure the distances between the imaging 
planes following the centre-line of the vessel.  Where the right or left pulmonary artery lay 
on different slices from the main pulmonary artery a vertical height was calculated from 
the slice thickness and number of slices.  Using this vertical height and horizontal length 
measured on the axial slices the final distance was calculated using Pythagoras theorem.  
For the time component the phase and magnitude images were pulled up side by side.  A 
contour was manually drawn around the perimeter of the vessel on the magnitude image.  
This was then automatically propagated throughout the remainder of the images, and 
manually corrected where malposition occurred.  The program then automatically 
calculated area, flow and velocity data, which was exported to Excel 2010 (Microsoft, US).  
The flow curves from the MPA, RPA and LPA were plotted, and the time to the systolic 
upstroke of the waves then calculated.  The arrival time of the flow wave was identified as 
the intersection between the systolic upstroke and baseline flow.  The systolic upstroke 
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was calculated as the line through the data points that lay between 20% and 80% levels of 
the maximum flow rate.  The use of which was determined based on previous work by a 
previous PhD student at our institution (Deirdre Cassidy, Unpublished) and the work of 
Dogui et al.(260)  The baseline was the horizontal line at minimum velocity before systole.  
Pulse wave was calculated for both RPA and LPA using equation 1: 
 
 
𝑇𝑇𝑇𝑇 𝑃𝑃𝑊𝑊𝑉𝑉 =  
∆𝑑𝑑
∆𝑡𝑡  
(1) 
 
Where Δd is the distance between the planes and Δt is the difference in the time to foot 
between the MPA and RPA/LPA (See Figure 3-6). 
 
 
Figure 3-6: Transit time technique for calculation of PWV 
 
A – Axial HASTE through the pulmonary trunk bifurcation; B – short axis RPA; C – short axis MPA; D – short 
axis LPA; E – flow curves from the three pulmonary arteries.  Time delay between the arrival of the three flow 
curves can then be derived, while the distance is measured from the axial HASTE image. 
 
3.5.2.2 Flow area technique 
For the flow-area (QA) method the phase and magnitude images were pulled up side by 
side.  A contour was manually drawn around the perimeter of the vessel on the magnitude 
image on each image for the first 200ms of the cardiac cycle.  From this the programme 
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calculated the total area and flow within the cross section of the pulmonary vessel.  The 
area and flow were then plotted against one another during early systole.  Early systole 
was defined as the time period in systole during which both the vessel area and flow were 
simultaneously increasing.  Three techniques have been described for the calculation of QA 
PWV with all being variations on the basic premise of equation (2): 
 
 
𝑄𝑄𝑄𝑄 𝑃𝑃𝑊𝑊𝑉𝑉 =  
∆𝑄𝑄
∆𝑄𝑄 
(2) 
 
Where Q is the flow and A is the area through the pulmonary artery. The first is as 
described by Peng et al.(207) whereby the gradient of the line is fitted through these points 
using a minimum squared difference technique hereby known as QATrad (Figure 3-7). The 
technique proposed by Quail et al.(261) follows the same principle but restricts analysis to 
the first 3 data points of the systolic upstroke in order to avoid the influence of reflected 
waves (QA3). Finally, Davies et al.(262) have proposed a technique that accounts for the 
effects of reflected waves thereby allowing usage of more data-points than the Quail et al. 
technique whilst maintaining accuracy.  This was originally described for pressure and 
velocity data derived from invasive catheter measurements, however has been adapted to 
give equation (3): 
 
𝑃𝑃𝑊𝑊𝑉𝑉 = �
∑∆𝑄𝑄2
∑∆𝑄𝑄2  
(3) 
This used all datapoints in early systole, similar to the QATrad  technique. This technique for 
calculating PWV shall be entitled QAINV for the remainder of this chapter.  
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Figure 3-7: Assessment of the main pulmonary artery for calculation of the QA PWV. 
 
A and C demonstrate the magnitude and phase contrast images at the start of systole, while B and D 
demonstrate the magnitude and phase images at peak systolic flow.  Reproducibility of both techniques is 
discussed in detail in Chapter 4. 
 
3.5.2.3 Aortic PWV analysis: 
A retrospective ECG-gated gradient-echo pulse sequence with velocity encoding was 
applied to measure the through plane flow at two predefined locations in the ascending 
and abdominal aorta. The first slice was positioned through the aortic arch at the level of 
the pulmonary bifurcation, and the second slice was placed axial through the proximal 
abdominal aorta just distal to the aortic hiatus. The same phase contrast sequence was 
used as for the pulmonary PWV measurement. To determine the distance between the two 
aortic slices, a 2D gradient echo FLASH (fast low angle shot) was acquired of the aorta in a 
‘candy stick’ double-oblique orientation. TR/TE 40/1.2 ms; flip angle 15°, slice thickness of 
8 mm, 23 cardiac phases, 1 averages, a pixel size of 1.5 x1.5 mm2, bandwidth of 475 Hz/ pix 
and breath hold scan time of average 9 seconds. The distance was measured along the 
aorta between the two analyses planes (Δx value) using candy stick FLASH and the time 
delay calculated as the time delay between the arrival of the foot of the pulse wave at the 
ascending aorta and abdominal aorta (See Figure 3-8). 
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Figure 3-8: Aortic pulse wave velocity calculated using the transit time technique. 
 
 
The flow curves from the ascending thoracic aorta and the abdominal aorta were plotted, and the 
time to the systolic upstroke of the waves then calculated.  The arrival time of the flow wave was 
identified as the intersection between the systolic upstroke and baseline flow.  The systolic 
upstroke was calculated as the line through the data points that lay between 20% and 80% levels of 
the maximum flow rate.  The baseline was the horizontal line at minimum velocity before systole.  
Pulse wave was calculated using equation (1). 
 
3.6 SAMPLE SIZE CALCULATION 
Calculations were based on the typical RV mass in severe COPD – 57.6 ± 4.1 g/m2.(80) No 
data exists on the expected progression rates of right ventricular mass in COPD.  Therefore 
progression rates in mass in placebo groups in interventional studies for pulmonary 
hypertension have had to be used as a substitute.  These describe an increase in mass of 5-
8g (change in right ventricular mass detected over 4-36 months in groups of 21 and 44 
participants respectively).(263,264) 
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Based on these factors, n=17 will allow detection of a 4g change with study power of 80% 
and a p=0.05.  Further work by Bradlow et al. has shown a group size of 17 will allow 
detection of 10ml change in RV end diastolic volume which correlates with changes of 9-
15ml seen in the placebo arm of drug intervention studies.(263–265)   
 
Based on variability in healthy volunteers and patients with established pulmonary 
hypertension (207,208), n=26 will allow detection of a PWV difference of 0.64m/s between 
the groups with a study power of 80% and a p=0.05.  n=30 will be recruited to account for 
potential dropouts and patients unable to tolerate the MRI scan.  Ideally 30 patients will be 
recruited into those with mild, moderate and severe COPD to allow comparison of PWV 
between varying degrees of COPD severity. 
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CHAPTER 4: Assessment of proximal 
pulmonary arterial stiffness using magnetic 
resonance imaging: Effects of technique, 
age and exercise.  
 
 
4 INTRODUCTION 
The compliance of the pulmonary artery is a key component in decoupling the right ventricle from 
the pulmonary bed, allowing the right ventricle to work at maximum efficiency and protecting the 
microcirculation from large pressure gradients.(117,130,266)   We have seen in Chapter 1 that the 
pulmonary stiffness has significant implications for right ventricular function,(131) functional 
capacity,(134) and mortality.(135–139)  Its curvilinear relationship with RV function and its 
presence even in those with isolated exercise induced pulmonary hypertension(65,78,143,172) 
suggest pulmonary arterial stiffness as a promising biomarker for detection of early disease and as 
a potential therapeutic target before end stage arterial remodeling occurs with dire consequences 
for the failing right ventricle. 
 
While the majority of measures of pulmonary arterial stiffness require right heart catheterisation to 
derive pulmonary pressures pulse wave velocity (PWV) is an entirely non-invasive technique for 
measuring arterial stiffness that does not require knowledge of the arterial pressures.  This can be 
measured using MRI using one of two methods: the transit time (TT) technique which measures the 
time it takes for the pulse wave to travel between two separate points along the vessel; and the 
flow-area (QA) technique which measures the change in cross sectional area and flow across the 
vessel at this point to derive the pulse wave velocity. The results of these techniques have been 
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shown to correlate well with one another in the pulmonary circulation(208), and each individual 
technique has been shown to have good same day interscan reproducibility.(203,207)  However the 
reproducibility of the two techniques has not been directly compared in the pulmonary circulation.  
In addition the effects of age or physiological flow states on both these two measures of PWV has 
not been elucidated. 
 
The aim of this study is thus to assess and compare the reproducibility of the two MRI methods for 
measuring PWV in healthy volunteers, and to assess the effects of age and exercise on these 
measures. 
 
4.1 MATERIALS AND METHODS 
4.1.1 Population 
Two separate study populations were studied: 
1. Young healthy volunteers (YHV): Ten healthy volunteers under 40 (3 Males, 7 females, Mean 
age 31.5 ± 2.4 years) with no history of cardiovascular or lung disease were recruited to the study. 
All individuals underwent high temporal resolution phase contrast scans of their main pulmonary 
artery and branch pulmonary arteries at baseline, during exercise, and at 6 months follow-up. 
2. Older healthy volunteers (OHV): 20 healthy volunteers over the age of 55 (9 male, 11 female, 
mean age 60.2 ± 1.1 years) with no history of cardiovascular or lung disease were recruited to the 
study.  All individuals underwent high temporal resolution phase contrast scans of their main 
pulmonary artery and branch pulmonary arteries followed by a high spatial resolution phase 
contrast scan of their main pulmonary artery. All 4 sequences were repeated during the same 
scanning session. 
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4.1.2 MRI 
The high spatial resolution and high temporal resolution phase contrast sequences of the 
pulmonary artery were acquired as described in section 3.4.  Aortic PWV was similarly performed 
as described. The pulmonary PWV was analysed using the transit time technique, and the 
traditional, 3 point technique and Davies technique for flow-area PWV calculation. 
 
4.1.2.1 Exercise 
Isometric exercise was performed by the volunteer by crossing their feet and then forcefully 
plantarflexing the superior foot while dorsiflexing the inferior foot against each other.  The 
participant was instructed that if any discomfort developed they should swap the positions of the 
feet and to continue the exercise.  Image acquisition began after five minutes of this exercise with 
the exercise continued throughout the duration of the image acquisition.  Gentle encouragement 
was given to ensure sustained effort throughout the process. 
 
4.1.3 Statistics 
Descriptive statistics were used for the analysis of the demographic and clinical features of the 
cohorts with data expressed as mean ± SEM.  Normality and equality of variances of the variables 
was tested.  A dependent sample t-test was used to compare the difference between the first scan 
and the repeated measure, inter-scan measure and the exercise measure. ANOVA was used to 
compare PWV between the two cohorts.  Bland-Altman plots were used to further investigate the 
inter-scan and inter-observer reproducibility.  All data were analysed using SPSS statistical package 
(version 21.0, SPSS Inc. Chicago, Illinois). Significance was assumed when p < 0.05. 
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4.2 RESULTS 
4.2.1 PWV measurements 
Using the TT technique PWV was measurable in all individuals, however in 5 individuals, one of the 
sides produced grossly inaccurate results (PWV excessively high or negative), this error was 
slightly more common on the left (n=3) than the right (n=2).  Using the high temporal resolution QA 
technique, PWV was measurable in 29/30 of the study participants at the MPA, 29/30 at the RPA, 
and 29/30 at the LPA. Using the high spatial resolution QA technique, PWV was measurable in 
29/30 participants. 
 
Using the TT technique MPA-RPA PWV was 2.7±0.1 ms-1 while the MPA-LPA PWV was 3.3±0.2 ms-1.  
There was a significant difference between the PWV using the right pulmonary artery and the left 
pulmonary artery: mean (95% CI) of the differences -0.55 (-1.1 - -0.03), P=0.038.     
 
The results of the three QA techniques for both the high temporal resolution and low temporal 
resolution sequences are described in Table 4-1.  Using the high temporal resolution sequences the 
QATrad produced significantly higher results than the QA3 (p<0.001) or the QAInv (p<0.001), whilst 
there was no difference between the QA3 and QAInv techniques (p=0.41). Similar findings were 
observed with the high spatial resolution sequence with the QATrad produced significantly higher 
results than the QA3 (p=0.004) or the QAInv (p<0.001), whilst there was no significant difference 
between the QA3 and QAInv techniques (p=0.47).  There was no difference in PWV between the two 
sequences using QATrad, however the higher temporal resolution yielded consistently lower PWV 
than the high spatial resolution sequence for both the QA3 (p=0.028) and QAInv (p=0.001).  Using the 
QATrad method the PWV was 1.99 ± 0.14 ms-1 in the MPA, 1.49 ± 0.11 ms-1 in the RPA and 1.37 ± 0.11 
ms-1 in the LPA.  The PWV was significantly higher in the MPA compared to the RPA (mean (95% 
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CI) of the differences: 0.49 (0.15-0.89), P=0.006) and the LPA (mean (95% CI) of the differences 
0.63 (0.36-0.89), P<0.001).  There was no significant difference between the RPA and LPA (mean 
(95% CI) of the differences 0.12 (-0.11-0.34), P=0.29). 
 
Table 4-1: Comparison of PWV between the two phase contrast sequences and 3 post 
processing techniques 
 QATrad QA3 QAInv 
High Temporal 
resolution 1.98 ± 0.13 1.0 ± 0.11 1.1 ± 0.08 
High Spatial 
resolution 2.11 ± 0.17 1.55 ± 0.16 1.67 ± 0.13 
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4.2.2 Within scan reproducibility 
Within scan reproducibility was assessed in the 20 OHVs.  Bland-Altman plots of the between scan 
differences are shown in Figure 4-1.  
 
Figure 4-1: Bland-Altman plots comparing PWV repeatability during the same visit. 
 
The middle line represents the mean difference while the upper and lower lines represent the ±2SD limit. 
 
Using the TT technique, the MPA-RPA PWV had better precision but lower accuracy than the MPA-
LPA PWV (mean (95% CI) of PWV differences = 0.21 (-1.01-1.42) ms-1 and 0.13 (-3.57-3.83) ms-1 for 
the MPA-RPA and MPA-LPA respectively).  Using the QA technique, the QAInv technique again 
consistently yielded improved accuracy and precision over the QATrad and QA3 technique (mean 
(95% CI) of PWV differences = -0.46 (-2.39-1.47) ms-1, 0.05 (-1.68-1.77) ms-1, and 0.01 (-1.23-1.25) 
ms-1 for the QATrad, QA3, and QAInv of the MPA respectively; 0.17 (-0.68-1.02) ms-1, 0.19 (-1.43-1.81) 
ms-1 and 0.06 (-0.42-0.55) ms-1 for the QATrad, QA3, and QAInv of the RPA respectively; and -0.29 (-
0.91-0.32) ms-1, -0.01 (-0.78-0.76) ms-1 and -0.06 (-0.69-0.56) ms-1 for the QATrad, QA3, and QAInv of 
the LPA respectively).  The high spatial resolution yielded poorer reproducibility than the high 
 97 
temporal resolution sequence (mean (95% CI) of QAInv PWV differences = 0.01 (0.63) ms-1, and 0.3 
(0.86) ms-1 respectively).  A combination of a high temporal resolution sequence through the RPA 
combined with the QAInv post processing yielded the best reproducibility.  
 
4.2.3 Inter-scan reproducibility 
The scans were repeated at 6 months in 9 of the 10 YHVs.  This resulted in reproducible results 
with no significant differences in the two measurements (P>0.5).  Bland-Altman plots of the 
between scan differences are shown in Figure 4-2.  
 
Figure 4-2: Bland-Altman plots comparing PWV repeatability on separate visits. 
 
The middle line represents the mean difference while the upper and lower lines represent the ±2SD limit. 
 
Using the TT method, the MPA-RPA PWV had better precision but lower accuracy than the MPA-
LPA PWV (mean (95% CI) of PWV differences = 0.56 (-0.86-1.99) ms-1 and 0.19 (-1.47-1.84) ms-1 for 
the MPA-RPA and MPA-LPA respectively).  Using the QA technique, the QAInv technique again 
consistently yielded improved accuracy and precision over the QATrad and QA3 technique (mean 
 98 
(95% CI) of PWV differences = 0 (-3.24-3.24) ms-1, -0.07 (-2.11-1.96) ms-1, and -0.43 (-2.18-1.32) 
ms-1 for the QATrad, QA3, and QAInv of the MPA respectively; -0.5 (-3.18-2.18) ms-1, -0.13 (-1.22-0.96) 
ms-1 and -0.52 (-1.46-0.43) ms-1 for the QATrad, QA3, and QAInv of the RPA respectively; and 0.31 (-
1.51-2.14) ms-1, -0.59 (-1.84-0.67) ms-1 and -0.24 (-1.22-0.75) ms-1 for the QATrad, QA3, and QAInv of 
the LPA respectively).  A combination of a high temporal resolution sequence through the RPA 
combined with the QAInv post processing yielded the best reproducibility.  
 
4.2.4 Intra-observer reproducibility 
Bland-Altman plots of the between scan differences are shown in Figure 4-3.    
 
Figure 4-3: Bland-Altman plots comparing intra-observer PWV repeatability. 
 
The middle line represents the mean difference while the upper and lower lines represent the ±2SD limit. 
 
Using the TT method, the MPA-RPA PWV had better precision but lower accuracy than the MPA-
LPA PWV (mean (95% CI) of PWV differences = 0.28 (-1.63-2.19) ms-1 and 0.19 (-3.11-3.48) ms-1 for 
the MPA-RPA and MPA-LPA respectively).  Using the QA technique, the QAInv technique again 
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consistently yielded improved accuracy and precision over the QATrad and QA3 technique (mean 
(95% CI) of PWV differences = -1.41 (-4.29-1.48) ms-1, -0.36 (-2.01-1.28) ms-1, and -1.51 (-3.74-
0.73) ms-1 for the QATrad, QA3, and QAInv of the MPA respectively; -0.31 (-1.12-0.5) ms-1, -0.95 (-3.1-
1.2) ms-1 and -0.58 (-1.06- -0.1) ms-1 for the QATrad, QA3, and QAInv of the RPA respectively; and -0.74 
(-2.12-0.64) ms-1, -0.89 (-2.93-1.15) ms-1 and -0.78 (-1.79-0.22) ms-1 for the QATrad, QA3, and QAInv of 
the LPA respectively).  The high spatial resolution yielded better reproducibility than the high 
temporal resolution sequence (mean (95% CI) of QAInv PWV differences = -1.51 (-3.74-0.73) ms-1, 
and -0.70 (-2.31-0.9) ms-1 for the high temporal resolution and high spatial resolution sequences 
respectively). A combination of a high temporal resolution sequence through the RPA combined 
with the QAInv post processing yielded the best intra-observer reproducibility. 
 
  
 100 
4.2.5 Inter-observer reproducibility 
Bland-Altman plots of the between scan differences are shown in Figure 4-4.    
 
Figure 4-4: Bland-Altman plots comparing inter-observer PWV repeatability. 
 
The middle line represents the mean difference while the upper and lower lines represent the ±2SD limit. 
 
Using the TT method, the MPA-RPA PWV had better precision but lower accuracy than the MPA-
LPA PWV (mean (95% CI) of PWV differences = 0.23 (-0.64-1.1) ms-1 and 0.02 (-0.97-1.01) ms-1 for 
the MPA-RPA and MPA-LPA respectively).  Using the QA technique, the QAInv technique again 
consistently yielded improved accuracy and precision over the QATrad and QA3 technique (mean 
(95% CI) of PWV differences = -0.2 (-1.86-1.47) ms-1, 0.02 (-1.25-1.29) ms-1, and 0.01 (-1.47-1.5) 
ms-1 for the QATrad, QA3, and QAInv of the MPA respectively; 0.01 (-1.67-1.69) ms-1, -0.67 (-2.24-0.9) 
ms-1 and -0.08 (-1.58-1.42) ms-1 for the QATrad, QA3, and QAInv of the RPA respectively; and 0.03 (-
1.57-1.63) ms-1, -0.32 (-2.04-1.41) ms-1 and 0.14 (-1.13-1.42) ms-1 for the QATrad, QA3, and QAInv of 
the LPA respectively).  The high temporal resolution yielded better reproducibility than the high 
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spatial resolution sequence (mean (95% CI) of QAInv PWV differences = 0.01 (-1.47-1.5) ms-1, and -
0.18 (-2.61-2.25) ms-1 for the high temporal resolution and high spatial resolution sequences 
respectively).  The TT method through the right pulmonary artery yielded the best overall inter-
observer reproducibility, while the combination of a high temporal resolution sequence through the 
RPA combined with the QAInv post processing yielded the best inter-observer reproducibility for the 
QA technique. 
 
Inter-observer and intra-observer variability account for the majority of the inter-scan variability, 
with the impact more pronounced in the QA technique than in the TT technique. 
 
4.2.6 Age 
There was no difference between the 2 groups in terms of age, sex, smoking status, height, weight, 
BMI, or resting heart rate (See Table 4-2).  However the older population had a significantly higher 
resting systolic (YHV 113 ± 1 vs. OHV 128 ± 3 mmHg, p=0.002) and diastolic blood pressure (YHV 
68 ± 2 vs. OHV 75 ± 2, p=0.028).  The pulmonary PWV did not differ between the young healthy 
volunteers and older healthy volunteers using either the TT technique (YHV 2.4 ± 0.3 vs. OHV 2.9 ± 
0.2, p=0.1) or the QAInv technique (YHV 0.95 ± 0.1 vs. OHV 1.15 ± 0.1, p=0.1).  However a significant 
difference was observed between the two groups for the aortic arch pulse wave velocity (YHV 7.4 ± 
1.6 vs. OHV 10.7 ± 1.6, p=0.014) (See Table 4-3).  To further examine the results, a post hoc power 
calculation was performed using the reported means and standard deviations.  Based on the sample 
size and observed variability, with a p=0.05, the study had a 80% power to detect a difference of 
0.26ms-1 between the groups.   
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Table 4-2: Comparison of the demographic and anthropomorphic measures of the two 
study groups 
 YHV OHV p 
Age 31.5 ± 2.4 60.1 ± 1.1 <0.001 
Sex (%male) 3 (30%) 9 (45%) 0.7 
Height 1.71 ± 0.02 1.73 ± 0.03 0.8 
Weight 76.3 ± 6.5 73.9 ± 3.2 0.7 
BMI 25.8 ± 1.9 24.6 ± 0.6 0.5 
Current smoker 1 (10%) 3 (15%) 1 
Ex-smoker 3 (30%) 6 (30%) 1 
Never smoker 6 (60%) 11 (55%) 1 
Heart rate 65.3 ± 1.9 64.4 ± 2.8 0.8 
Systolic BP 113 ± 1 128 ± 3 0.002 
Diastolic BP 68 ± 2 75 ± 2 0.028 
 
 
Table 4-3: Effects of age on Pulmonary and Aortic PWV 
 YHV OHV p 
Pulmonary PWV 
TT (MPA-RPA) 2.4 ± 0.3 2.9 ± 0.2 0.1 
TT (MPA-LPA) 3.0 ± 0.3 3.3 ± 0.3 0.5 
MPA QAInv 1.0 ± 0.08 1.2 ± 0.1 0.2 
RPA QAInv 1.0 ± 0.06 0.8 ± 0.07 0.1 
LPA QAInv 1.0 ± 0.2 0.7 ± 0.05 0.1 
Aortic PWV 
Aortic Arch PWV 7.4 ± 1.6 10.7 ± 1.6 0.014 
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4.2.7 Exercise 
The isometric calf exercises resulted in a significant and sustained rise in heart rate from 65 ± 2 to 
87 ± 3 (P<0.0001) and in blood pressure from 113/68 to 130/84 (P<0.0001).  A significant increase 
in cardiac output was also observed from 5.5 ± 0.4 to 6.7 ± 0.6 L/min (P=0.004), which was 
mediated through an increase in heart rate rather than an increase in stroke volume (P=0.98).  
Exercise resulted in erroneous measures in 2 participants using the TT technique, and in 1 using 
the QA technique. 
 
Using the TT technique: the MPA-RPA PWV changed from 2.43 ± 0.26 at rest to 2.86 ± 0.25 during 
exercise (mean (95% CI) of PWV differences = -0.42 (-1.2-0.4) ms-1, P=0.24); while the MPA-LPA 
PWV changed from 3.03 ± 0.27 at rest to 3.35 ± 0.39 during exercise (mean (SD) of PWV differences 
= -0.32 (-1.6-1) ms-1, P=0.57) (see Figure 4-5). 
 
Using the QAInv technique: the MPA PWV went from 0.95 ± 0.09 at rest to 0.91 ± 0.1 during exercise 
(mean (95% CI) of PWV differences = 0.03 (-0.2-0.3) ms-1, P=0.77); the RPA PWV went from 1.03 ± 
0.06 at rest to 0.92 ± 0.17 during exercise (mean (95% CI) of PWV differences = 0.11 (-0.3-0.5) ms-1, 
P=0.53); the LPA PWV went from 1.03 ± 0.16 at rest to 1.05 ± 0.11 during exercise (mean (95% CI) 
of PWV differences = -0.02 (-0.4-0.3) ms-1, P=0.9).  To further examine the results, a post hoc power 
calculation was performed using the reported means and standard deviations.  Based on the sample 
size and observed variability, with a p=0.05, and a study power of 80%, the study would be 
powered to detect a difference of 0.3ms-1.   
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4.3 DISCUSSION 
We have shown that: (i) The QA method using a high temporal resolution sequence through the 
right pulmonary artery using a calculation that accounts for wave reflections yields consistently 
better within scan, inter-scan, intra-observer and inter-observer reproducibility; (ii) Age related 
arterial stiffening as seen in the systemic circulation does not occur in the pulmonary vessels; (iii) 
Pulmonary PWV is stable and consistent at both rest and exercise. 
 
This is the most comprehensive analysis of the techniques for measuring pulmonary PWV to date.  
Prior studies have either provided within scan reproducibility in n=10 using just the TT 
technique,(203) within and between scan reproducibility in n=17 using just the QA technique,(207) 
Figure 4-5: Bar and scatter plot of change of PWV with exercise 
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or inter-observer comparison but without interscan assessment in n=33.(208) Thus our study of 
both measurement techniques as well as interrogating the effects of different acquisition sequences 
and different post-processing methods provides the first in depth and rigorous assessment of 
pulmonary PWV assessment.   
 
It is perhaps not surprising that the RPA QA PWV measurements were the most precise as the RPA 
suffers from significantly less through plane motion during the cardiac cycle than the MPA as well 
as suffering from less respiratory variation in location. However justification of focusing on one of 
the branch pulmonary arteries rather than the main pulmonary artery relies on changes affecting 
all three arteries equally.  Whilst it may be reasonable to assume this in diffuse pulmonary disease 
states such as COPD or idiopathic pulmonary arterial hypertension, prior work in chronic 
thromboembolic pulmonary hypertension (CTEPH) has demonstrated that the capacitance varies 
between the left and right pulmonary arteries.(267) Thus while the RPA may provide the best 
results in terms of reproducibility, care may have to be taken when using this in disease states, 
particularly CTEPH where despite its greater inter measure variability the MPA may be better 
suited.  Further work is required in other disease states to evaluate the degree of variability in 
measures of pulmonary stiffness.  Further consideration must be given to the fact that there 
appears to be a change in stiffness between the main pulmonary trunk and the branch pulmonary 
arteries observed in our study with both the right and left pulmonary arteries exhibiting lower 
stiffness than the main pulmonary artery.  Current studies demonstrating prognostic significance of 
proximal pulmonary arterial stiffness have all focused on changes in the main pulmonary artery, 
thus these findings will have to be replicated in the right pulmonary artery in order to validate its 
usefulness as a marker of arterial stiffness of prognostic significance. 
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Our finding of improved reproducibility with a lower spatial resolution and higher temporal 
resolution is slightly counter intuitive as it has previously been thought that high spatial resolution 
was the more important factor in QA assessment due to the need for accurate area 
measurement.(193,208) However it may be that increasing the temporal resolution increases the 
datapoints for deriving the flow-area gradient thus improving the reproducibility. Indeed the QAInv, 
which uses all the points in early systole, was seen to be more precise than the QA3 technique, 
which uses only the first three.  The good agreement of QAInv and QA3 compared with QATrad despite 
their different sampling windows and different calculations also shows the importance of 
correcting for the reflected wave in early systole as they both produced significantly lower results 
than the QATrad using both the high spatial resolution and high temporal resolution sequences.  
Previous animal models have shown an early expansion wave arriving during systole in the 
MPA,(157,195) and this becomes even more important in disease when a backward compression 
wave starts to arrive in systole.(189) Recently a phase contrast acquisition technique utilising a 
golden angle radial acquisition has been described in the pulmonary circulation which maintains 
high edge sharpness whilst maintaining good temporal resolution which may further improve the 
reproducibility of this technique.(261) Given that segmentation errors affect both the area and flow 
measurements it would be assumed that this would result in lower reproducibility than the TT 
technique, especially as previous studies in the aorta have shown exactly this.(193,208) It is likely 
that due to the short path length inherent in measuring pulse wave velocity in the pulmonary 
circulation, that small changes in RR variability and flow states result in greater impact on the short 
transit times compared to the relatively longer transit times in the aorta where imaging planes can 
be positioned significant distances apart. 
 
In our study we found no change in pulmonary arterial PWV with exercise.  This is in 
contradistinction to the recent findings of Forouzan et al.(268) who demonstrated an increase in 
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PWV on exercise in a study of n=15 using the QA technique.  This previous study obtained a larger 
increase in cardiac output compared to our own, and was larger than our current exercise group 
(n=10) thus it may be that in our study the participants were insufficiently stressed to illicit a 
change in the proximal pulmonary arterial stiffness, or that the sample size was too small.  However 
there are several reasons to support the accuracy of the findings of the current study. Firstly, our 
measures were obtained during rather than after exercise, and we have used both the TT and QA 
technique with a similar lack of change seen with both.  Secondly, the previous study used the 
QATrad method for calculating the data, which we have shown provides a higher measurement of 
PWV than methods accounting for wave reflections.  Wave reflections are known to increase 
substantially during exercise states thus the change in their PWV may have been due to a change in 
the magnitude of wave reflections rather than a change in arterial stiffness.(157)  Finally our 
observations are in agreement with two prior invasive studies: the first of these by Laskey et 
al.(198) using invasive pressure and velocity wires to calculate the arterial input impedance 
spectrum demonstrated no change in PWV with exercise in healthy controls; and a second by 
Domingo et al. using right heart catheterisation and intravascular ultrasound demonstrating an 
increased pulsatility, but with a fall in elastic modulus and no significant change in capacitance on 
exercise.(269)  
 
We have shown a lack of change in the pulmonary arterial PWV with age in comparison with the 
aorta where the expected increase in PWV was observed. This is in contra-distinction to a recent 
study by Dawes et al. which demonstrated a correlation between pulmonary PWV and age in a 
cohort of n=156.(270)  The fact that using the same technique in the systemic circulation we were 
able to observe a significant change in aortic PWV suggests our technique is robust, but that the 
changes with age in the pulmonary circulation are far smaller than those within the aorta and thus 
require far larger populations to detect. 
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Several limitations must be mentioned regarding this study.  First, no gold standard was used to 
compare the techniques against.  The main reason for this is that the gold standard is invasive right 
heart catheterisation, which in a healthy population with no comorbidities would be difficult to 
justify.  However use of the technique in patients due to undergo a clinically indicated right heart 
catheterisation would be a useful avenue for future work.  In addition, while none were compared 
to the gold standard, reproducibility and reduced interscan variability is as, if not more, important 
than accuracy as it allows detection of smaller changes within the study group of patient cohort of 
interest.  Secondly a high spatial resolution sequence was not applied through either the RPA or 
LPA, thus whilst it is unlikely given the trend of results seen in the MPA, it cannot be excluded that 
higher spatial resolution sequences through these regions would not result in improved 
reproducibility compared with the high temporal resolution sequences.  Thirdly, while the number 
undergoing repeat measurement whilst on table was reasonably sized, those undergoing repeat 
measurement at 6 months was substantially smaller, however the results of this largely mirrored 
the results of the on-table repeat measure thus aiding in the validation of their findings. 
 
4.4 CONCLUSION 
In conclusion use of the QA technique through the right pulmonary artery combined with a high 
temporal resolution acquisition and a post processing technique to account for wave reflections 
yields the most reproducible measurements of pulmonary PWV.    
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CHAPTER 5: Pulmonary arterial stiffness in 
COPD and its role in right ventricular 
remodeling 
 
5 INTRODUCTION 
COPD is the second most common cause of pulmonary hypertension after left sided heart disease 
with the prevalence of this increasing with increasing severity of COPD.(63)  In comparison to other 
causes of pulmonary hypertension the pulmonary pressure elevations are modest, however 
survival is poor and correlates better with the pulmonary pressures and pulmonary vascular 
resistance than with the severity of airflow obstruction.(67–70) The notion of an elevated rest 
pressure as a cut-off is also restrictive in evaluating the role of the pulmonary arteries and right 
heart as even minimal exertion causes marked elevations in mPAP and oxygen desaturation in 
COPD, with exercise induced pulmonary hypertension present in 35%-58% of patients with 
normoxaemia or mild hypoxia.(67,85–87)   
 
The role of pulmonary arterial stiffness in COPD was highlighted in a recent study where an 
increase in pulmonary arterial stiffness was observed during exercise with a greater contribution 
from this to changes in the mean pulmonary arterial pressures (mPAP) than the peripheral vascular 
resistance (PVR).(65)  Pulmonary arterial wall thickness is also related to exercise pulmonary 
pressures rather than resting pulmonary pressures, and to correlate highly with change in pressure 
from rest to exercise.(165)     
 
Pulmonary PWV has been demonstrated to be feasible for the measurement of pulmonary arterial 
stiffness, and to be increased in those with pulmonary hypertension, however has never been used 
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to examine the pulmonary vasculature in COPD.(207,208,271,272)  Thus the aim of the current 
study was to examine pulmonary arterial PWV in COPD and establish its role in right ventricular 
remodeling with the hypothesis that i) PWV would be elevated in those with COPD and ii) that 
elevated PWV would be associated with right ventricular remodeling. 
 
5.1 MATERIAL AND METHODS 
COPD and age and sex matched controls were identified and screened as described in Chapter 3. 
104 COPD participants were screened with 37 excluded due to co-existent coronary artery disease, 
AF, prior thoracotomy, co-existent lung condition, left ventricular systolic dysfunction on echo, or 
no history of smoking.  This left 67 in the cohort.  Of these 58 were included in the final analysis (6 
excluded due to incomplete scan secondary to claustrophobia, 1 due to a history of metal fragments 
in the orbits not picked up in screening, and 2 due to inadequate image quality for analysis).  
 
A healthy control (HC) group was recruited to be approximately age and sex matched, with no prior 
history of cardiac or pulmonary pathology. 
 
All COPD participants underwent spirometry, DLCO, body plethysmography, a 6-minute walk test, 
and a cardiac MRI on the same day.  All study visits were coordinated so that the study participant 
had been free from a COPD exacerbation for 8 weeks prior to attendance for these tests.  All healthy 
controls underwent a cardiac MRI.  Spirometry, DLCO and 6MWT were performed as per ERS/ATS 
guidelines.(255,256)  
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5.1.1 MRI 
All study participants underwent pulmonary phase contrast acquisition of the main pulmonary 
artery using the high temporal resolution sequence described in Chapter 3.  These images were 
analysed using the Davies et al technique (QAINV).  The phase contrast sequence was also used for 
the calculation of pulmonary acceleration time.  A pulmonary cine sequence was used to calculate 
pulmonary pulsatility.  A short axis stack of the ventricles was acquired and used for the analysis of 
right ventricular mass, volumes and function. 
 
5.1.2 Statistics 
Descriptive statistics were used for the analysis of the demographic and clinical features of the 
cohorts with data expressed as mean ± SD.  Normality and equality of variances of the variables was 
tested.  An independent sample t-test was used to compare the differences in continuous variables 
between the HC and COPD cohort, and to compare the difference in continuous variables between 
the top and bottom tertiles of PWV within the COPD cohort. Chi-square, Fisher exact or Mann-
Whitney U tests were used as appropriate to compare differences in ordinal and nominal data 
between the groups.  Pearson or spearman rank co-efficients were used to assess the correlation 
between PWV and demographic, spirometric and MRI factors. All data were analysed using SPSS 
statistical package (version 21.0, SPSS Inc. Chicago, Illinois). Significance was assumed when p < 
0.05. 
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5.2 RESULTS 
58 COPD patients (67.4 ± 9.0 years, 55% male) and 21 healthy controls (60.4 ± 5.1, 48% male) 
completed the study protocol.  Despite approximate age and sex matching, those with COPD were 
significantly older (p<0.001), had a higher BMI (COPD: 26.8 ± 5.2 kg/m2 vs. HC: 24.7 ± 2.5 kg/m2, 
p=0.02), and a higher resting heart rate (COPD: 73.8 ± 20.3 bpm vs. HC: 64.2 ± 11.8 bpm, p=0.05).  
Of those with COPD the majority had moderate COPD with n=12 with GOLD I, n=32 with GOLD II, 
n=13 with GOLD III and n=1 with GOLD IV COPD.  Using the modified British Medical Research 
Council (mMRC) breathlessness score experienced breathlessness was also on the milder end of the 
spectrum with n=5 grade 0, n=26 grade 1, n=14 grade 2, n=11 grade 3 and n=2 grade 4. Full 
baseline characteristics are detailed in Table 5-1. 
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Table 5-1: Demographics of the COPD and healthy control cohorts 
 Healthy controls COPD p 
N 21 58  
Age 60.4 ± 5.1 67.5 ± 9.2 <0.001 
Sex (male) 10 (48%) 30 (52%) 0.75 
BMI (kg/m2) 24.7 ± 2.5 26.8 ± 5.2 0.02 
Heart rate (bpm) 64.2 ± 11.8 73.8 ± 20.3 0.05 
Systolic BP (mmHg) 127.6 ± 13.9 131.1 ± 20.0 0.47 
Diastolic BP (mmHg) 74.7 ± 7.8 75.1 ± 8.5 0.85 
Smoking status 
Current smoker 2 (10%) 17 (29%) 0.07 
Ex-smoker 7 (33%) 41 (71%) 0.003 
Never smoker 12 (57%) 0 (0%) <0.001 
Pack years 4.68 ± 7.4 48.5 ± 24.0 <0.001 
Medications 
SABA  54 (93%)  
SAMA  1 (2%)  
LABA  8 (14%)  
LAMA  36 (62%)  
ICS  7 (12%)  
LABA/ICS combo   28 (48%)  
Oral steroid 2 (10%) 4 (7%)  
Antibiotics  2 (3%)  
Theophylline  4 (7%)  
Mucolytics  9 (16%)  
GOLD status 
I  12 (21%)  
II  32 (55%)  
III  13 (22%)  
IV  1 (2%)  
mMRC grade 
0  5 (9%)  
1  26 (45%)  
2  14 (24%)  
3  11 (19%)  
4  2 (3%)  
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Those with COPD demonstrated evidence of pulmonary arterial stiffening and pulmonary vascular 
remodeling with higher pulmonary artery area at end diastole (COPD: 2.36 ± 0.56 cm2/m1.7 vs. HC: 
2.14 ± 0.28 cm2/m1.7, p=0.027), reduced pulsatility (COPD: 24.88 ± 8.84 % vs. HC: 30.55 ± 11.28 %, 
p=0.021), reduced PAT (COPD: 104.0 ± 22.9 ms vs. HC: 128.1 ± 32.2 ms, p<0.001) and higher PWV 
(COPD: 2.62 ± 1.29 ms-1 vs. HC: 1.78 ± 0.72 ms-1, p=0.001).  Compared with the HCs those with 
COPD had significantly smaller right ventricular end diastolic volumes (HC: 59.9 ± 13.0 ml/m1.7 vs. 
COPD: 53.6 ± 11.1 ml/m1.7, p=0.037), stroke volume (HC: 37.1 ± 6.2 ml/m1.7 vs. COPD: 31.9 ± 6.9 
ml/m1.7, p=0.003), and right ventricular mass:volume ratio (HC: 0.27 ± 0.04 g/ml vs. COPD: 0.31 ± 
0.06 g/ml, p=0.004) (See Table 5-2 for full right ventricular and pulmonary arterial parameters). 
 
Table 5-2: Ventricular quantification and measures of pulmonary arterial stiffness and 
haemodynamics in the healthy control and COPD cohort. 
 Healthy controls COPD p 
N 21 58  
Right ventricle 
RVEDV (ml/m1.7) 59.9 ± 13.0 53.6 ± 11.1 0.037 
RVESV (ml/m1.7) 22.9 ± 8.6 21.8 ± 7.3 0.58 
RVSV (ml/m1.7) 37.1 ± 6.2 31.9 ± 6.9 0.003 
RVEF (%) 63.0 ± 7.9 59.8 ± 7.8 0.10 
RVM (g/m1.7) 15.8 ± 3.2 16.3 ± 3.4 0.53 
RVMVR (g/ml) 0.27 ± 0.04 0.31 ± 0.06 0.004 
Pulmonary artery 
Max area (cm2/m1.7) 2.80 ± 0.48 2.94 ± 0.74 0.33 
Min Area (cm2/m1.7) 2.14 ± 0.28 2.36 ± 0.56 0.027 
Pulsatility (%) 30.55 ± 11.28 24.88 ± 8.84 0.021 
PAT (ms) 128.1 ± 32.2 104.0 ± 22.9 <0.001 
PWV (ms-1) 1.78 ± 0.72 2.62 ± 1.29 0.001 
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PWV was associated with BMI (R=-0.28, p=0.03) and diastolic blood pressure (R=0.35, p=0.009), 
and total lung capacity (R=0.28, p=0.039), but did not demonstrate any significant association with 
any right ventricular parameters (see Table 5-3).  To further explore any potential relationship 
between right ventricular mass and end diastolic volumes, scatter plots were performed looking at 
linear and quadratic associations (see Figure 5-1) however neither of these revealed a significant 
association. 
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Figure 5-1:  Scatter plots comparing pulmonary PWV against RVM (A and B) and RVEDV (C 
and D) 
A.      B. 
 
C.      D. 
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Table 5-3: Correlation co-efficients of PWV with demographic, spirometric and right 
ventricular measures. 
 PWV 
 R p 
Age 0.04 0.15 
BMI (kg/m2) -0.28 0.03 
Heart rate (bpm) 0.20 0.14 
Systolic BP (mmHg) 0.14 0.29 
Diastolic BP (mmHg) 0.35 0.009 
SpO2 -0.06 0.65 
Pack years 0.01 0.94 
FEV1, % predicted -0.16 0.24 
FVC, % predicted -0.07 0.61 
FEV1/FVC -0.18 0.18 
FEF 25-75, % predicted -0.11 0.40 
DLCO, % predicted -0.05 0.73 
DLCO/VA, % predicted -0.07 0.60 
RLV, % predicted 0.25 0.067 
VC, % predicted -0.02 0.88 
TLC, % predicted 0.28 0.039 
RLV /TLC 0.21 0.13 
6MWT (m) -0.17 0.20 
RVEDV (ml/m1.7) -0.12 0.39 
RVESV (ml/m1.7) -0.20 0.14 
RVSV (ml/m1.7) 0.02 0.86 
RVEF (%) 0.18 0.18 
RVM (g/m1.7) -0.24 0.067 
RVMVR (g/ml) -0.14 0.31 
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As the pulmonary stiffness did not appear to affect cardiac remodeling and the cardiac remodeling 
appeared to be that of a reduced preload rather than an increased afterload the determinants of the 
cardiac volumes were examined as detailed in Table 5-4.  RVEDV and LVEDV demonstrated a 
strong correlation with one another (R=0.64, p<0.001).  Both RVEDV and LVEDV demonstrated 
significant correlations with heart rate (RVEDV R=-0.41, p=0.04; LVEDV R=-0.30, p=0.02) and DLCO 
(RVEDV R=0.29, p=0.03; LVEDV R=0.28, p=0.03), with RVEDV also showing a significant correlation 
with KCO (RVEDV R=0.27, p=0.046) and BMI (RVEDV R=0.27, p=0.04). 
 
Table 5-4: Correlation co-efficients between right and left ventricular end diastolic volumes 
and demographic, spirometric and pulmonary measures. 
 RVEDV LVEDV 
r p r p 
Age -0.05 0.69 -0.02 0.99 
BMI (kg/m2) 0.27 0.04 0.21 0.11 
Heart rate (bpm) -0.41 0.002 -0.30 0.02 
Systolic BP (mmHg) 0.02 0.90 0.14 0.31 
Diastolic BP (mmHg) -0.13 0.35 -0.07 0.63 
SpO2 (%) -0.02 0.91 0.03 0.85 
Pack years 0.11 0.41 0.05 0.69 
FEV1, % predicted 0.22 0.09 0.18 0.17 
FVC, % predicted 0.13 0.35 0.03 0.81 
FEV1/FVC 0.21 0.12 -0.11 0.44 
FEF 25-75, % predicted 0.23 0.08 0.23 0.08 
DLCO, % predicted 0.29 0.03 0.28 0.03 
KCO, % predicted 0.27 0.046 0.25 0.06 
RLV, % predicted -0.21 0.12 -0.02 0.91 
TLC, % predicted -0.23 0.10 0.12 0.38 
VC, % predicted 0.11 0.44 0.21 0.12 
RLV/TLC -0.20 0.15 -0.17 0.23 
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5.3 DISCUSSION 
COPD is associated with significant pulmonary arterial remodeling and stiffening, however this 
stiffening is not associated with adverse right ventricular remodeling.  The former confirms our 
pre-study hypothesis but the latter goes against it thus requiring some examination.   
 
This is the first study examining PWV in COPD, demonstrating an elevated pulmonary PWV.  The 
fact that an increased PWV was accompanied by a fall in PAT and a fall in the pulsatility provides 
further confirmatory evidence that significant central pulmonary vascular remodeling is present 
within the COPD cohort.  This is consistent with histological observation in those with severe COPD 
undergoing volume reduction surgery.(165) In the current study we found that while there was a 
significant elevation in PWV, this was not associated with right ventricular remodeling or a 
significant decline in functional status or performance.  A previous echocardiographic study has 
demonstrated reduced right artery pulsatility in a cohort of 54 COPD patients, with this correlating 
with New York Heart Association (NYHA) functional status.(186) However the limitation of using 
pulsatility is that it falls as stroke volume falls independent of the vascular wall stiffness.  As a 
reduced right ventricular function was indeed present in this prior study, with this also falling with 
worsening NYHA status and no multivariable analysis performed, the true impact of pulmonary 
stiffness on functional status cannot be determined. Another previous study in n=98 COPD patients 
has shown elevated pulmonary arterial stiffness on exercise with this correlating better with 
exercise induced pulmonary hypertension than pulmonary vascular resistance.  This previous study 
examined the more severe end of the COPD spectrum with 62% of their cohort being either GOLD 
III or IV compared with only 24% in the current study.  Previous work in pulmonary hypertension 
has demonstrated a significant increase in pulmonary arterial stiffness before a rapid 
decompensation occurs in right ventricular function.(141) Thus the lack of association between 
PWV and right ventricular function in the current study may be secondary to the milder disease 
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present in the current cohort with the cohort yet to enter the level of arterial stiffening associated 
with rapid ventricular decompensation. 
 
In fact, despite the elevated arterial stiffness, the right ventricular remodeling evident in our study 
was that of a reduced preload rather than an increased afterload with evidence of smaller right 
ventricular volumes, smaller stroke volume and no significant increase in right ventricular mass.  A 
similar pattern was observed in a small study of 24 COPD patients by Wells et al., where pulmonary 
arterial dilation was not associated with any increase in right ventricular mass despite being 
associated with a fall in RVEF.(273) In the current work, both right and left ventricular volumes 
demonstrated a moderate correlation with DLCO suggesting that emphysema is somehow causing 
the reduction in cardiac volumes.  This observation is consistent with observations in the MESA-
COPD cohort which also showed reduced right ventricular volumes with increasing emphysema 
burden.(274) A further argument in favour for this is the strong correlation between RVEDV and 
LVEDV, with both being associated with the same factors.  In pulmonary hypertension the right 
ventricle is classically dilated and hypertrophied with the left ventricle being underfilled with a 
reduced mass, thus remodeling occurring in parallel between the two chambers suggests it is not 
the vasculature that lies between them, but a more systemic influence affecting this.(275) Thus the 
current study adds to the current literature that in a contemporary community population with 
COPD, the primary cardiac effects are those of emphysema induced preload reduction rather than 
that of cor pulmonale.(274,276) The precise mechanism by which emphysema results in 
underfilling of the ventricles remains unclear.  While a single study utilising echocardiography 
found a significant link between hyperinflation and ventricular underfilling,(277) both this study 
and the MESA-COPD study utilising cardiac MRI found no link between hyperinflation and 
ventricular volumes.  Given that MRI is the gold standard for the assessment of ventricular volumes 
and mass, and the agreement between these two CMR based studies the evidence would suggest 
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that it is not emphysema induced hyperexpansion and hyperinflation that is causing the 
underfilling.  Remaining possibilities are that the emphysema causes increased intra-thoracic 
pressure resulting in an increased pressure gradient between the thoracic cavity and abdominal 
and extra-thoracic venous return impeding the inflow to the heart.  Alternately it may be that 
emphysema is associated with global ventricular stiffening and diastolic dysfunction.  Indeed 
multiple studies have demonstrated diastolic dysfunction in COPD,(78,278,279) however others 
have suggested the impaired relaxation of the ventricles is itself due to impaired venous return 
rather than true ventricular stiffening.(46) 
 
As both the MESA-COPD cohort and the current study are predominantly within the milder 
spectrum of COPD, further work is required to determine if, as the disease progresses into the very 
severe end of the spectrum a shift occurs from a preload driven phenotype into an afterload driven 
phenotype.  This is an important clinical consideration as both require different management 
strategies with the former benefiting from volume reduction strategies(280), while the latter 
benefits from medications targeting the pulmonary vasculature.(216) Further examination in a 
more severe disease cohort is even more important as, if the same right ventricular pattern of 
preload remodeling is still present, it may provide a significant explanatory factor as to the 
continued failure of traditional pulmonary hypertension medications in a COPD cohort.(213–
215,217) 
 
One final consideration must be made, and that is that central pulmonary arterial stiffening as 
captured by PWV is not in fact a manifestation of pulmonary disease but that of a global arterial 
stiffening affecting both the pulmonic and systemic arteries.  Multiple studies have demonstrated 
systemic arterial stiffening in those with COPD when compared with matched smokers, for this to 
correlate with the percentage of emphysema, and to reduce with inhaler treatment for 
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COPD.(23,24,26)  It has also been shown that those with COPD who are taking statins have lower 
pulmonary pressures on right heart catheterisation than those not on statins, and that statins are 
associated with improved functional capacity and lower mortality in COPD.(222,224,225)  One 
supportive finding in the current study is that pulmonary PWV was associated with an elevated 
diastolic blood pressure which is increased in those with elevated systemic PWV.(23,281) Thus the 
disease process afflicting the pulmonary arteries may simply be the same pathological process 
underpinning the well documented systemic arterial remodeling. 
 
There are several limitations within the current study.  As previously mentioned the current cohort 
were predominantly earlier stage COPD, although as this is the main subtype seen in the 
community this more accurately reflects the clinical environment rather than a study focusing on 
the severe end of the spectrum.  The healthy controls included smokers, with no pulmonary 
function tests performed within this cohort, thus subclinical COPD may have been present.  
However this would only have lessened any observed differences in pulmonary arterial stiffness or 
right ventricular remodeling, thus our observation of increased pulmonary arterial stiffness and 
reduced cardiac volumes in the COPD cohort remains robust to this confounder.  Finally, in the 
previous chapter we have seen that a high temporal resolution in excess of the one used in the 
current study (7ms versus 12ms used in the current cohort) through the right pulmonary artery 
provides more reproducible measures of pulmonary arterial PWV than an acquisition through the 
main pulmonary artery using a slightly lower temporal resolution.(282)  However, arterial 
stiffening is known to occur asymmetrically between the right and left pulmonary artery in some 
disease states,(267) thus the main pulmonary artery was chosen in the current study to ensure 
early remodeling was not missed or underestimated by inadvertently choosing a side with lower 
disease burden. 
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5.4 CONCLUSION 
In conclusion, while pulmonary artery stiffening is present in those with COPD this has no 
significant associations with right ventricular remodeling or functional capacity. 
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CHAPTER 6:  Pulmonary arterial stiffness: 
Pulmonary induced or merely another 
manifestation of systemic atherosclerosis  
  
 
6 INTRODUCTION 
Despite being a disease of the pulmonary parenchyma, chronic obstructive pulmonary disease 
(COPD) is associated with significant cardiac morbidity and mortality, with up to 43% of mortality 
in COPD secondary to cardiovascular causes.(283–285)  However the precise cause of this is 
controversial with several mechanisms proposed.(1)  One proposed mechanism is that of COPD 
causing downstream inflammatory changes and resultant increased arterial stiffness – a known risk 
factor for future cardiovascular mortality.(199)  Indeed, multiple studies have demonstrated 
systemic arterial stiffening in those with COPD when compared with matched smokers, and for this 
to correlate with the percentage of emphysema, and for COPD therapy to result in an improvement 
in arterial stiffness.(23,24,26) 
 
Another viable hypothesis is that of COPD related pulmonary vascular remodeling resulting in heart 
failure.  Pulmonary hypertension is prevalent in those with moderate to severe COPD, and is 
associated with a poor prognosis.(67,68,70)  In addition, pulmonary arterial stiffness is raised in 
those with pulmonary hypertension in COPD and correlates with exercise capacity.  It has also been 
shown that those with COPD who are taking statins have lower pulmonary pressures on right heart 
catheterisation than those not on statins, and that statins are associated with improved functional 
capacity and lower mortality in COPD.(222,224,225)  Given that statins improve systemic 
cardiovascular disease and mediate adverse vascular remodeling in atherosclerosis,(228,286) it 
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may thus be posited that the disease process afflicting the pulmonary arteries may simply be the 
same pathological process underpinning the well documented systemic arterial remodeling.  We 
saw in the previous chapter that pulmonary PWV was elevated in COPD but did not correlate with 
right ventricular remodeling, adding further weight to this consideration. 
 
Thus the aim of the current study was to examine the association between aortic and pulmonary 
arterial remodeling and their effects on cardiac remodeling with the hypothesis that i) aortic and 
pulmonary stiffening occur independently of each other and ii) that elevated systemic PWV would 
be associated with ventricular remodeling in the left but not the right ventricle. 
 
6.1 MATERIALS AND METHODS 
COPD and age and sex matched controls were identified and screened as described in Chapter 3. 
104 COPD participants were screened with 37 excluded due to co-existent coronary artery disease, 
AF, prior thoracotomy, co-existent lung condition, left ventricular systolic dysfunction on echo, or 
no history of smoking.  This left 67 in the cohort.  Of these, 56 were included in the final analysis (6 
excluded due to incomplete scan secondary to claustrophobia, 1 due to a history of metal fragments 
in the orbits not picked up in screening, and 4 due to inadequate image quality for analysis).  
 
All COPD participants underwent spirometry, DLCO, a six-minute walk test (6MWT), and a cardiac 
MRI on the same day.  All healthy controls underwent a cardiac MRI.  Spirometry, DLCO and 6MWT 
were performed as per ERS/ATS guidelines.(255,256)  
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6.1.1 MRI 
All study participants underwent pulmonary phase contrast acquisition of the main pulmonary 
artery using the high temporal resolution sequence described in Chapter 3.  These images were 
analysed using the Davies et al technique (QAINV).  Similarly, the aortic PWV was calculated as 
previously described.  A short axis stack of the ventricles was acquired and used for the analysis of 
right and left ventricular mass, volumes and function. 
 
6.1.2 Statistics 
Descriptive statistics were used for the analysis of the demographic and clinical features of the 
cohorts with data expressed as mean ± SD.  Normality and equality of variances of the variables was 
tested.  An independent sample t-test was used to compare the differences in continuous variables 
between the HC and COPD cohort. Chi-square, Fisher exact or Mann-Whitney U tests were used as 
appropriate to compare differences in ordinal and nominal data between the groups.  Pearson or 
spearman rank co-efficients were used to assess the correlation between aortic and pulmonary 
PWV, and to look at the correlates of both of these with baseline demographic, spirometric and MRI 
factors in the COPD cohort, excluding the healthy cohort from this and the linear regression.  
Multiple linear regression analysis was performed with sPWV and pPWV entered separately as the 
dependent variable with those factors which were p<0.1 on single variable analysis entered as 
independent variables.  All data were analysed using SPSS statistical package (version 21.0, SPSS 
Inc. Chicago, Illinois). Significance was assumed when p < 0.05. 
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6.2 RESULTS 
56 COPD patients (67.4 ± 9.0 years, 55% male) and 20 healthy controls (60.4 ± 5.1, 48% male) 
completed the study protocol.  Despite approximate age and sex matching, those with COPD were 
significantly older (p<0.001), had a higher BMI (COPD: 26.8 ± 5.3 kg/m2 vs. HC: 24.6 ± 2.5 kg/m2, 
p=0.02).  While those with COPD had a significantly higher prevalence of hypertension, there was 
no significant difference in blood pressure or pulse pressure due to a higher prevalence of 
antihypertensive medication prescription. Full baseline characteristics are detailed in Table 6-1. 
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Table 6-1: Demographics of the COPD and healthy control cohorts 
 Healthy controls COPD p 
N 20 56  
Age 60.1 ± 4.9 67.5 ± 9.3 <0.001 
Sex (male) 9 (45%) 29 (52%) 0.60 
BMI (kg/m2) 24.6 ± 2.5 26.8 ± 5.3 0.02 
Heart rate (bpm) 64.4 ± 12.1 74.0 ± 20.7 0.061 
Systolic BP (mmHg) 128.5 ± 13.7 130.8 ± 20.4 0.65 
Diastolic BP (mmHg) 75.0 ± 7.9 75.1 ± 8.6 0.95 
Pulse Pressure (mmHg) 53.5 ± 9.4 55.7 ± 18.7 0.63 
Hypertension 2 (10%) 24 (43%) 0.012 
Hypercholesterolaemia 3 (15%) 3 (5%) 0.18 
Diabetes 0 (0%) 9 (16%) 0.1 
Smoking status 
Current smoker 2 (10%) 17 (30%) 0.08 
Ex-smoker 7 (35%) 39 (70%) 0.009 
Never smoker 11 (55%) 0 (0%) <0.001 
Pack years 4.92 ± 7.5 48.5 ± 23.6 <0.001 
Medications 
Aspirin 1 (5%) 9 (16%) 0.28 
Beta-blocker 1 (5%) 3 (5%) 1 
Diuretic 0 (0%) 9 (16%) 0.10 
Calcium-channel blocker 1 (5%) 15 (27%) 0.055 
ACEi/AIIA 0 (0%) 8 (14%) 0.10 
Statin 4 (20%) 14 (25%) 0.77 
GOLD status 
I  11 (20%)  
II  31 (55%)  
III  13 (23%)  
IV  1 (2%)  
mMRC grade 
0  5 (9%)  
1  26 (46%)  
2  13 (23%)  
3  10 (18%)  
4  2 (4%)  
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Those with COPD demonstrated a higher aortic PWV although this was not statistically significant 
(COPD: 8.7 ± 2.7 ms-1 vs. HC: 7.4 ± 2.1 ms-1, p=0.06) and a significantly higher pulmonary PWV 
(COPD: 2.6 ± 1.3 ms-1 vs. HC: 1.8 ± 0.7 ms-1, p=0.006).  Compared with the HCs those with COPD had 
a significantly lower RV stroke volume (COPD: 31.7 ± 7.0 ml/m1.7 vs. HC: 36.6 ± 5.9 ml/m1.7, 
p=0.007), and a higher right ventricular mass:volume ratio (COPD: 0.29 ± 0.05 g/ml vs. COPD: 0.25 
± 0.04 g/ml, p=0.012).  Those with COPD also had significantly higher left ventricular mass:volume 
ratio (COPD 0.78 ± 0.13 g/ml vs. 0.70 ± 0.09 g/ml, p=0.009). (See Table 6-2 for full ventricular and 
pulmonary arterial parameters). 
 
Table 6-2: Ventricular quantification and measures of PWV in the healthy control and COPD 
cohort. 
 Healthy controls COPD p 
N 21 56  
Right ventricle 
RVEDV (ml/m1.7) 58.7 ± 12.1 53.6 ± 11.2 0.09 
RVESV (ml/m1.7) 22.2 ± 8.2 21.9 ± 7.4 0.87 
RVSV (ml/m1.7) 36.6 ± 5.9 31.7 ± 7.0 0.007 
RVEF (%) 63.3 ± 7.9 59.6 ± 7.9 0.08 
RVM (g/m1.7) 14.7 ± 2.4 15.2 ± 3.2 0.50 
RVMVR (g/ml) 0.25 ± 0.04 0.29 ± 0.05 0.012 
Left ventricle 
LVEDV (ml/m1.7) 59.0 ± 9.2 56.1 ± 12.1 0.33 
LVESV (ml/m1.7) 23.4 ± 6.1 23.4 ± 9.4 0.99 
LVSV (ml/m1.7) 35.6 ± 4.8 32.7 ± 6.7 0.09 
LVEF (%) 60.7 ± 6.0 59.1 ± 8.6 0.46 
LVM (g/m1.7) 41.0 ± 7.4 43.3 ± 9.5 0.33 
LVMVR (g/ml) 0.70 ± 0.09 0.78 ± 0.13 0.009 
Pulse wave velocity 
Aortic PWV 7.35 ± 2.1 8.67 ± 2.7 0.06 
Pulmonary PWV 1.76 ± 0.7 2.63 ± 1.3 0.006 
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Pulmonary PWV correlated with percentage predicted total lung capacity (rho=0.28, p=0.046), 
inversely correlated with BMI (rho=-0.28, p=0.04) and correlated with increasing diastolic blood 
pressure (rho=0.36, p=0.01).  See Table 6-3 for full correlates.  On multiple variable backward 
linear regression, diastolic blood pressure (ß = 0.28, p=0.035) and percentage predicted total lung 
capacity (ß = 0.30, p=0.028) remained significantly associated with pPWV. 
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Table 6-3: Correlation co-efficients between Aortic PWV and Pulmonary PWV and 
demographic and ventricular measures. 
 Pulmonary PWV Aortic PWV 
r p r p 
Age 0.03 0.81 0.45 0.001 
BMI (kg/m2) -0.28 0.036 -0.04 0.78 
Heart rate (bpm) 0.21 0.15 0.02 0.91 
Systolic BP (mmHg) 0.15 0.29 0.31 0.03 
Diastolic BP (mmHg) 0.36 0.01 0.22 0.12 
Pulse Pressure (mmHg) 0.000 1 0.24 0.09 
SpO2 (%) -0.06 0.68 -0.07 0.64 
Pack years 0.004 0.98 -0.13 0.36 
FEV1, % predicted -0.15 0.28 0.05 0.70 
FVC, % predicted -0.06 0.64 -0.03 0.85 
FEV1/FVC -0.17 0.21 0.07 0.64 
DLCO, % predicted -0.05 0.73 0.30 0.03 
KCO, % predicted -0.08 0.56 0.46 <0.001 
RLV, % predicted 0.25 0.08 -0.10 0.50 
TLC, % predicted 0.28 0.046 -0.05 0.71 
VC, % predicted -0.02 0.90 0.03 0.83 
RLV/TLC 0.20 0.15 0.12 0.40 
RVEDV (ml/m1.7) -0.12 0.39 0.08 0.59 
RVESV (ml/m1.7) -0.21 0.13 0.19 0.17 
RVSV (ml/m1.7) 0.03 0.83 -0.07 0.62 
RVEF (%) -0.19 0.19 -0.19 0.16 
RVM (g/m1.7) -0.25 0.067 0.19 0.18 
RVMVR (g/ml) -0.15 0.27 0.19 0.17 
LVEDV (ml/m1.7) -0.08 0.58 -0.03 0.83 
LVESV (ml/m1.7) -0.11 0.44 0.02 0.89 
LVSV (ml/m1.7) 0.001 0.99 -0.08 0.55 
LVEF (%) 0.14 0.30 -0.06 0.67 
LVM (g/m1.7) -0.18 0.20 0.17 0.22 
LVMVR (g/ml) -0.13 0.33 0.34 0.01 
Pulmonary PWV - - -0.004 0.97 
Aortic PWV -0.004 0.97 - - 
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In comparison aortic PWV showed a significant association with age (rho=0.47, p<0.001), systolic 
blood pressure (rho=0.32, p=0.02), and percentage predicted KCO (rho=0.43, p=0.001). On linear 
regression, age (ß = 0.30, p=0.02), systolic blood pressure (ß = 0.27, p=0.04), and percentage 
predicted KCO (ß = 0.37, p=0.003) all remained significantly associated with aortic PWV. 
 
sPWV was significantly associated with LVMVR (rho=0.34, p=0.01), while no such correlation was 
seen between pPWV and RVMVR (rho= -0.15, p=0.27).  Similarly, there was no significant 
association between aortic and pulmonary PWV (rho=-0.004, p=0.97) – See Figure 6-1.  
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Figure 6-1: Scatterplots of (A) Aortic PWV against Pulmonary PWV; (B) Pulmonary PWV 
against RVMVR; and (C) Aortic PWV against LVMVR 
A)   
 
B) 
 
C) 
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6.3 DISCUSSION 
In this study we have seen that while both pulmonary and systemic arteries are stiffer in COPD 
compared with matched controls, these processes occur independently from one another.  Not only 
was no correlation seen between the systemic and pulmonary PWV, but also they are associated 
with different risk factors from one another.  While aortic PWV was associated with age and systolic 
blood pressure, pulmonary PWV showed an association with lung hyperexpansion, and diastolic BP.  
Finally while there was no significant association between pulmonary PWV and right ventricular 
remodeling, a correlation was seen between aortic PWV and left ventricular mass:volume ratio 
which is a marker of concentric myocardial remodeling.(287) 
 
Our finding of increased aortic stiffness is consistent with previous work demonstrating increased 
sPWV in those with COPD.  The underlying cause of the increased systemic arterial stiffness in 
COPD is still a topic of debate.  Several groups have demonstrated an association between aortic 
PWV and inflammatory markers,(25) FEV1,(288) or %emphysema measured on CT,(24) while 
other groups have found no such correlation with any of these metrics.(25,289,290)  In the current 
study we found that those with COPD the aortic PWV to be independently associated with age and 
blood pressure, but not FEV1 or measures of hyperexpansion.  Of note we also observed a 
significant positive correlation with KCO, only one other group has simultaneously examined KCO 
and aortic PWV in COPD, finding no significant correlation, thus the significance of this is 
uncertain.(25) Our finding of a significant association between LVMVR – a marker of concentric left 
remodeling – and aortic PWV provides significant mechanistic insight into the interface between 
the pulmonary and cardiovascular disease evident in COPD.  As with increased aortic PWV multiple 
studies have documented left ventricular hypertrophy in COPD, demonstrating both a high 
prevalence and with significant implications for mortality in a COPD cohort.(40,41,291) While the 
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association of PWV and left ventricular mass has been described in the general 
population,(292,293) to the best of the authors knowledge, no studies have examined the role of 
pulmonary arterial stiffness as a linking mechanism in COPD.  Given that LVMVR is a known risk 
factor for future cardiovascular events this association may help explain both the increased 
cardiovascular risk in COPD and the beneficial effects in COPD of beta-blockers - a known regressor 
of left ventricular mass (albeit less pronounced than other anti-hypertensives).(43,294,295) 
 
Pulmonary PWV was not associated with age or systolic blood pressure, but was instead associated 
with pulmonary hyperinflation and diastolic blood pressure.  In addition it did not show any 
significant association with right ventricular remodeling, unlike aortic PWV. Previous work has 
described pulmonary arterial stiffening to be significantly associated with exercise induced 
elevations in pulmonary pressures,(65,165) however we found no link between this and right 
ventricular remodeling, therefore while the pressures may elevated in exercise the clinical 
significance of this is uncertain.  Longitudinal studies will be required to determine the long-term 
implications of pulmonary arterial stiffening.   
 
There are several limitations to the current study.  Patients with known coronary artery disease 
were excluded, thus the results may not be representative of the wider COPD cohort in whom 
cardiovascular disease is common.  We also used two different techniques for the MRI assessment 
of the aortic and pulmonary PWV, using a transit time method in the aorta and a flow-area 
technique within the pulmonary artery.  This was done as the former is more accurate in longer 
vessels such as the aorta,(193) however the short pulmonary artery is less amenable to this due to 
the rapid transition times and prior work has shown the transit time within the pulmonary arteries 
to be less reproducible than the flow-area technique.(282)  In addition the two techniques 
demonstrate reasonable agreement with one another.(296) 
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6.4 CONCLUSION 
In conclusion, both aortic and pulmonary arterial stiffening occur in COPD, but these processes 
develop independent of one another with aortic but not pulmonary PWV demonstrating a 
significant association with remodeling in the ventricle.    
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CHAPTER 7: Effect of pulmonary arterial 
stiffness on longitudinal changes in cardiac 
remodeling. 
 
 
7 INTRODUCTION 
In the preceding chapters we have seen that pulmonary PWV is elevated in COPD but that it does 
not correlate with spirometric markers of COPD, right ventricular parameters, or functional 
capacity.  However while a lack of correlation combined with a cardiac phenotype of a reduced 
preload rather than an increased afterload would suggest that there is no causative link between 
pulmonary arterial stiffness and cardiac remodeling and morbidity, longitudinal studies are 
required to determine these.   
 
The aim of the current arm of the study was to answer this point, following the COPD participants 
up at 1 year to examine changes in right ventricular remodeling with the hypothesis that those with 
stiffer arteries at baseline would undergo greater cardiac remodeling evidenced by an increase in 
right ventricular mass. 
 
7.1 MATERIALS AND METHODS 
All participants recruited and scanned for the main study before August 2015 went on to have a 1-
year follow-up scan.   Of the 49 who were scanned prior to this date, 35 underwent their follow-up 
examination.  16 were lost due to: pacemaker insertion (n=1), lung cancer diagnosed on initial CMR 
and receiving treatment for this (n=2), interval diagnosis of bladder cancer (n=2), unwilling to 
undergo repeat CMR (n=1), recurrent chest infections (as needed to be free from exacerbations for 
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2 months)(n=2), withdrawal from the study (n=2), unable to contact (n=6).  Of the 35 scanned, 1 
had to be abandoned due to claustrophobia despite having successfully completed their CMR the 
preceding year, leaving 34 in the final analysis. 
 
All participants underwent spirometry, DLCO, body plethysmography, a 6-minute walk test, and a 
cardiac MRI on the same day using the same techniques and machines as on the first visit.  These 
were performed as described in chapter 3. 
 
7.1.1 Statistics 
Descriptive statistics were used for the analysis of the demographic and clinical features of the 
cohorts with data expressed as mean ± SD.  Normality and equality of variances of the variables was 
tested. A paired sample t-test was used to compare baseline and 1 year follow-up metrics and to 
compare those that underwent follow-up imaging compared to those who only underwent a 
baseline visit.  A bonferroni correction factor was applied to ameliorate the risk of alpha error from 
multiple pairwise comparisons.   An independent sample t-test was used to compare the difference 
in continuous variables between the top and bottom tertiles of PWV within the COPD cohort. Chi-
square, Fisher exact or Mann-Whitney U tests were used as appropriate to compare differences in 
ordinal and nominal data between the groups.  Pearson or spearman rank co-efficients were used 
to assess the correlation between PWV and demographic, spirometric and MRI factors. All data 
were analysed using SPSS statistical package (version 21.0, SPSS Inc. Chicago, Illinois). Significance 
was assumed when p < 0.05. 
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7.2 RESULTS 
32 (68.6 ± 8.2 years, 50% male) completed the full study protocol.  Those who completed the study 
protocol had a significantly lower baseline heart rate than those who dropped out (69.1 ± 18.2 vs. 
80.5 ± 21.7 bpm, p=0.039), but were otherwise matched in demographics, pulmonary 
function, and cardiac mass and function.   The demographics and baseline characteristics of the 
32 who underwent repeat CMR compared with those who only attended the baseline visit are 
described in Table 7-1. 
 
At follow-up ten participants had had a serious adverse health event in the interval:  Infective 
exacerbation of COPD, n=4; TIA, n=1, Ureteronephrectomy for urothelial malignancy n=1; Head 
injury, n=1; Ankle fracture, n=1, Wrist fracture, n=1; Colitis, n=1.  Ten participant had had their 
medications changed with those pertinent to COPD being: Seretide exchanged for Fostair, n=1; 
Glycopyrronium started, n=2; Indacaterol started, n=1; Combined glycopyrronium/indacaterol 
inhaler started, n=1. 
 
At 1 year follow up, there was no significant change in allometric measures or clinical observations.  
On repeat pulmonary function testing there was significant increase in KCO (from 71.4±19.8 to 
78.0±19.5 % predicted, p<0.001), and a significant fall in 6MWT (from 473±97 to 445±99m, 
p=0.001). The pulmonary PWV also showed a significant interval increase from 2.31±1.0 to 3.4 ±1.4 
ms-1 (+47%, p<0.001)(See Figure 7-1).  
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Table 7-1: Comparison of those who only underwent baseline scan compared with those 
who completed both study visits. 
 Baseline only cohort Follow-up cohort p 
N 26 32  
Age 66.1 ± 10.4 68.6 ± 8.2 0.31 
Sex (male) 14 (54%) 16 (50%) 0.77 
BMI (kg/m2) 26.4 ± 5.3 27.1 ± 5.3 0.63 
Heart rate (bpm) 80.5 ± 21.7 69.1 ± 18.2 0.039 
Systolic BP (mmHg) 130 ± 24 132 ± 17 0.74 
Diastolic BP (mmHg) 76 ± 9 74 ± 8 0.39 
SpO2 95.9 ± 1.9 95.9 ± 1.7 0.98 
Smoking status 
Current smoker 11 (42%) 6 (19%) 0.08 
Ex-smoker 15 (58%) 26 (81%) 0.08 
Never smoker 0 0 1 
Pack years 44.0 ± 18.7 52.1 ± 27.3 0.20 
Medications 
SABA 25 (96%) 29 (91%) 0.62 
SAMA 1 (4%) 0 0.45 
LABA 4 (15%) 4 (13%) 1 
LAMA 16 (62%) 20 (77%) 0.94 
ICS 1 (4%) 6 (19%) 0.12 
LABA/ICS combo  15 (58%) 13 (41%) 0.20 
Oral steroid 1 (4%) 3 (9%) 0.62 
Antibiotics 1 (4%) 1 (3%) 1 
Theophylline 2 (8%) 2 (6%) 1 
Mucolytics 4 (15%) 5 (16%) 1 
GOLD status 
I 4 (15%) 8 (25%) 0.61 
II 16 (62%) 16 (50%)  
III 6 (23%) 7 (22%)  
IV 0 1 (3%)  
mMRC grade 
0 2 (8%) 3 (9%) 0.17 
1 10 (38%) 16 (50%)  
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2 9 (73%) 5 (16%)  
3 3 (12%) 8 (25%)  
4 2 (8%) 0  
Pulmonary Function tests    
FEV1, % predicted 66.9 ± 22.7 65.5 ± 21.0 0.81 
FVC, % predicted 99.2 ± 21.5 100.0 ± 19.6 0.87 
FEV1/FVC 53.3 ± 10.2 51.2 ± 11.6 0.49 
FEF 25-75, % predicted 25.5 ± 12.1 24.2 ± 12.5 0.70 
DLCO, % predicted 61.2 ± 23.5 54.5 ± 16.7 0.22 
DLCO/VA, % predicted 79.4 ± 23.9 71.1 ± 19.5 0.16 
RLV, % predicted 176 ± 49 176 ± 56 0.97 
VC, % predicted 98.9 ± 20.0 100.6 ± 17.4 0.74 
TLC, % predicted 124.2 ± 16.6 124.8 ± 22.9 0.92 
RLV /TLC 0.55 ± 0.11 0.55 ± 0.11 0.92 
6MWT (m) 428 ± 121 471 ± 97 0.14 
CMR    
RVEDV (ml/m1.7) 53.9 ± 12.8 53.4 ± 12.8 0.87 
RVESV (ml/m1.7) 21.9 ± 8.1 21.7 ± 6.7 0.92 
RVSV (ml/m1.7) 32.1 ± 7.0 31.7 ± 7.0 0.84 
RVEF (%) 60.0 ± 7.0 59.7 ± 8.5 0.37 
RVM (g/m1.7) 16.5 ± 3.5 16.3 ± 3.4 0.83 
RVMVR (g/ml) 0.31 ± 0.07 0.31 ± 0.05 0.65 
LVEDV (ml/m1.7) 57.0 ± 14.8 55.5 ± 9.4 0.66 
LVESV (ml/m1.7) 24.5 ± 12.6 22.3 ± 5.6 0.42 
LVSV (ml/m1.7) 32.5 ± 7.3 33.2 ± 6.3 0.72 
LVEF (%) 58.5 ± 11.0 60.0 ± 6.0 0.53 
LVM (g/m1.7) 44.1 ± 10.2 42.9 ± 8.8 0.63 
LVMVR (g/ml) 0.79 ± 0.16 0.77 ± 0.11 0.59 
Pulmonary PWV 2.97 ± 1.6 2.34 ± 0.97 0.09 
Pulmonary Pulsatility 25.6 ± 7.7 24.1 ± 8.7 0.50 
Pulmonary acceleration 
time 
102.8 ± 22.8 105.1 ± 23.5 0.71 
Aortic PWV 9.3 ± 3.1 8.2 ± 2.2 0.13 
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Table 7-2 provides full details of changes between the baseline and follow-up visit. As 5 
participants had an uptitring of their medications over the course of the year between the visits 
which could potentially skew the results, the analyses was re-run with these cases excluded.  This 
did not result in any significant change in the results. 
Figure 7-1:  Bar (representing the mean) and dot (representing the individual participants) 
plot of the change in Right Ventricular Mass (A), PWV (B), and Six minute walk distance (C). 
A. 
 
 
B.      C. 
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Table 7-2: Change in demographics, pulmonary function tests and CMR parameters at 1-
year follow-up. 
 Baseline 1 year Interval change 
(%) 
P* 
Age 68.6 ± 8.2 69.9 ± 8.2   
BMI (kg/m2) 27.1 ± 5.3 27.2 ± 5.2 +0.2% 0.82 
Heart rate (bpm) 67.1 ± 11.2 68.2 ± 10.6 +2% 0.62 
Systolic BP (mmHg) 133.4 ± 12.9 129.8 ± 18.2 -3% 0.19 
Diastolic BP (mmHg) 75.8 ± 9.6 73.3 ± 9.6 -1% 0.18 
SpO2 95.9 ± 1.7 96.3 ± 2.2 +0.4% 0.20 
FEV1, % predicted 65.5 ± 21.0 63.6 ± 20.2 -3% 0.24 
FVC, % predicted 100 ± 20 100 ± 22 0% 0.88 
FEV1/FVC 51.3 ± 11.6 49.7 ± 9.9 -3% 0.05 
DLCO, % predicted 54.4 ± 17.0 59.1 ± 18.1 +9% 0.002 
DLCO/VA, % predicted 71.4 ± 19.8 78.0 ± 19.5 +9% <0.001 
6MWT (m) 473 ± 97 445 ± 99 -6% 0.001 
RVEDV (ml/m1.7) 53.4 ± 9.6 52.1 ± 10.8 -2% 0.37 
RVESV (ml/m1.7) 21.7 ± 6.7 21.8 ± 7.5 +3% 0.93 
RVSV (ml/m1.7) 31.7 ± 7.0 30.4 ± 7.1 -4% 0.14 
RVEF (%) 59.7 ± 8.5 58.6 ± 9.2 -2% 0.37 
RVM (g/m1.7) 16.3 ± 3.4 16.4 ± 3.1 0% 0.91 
RVMVR (g/ml) 0.31 ± 0.05 0.32 ± 0.05 +5% 0.19 
LVEDV (ml/m1.7) 55.5 ± 9.4 54.2 ± 9.7 -2% 0.34 
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LVESV (ml/m1.7) 22.3 ± 5.6 23.6 ± 6.9 +6% 0.16 
LVSV (ml/m1.7) 33.2 ± 6.3 30.6 ± 6.8 -8% 0.028 
LVEF (%) 60.0 ± 6.04 56.4 ± 9.0 -6% 0.02 
LVM (g/m1.7) 42.9 ± 8.8 43.1 ± 9.9 +1% 0.80 
LVMVR (g/ml) 0.77 ± 0.11 0.80 ± 0.15 +3% 0.23 
Pulmonary PWV 2.30 ± 0.97 3.39 ± 1.4 +47% <0.001 
Pulmonary Pulsatility 24.1 ± 8.7 26.8 ± 9.4 +11% 0.20 
PAT 105.2 ± 23.5 108.8 ± 17.8 +3% 0.35 
Aortic PWV 8.2 ± 2.3 8.5 ± 2.6 +4% 0.52 
 
* Significance set at p<0.0018 after bonferroni correction for multiple comparisons 
 
Those with the stiffest arteries at baseline (upper tertile of PWV) had no significant differences in 
right ventricular or left ventricular remodeling at follow-up than those with the most elastic 
arteries (bottom tertile of PWV).  For full comparison of the change in ventricular metrics between 
PWV tertiles see Table 7-3. 
 
Table 7-3: Comparison of change in 6MWT and CMR at follow up compared with baseline 
across baseline PWV tertiles 
 Tertile  
1 2 3 P* 
N 10 11 11  
Baseline PWV 1.31 ± 0.26 2.18 ± 0.32 3.42 ± 0.59  
∆6MWT (m) -38.8 ± 39.4 -22.5 ± 41.9 -26.8 ± 52.3 0.57 
CMR 
∆RVEDV (ml/m1.7) -3.9 ± 8.1 -1.6 ± 7.0 1.3 ± 8.9 0.18 
∆RVESV (ml/m1.7) -2.5 ± 7.0 0.6 ± 3.7 2.0 ± 5.9 0.13 
∆RVSV (ml/m1.7) -1.3 ± 5.6 -2.2 ± 3.9 -0.5 ± 5.9 0.75 
∆RVEF (%) 0.7 ± 8.6 -2.2 ± 3.3 -1.5 ± 7.3 0.55 
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∆RVM (g/m1.7) -0.66 ± 2.8 0.26 ± 4.2 0.53 ± 2.3 0.29 
∆RVMVR (g/ml) 0.01 ± 0.07 0.01 ± 0.08 0.02 ± 0.07 0.71 
∆LVEDV (ml/m1.7) -1.1 ± 7.7 -3.8 ± 5.1 1.1 ± 8.7 0.54 
∆LVESV (ml/m1.7) 0.54 ± 6.4 0.38 ± 4.7 3.0 ± 4.4 0.32 
∆LVSV (ml/m1.7) -1.7± 6.0 -4.2 ± 7.0 -1.8 ± 6.1 0.96 
∆LVEF (%) -2.3 ± 9.5 -3.9 ± 10.2 -4.4 ± 4.4 0.52 
∆LVM (g/m1.7) 0.55 ± 5.4 -0.38 ± 4.8 0.55 ± 5.77 0.99 
∆LVMVR (g/ml) 0.02 ± 0.13 0.05 ± 0.06 0.00 ± 0.13 0.76 
*P-value is tertile 3 compared to tertile 1 
 
Despite seeing a 54% increase in PWV between baseline and follow up visit, there was no 
significant correlation between baseline clinical observations or pulmonary function tests or 
interval change in PWV other than a negative correlation between heart rate and change in PWV 
(see Table 7-4). Scatter plots demonstrate a linear trend for this with no significant improvement 
of the R2 on mapping a curvilinear plot (see Figure 7-2).  
  
Table 7-4: Correlation co-efficients of ∆PWV and baseline demographic and spirometric 
measures. 
 ∆PWV 
Baseline Variable R p 
Age 0.07 0.72 
BMI (kg/m2) -0.11 0.54 
Heart rate (bpm) -0.38 0.032 
Systolic BP (mmHg) 0.23 0.20 
Diastolic BP (mmHg) -0.08 0.66 
SpO2 -0.005 0.98 
Pack years -0.26 0.14 
FEV1, % predicted 0.22 0.23 
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FVC, % predicted 0.10 0.59 
FEV1/FVC 0.20 0.28 
FEF 25-75, % predicted 0.22 0.22 
DLCO, % predicted 0.20 0.26 
DLCO/VA, % predicted 0.14 0.44 
RLV, % predicted -0.17 0.38 
VC, % predicted 0.23 0.21 
TLC, % predicted -0.15 0.44 
 
Figure 7-2: Scatter plots of baseline heart rate against change in PWV with linear (left) and 
curvilinear (right) lines of best fit applied. 
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As a significant fall in 6MWT was observed an unplanned analysis of the determinants of this 
change was performed.   6MWT distance walked at follow-up was strongly correlated with baseline 
6MWT, age, FEV1, FEV1/FVC, FEF25-75, DLCO, KCO, RLV/TLC, LVEF and pulmonary pulsatility (see 
Table 7-5).  On backward entry linear regression, baseline FEV1 percent predicted (ß=0.44, 
p=0.003) and pulmonary pulsatility (ß=0.48, p=0.003) were independently associated with follow-
up 6MWT.  However when baseline 6MWT was included in the model, this significance was lost 
with only baseline 6MWT predicting 6MWT distance at 1 year (ß=0.84, p<0.001). 
 
Previous reports have described a 30m cutoff as a clinical significant deterioration in functional 
performance,(297) thus a comparison was performed between those who’s 6MWT distance had 
fallen by greater than 30m compared with those who’s distance had fallen by less than 30m.  Those 
who had a clinically significant fall in 6MWT were older (73.2±6.3 years vs. 65.1±7.7 years, 
p=0.005) with significantly lower pulmonary pulsatility (19.7±7.1 vs. 26.7±8.9%, p=0.028) but 
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were otherwise similar (See Table 7-6).  After correction for multiple comparisons with a new 
significance threshold of p<0.0014, no significant difference between the groups remained.   
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Table 7-5: Correlation of change in 6MWT with demographic, spirometric and cardiac 
metrics at baseline. 
 Follow-up 6MWT 
Baseline measure* R p 
6MWT 0.9 <0.001 
Age -0.52 0.003 
BMI (kg/m2) -0.17 0.35 
Heart rate (bpm) -0.7 0.69 
Systolic BP (mmHg) -0.21 0.26 
Diastolic BP (mmHg) -0.11 0.56 
SpO2 0.17 0.36 
Pack years -0.18 0.32 
FEV1, % predicted 0.39 0.03 
FVC, % predicted 0.23 0.22 
FEV1/FVC 0.44 0.01 
FEF 25-75, % predicted 0.38 0.04 
DLCO, % predicted 0.5 0.004 
DLCO/VA, % predicted 0.37 0.04 
RLV, % predicted -0.16 0.41 
VC, % predicted 0.22 0.25 
TLC, % predicted -0.08 0.69 
RLV /TLC -0.38 0.04 
RVEDV (ml/m1.7) -0.04 0.82 
RVESV (ml/m1.7) -0.29 0.11 
RVSV (ml/m1.7) 0.22 0.23 
RVEF (%) 0.35 0.05 
RVM (g/m1.7) -0.02 0.94 
RVMVR (g/ml) 0.08 0.66 
LVEDV (ml/m1.7) 0.07 0.72 
LVESV (ml/m1.7) -0.22 0.23 
LVSV (ml/m1.7) 0.30 0.10 
LVEF (%) 0.41 0.02 
LVM (g/m1.7) 0.06 0.76 
LVMVR (g/ml) 0.03 0.88 
Pulmonary PWV -0.03 0.89 
Pulmonary Pulsatility 0.52 0.003 
Pulmonary acceleration time -0.18 0.33 
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Table 7-6: Comparison of the baseline demographic, pulmonary function and cardiac 
parameters between those with and without a clinically significant fall in 6-minute walking 
distance. 
 
 Fall in 6MWT  
 < 30m > 30m P+ 
N* 19 12  
Age 65.1 ± 7.7 73.2 ± 6.3 0.005 
Sex (male) 7 (37%) 9 (75%) 0.066 
BMI (kg/m2) 27.8 ± 4.7 26.2 ± 6.3 0.42 
Heart rate (bpm) 68.8 ± 21.9 70.8 ± 10.8 0.77 
Systolic BP (mmHg) 127 ± 18 136 ± 10 0.13 
Diastolic BP (mmHg) 73 ± 9 75 ± 8 0.55 
SpO2 96.1 ± 1.6 95.8 ± 2.0 0.64 
Smoking status 
Current smoker 5 (26%) 1 (8%) 0.36 
Ex-smoker 14 (74%) 11 (92%) 0.36 
Pack years 53.9 ± 24.7 53.3 ± 29.7 0.95 
COPD exacerbation since 
baseline 
3 0 0.27 
Uptitring of inhaler 
therapy 
1 3 0.27 
Pulmonary Function tests    
FEV1, % predicted 63.5 ± 18.4 65.9 ± 24.2 0.75 
FVC, % predicted 101.0 ± 18.6 97.3 ± 22.1 0.62 
FEV1/FVC 50.4 ± 11.6 51.3 ± 11.2 0.84 
FEF 25-75, % 
predicted 
22.4 ± 12.9 25.7 ± 11.7 0.48 
DLCO, % predicted 56.4 ± 17.9 51.8 ± 15.8 0.47 
DLCO/VA, % 
predicted 
69.7 ± 17.3 72.7 ± 23.9 0.69 
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RLV, % predicted 178.2 ± 55 173.8 ± 58.6 0.84 
VC, % predicted 98.8 ± 13.7 103.2 ± 22.2 0.50 
TLC, % predicted 124.9 ± 23.3 124.6 ± 23.3 0.97 
CMR    
RVEDV (ml/m1.7) 52.1 ± 10.3 56.2 ± 8.5 0.26 
RVESV (ml/m1.7) 20.1 ± 6.3 24.5 ± 6.9 0.08 
RVSV (ml/m1.7) 32.0 ± 8.4 31.7 ± 4.2 0.87 
RVEF (%) 61.4 ± 9.5 57.0 ± 6.7 0.18 
RVM (g/m1.7) 15.7 ± 3.3 17.6 ± 3.5 0.14 
RVMVR (g/ml) 0.31 ± 0.05 0.31 ± 0.05 0.69 
LVEDV (ml/m1.7) 54.9 ± 9.3 56.5 ± 10.2 0.64 
LVESV (ml/m1.7) 22.1 ± 4.4 22.9 ± 7.4 0.73 
LVSV (ml/m1.7) 32.8 ± 6.7 33.6 ± 6.0 0.72 
LVEF (%) 59.7 ± 5.1 60.2 ± 7.7 0.81 
LVM (g/m1.7) 41.1 ± 8.5 45.5 ± 9.2 0.18 
LVMVR (g/ml) 0.75 ± 0.11 0.81 ± 0.10 0.18 
Pulmonary PWV 2.35 ± 0.88 2.22 ± 1.12 0.72 
Pulmonary 
Pulsatility 
26.7 ± 8.9 19.7 ± 7.1 0.028 
Pulmonary 
acceleration time 
103.0 ± 19.6 107.3 ± 30.0 0.64 
Aortic PWV 8.19 ± 2.25 8.0 ± 2.22 0.81 
 
*Total n=31 rather than 32 as one patient had had a recent ankle fracture and was therefore 
excluded from repeat 6MWT. 
+Significance set at p<0.0013 after bonferroni correction for multiple comparisons. 
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7.3 DISCUSSION 
In this chapter we have seen that the primary study outcome – change in right ventricular mass at 1 
year – was negative.  Thus all other comparisons must be interpreted with caution.  
 
This is the first study to look at longitudinal changes in ventricular function in COPD.  Due to this 
lack of prior work, the primary study outcome – change in right ventricular mass – was powered 
according to the placebo arms of randomised control trials in pulmonary hypertension as this was 
the only data available.  These describe an increase in mass of 5-8g (change in right ventricular 
mass detected over 4-36 months in groups of 21 and 44 participants respectively).(263,264) Based 
on these factors, n=17 would allow detection of a 4g change with study power of 80% and a p=0.05.  
The rationale for this was that all the cardiac MRI studies at the time of the study design had 
described right ventricular hypertrophy, with the severity of this increasing with COPD 
severity.(79–81,298) However, as we have seen in chapter 4, we found a pattern of reduced 
ventricular volumes with no evidence of right ventricular hypertrophy, with our results mirroring 
those of the MESA-COPD study.(274) Our observed right ventricular mass of 39g is also 
significantly lower than the mass of 74-102g seen in the pulmonary hypertension interventional 
trials.  Thus it is perhaps not surprising that at one-year follow-up we detected no significant 
interval change in right ventricular mass.  Given that the change in absolute RV mass only equated 
to an increase of 0.44g, with a similarly small change in other ventricular metrics, this suggests that 
cardiac remodeling occurs slowly and can largely be considered stable over the usual time period 
used in interventional studies.  As a result we are unable to examine the longitudinal effects of 
pulmonary PWV on ventricular remodeling other than to say that if it is present it is likely small and 
beyond the power of this study to detect it. 
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The change in pulmonary arterial stiffness in the follow-up appears disproportionate to the findings 
of the changes or lack thereof of the remainder of the metrics. Indeed if one were to consider a 50% 
increment in pulmonary PWV per year, one would very rapidly see end stage pulmonary vascular 
changes with inordinately high PWV values.  However this was not the case with pulmonary PWV 
remaining significantly lower than the aortic values.  Therefore the inverse correlation between the 
heart rate and change in pulse wave velocity must also be viewed with caution and will require 
replication in future studies.  If validated it would however raise an interesting facet of pulmonary 
vascular remodeling.  Sympathetic over activation is common in COPD(299), with increased 
sympathetic activation associated with increased arterial stiffening.(300) However hypercapnia 
and metabolic acidosis are associated with increased parasympathetic activation, thus those with a 
reduced heart rate may represent a subset with more severe disease leading to more rapid 
pulmonary remodeling.(301) 
 
The observed rapid shift in PWV requires exploration.  While all visits were coordinated to occur 8 
weeks or more after an acute exacerbation it is not entirely inconceivable that patients could have 
been in the earliest stages of developing an exacerbation during one or both of their visits. While 
pulmonary arterial stiffness has not been directly assessed in the acute exacerbation phase of 
COPD, it is known that these are associated with a transient dilation of the main pulmonary artery 
during the acute episode.(302) Thus an early exacerbation of COPD could potentially cause an acute 
rise in arterial stiffness and thus PWV.  However in a cohort of 32, it is unlikely that enough people 
would develop early acute exacerbations at the time of their second visit but not their first in order 
to skew the results in such a fashion.  In addition the pulmonary pulsatility and pulmonary 
acceleration time - both metrics of pulmonary vascular status - remained stable, making significant 
interval changes in PWV somewhat less likely.  Thus the technique itself must be examined.  We 
saw in chapter 4 that the mean interscan difference for the QA-PWV was 0.43ms-1 with limits of 
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agreement of -2.18 - 1.32ms-1.  Therefore the observed rise in pulmonary PWV of 1.2ms-1 may be 
possibly be attributable to these rather wide limits of agreement producing a Type 1 error.  Given 
the width of the limits of agreement a similar consideration must also be made for the lack of 
observation of significant correlation between the pulmonary PWV and clinical and spirometric 
variables due to this providing a significant level of ‘noise’ thereby potentially obscuring significant 
associations.  Further work to improve pulmonary PWV measurement repeatability will allow for 
smaller temporal changes to be observed over time and greater accuracy of the determinants and 
associations of this.  Potential avenues for this include new phase contrast sequences using ‘radial’ 
and ‘stack of stars’ k-space acquisition which have been described to provide greater edge 
definition – an important factor in the flow-area PWV calculation.(261) 4D flow techniques may 
also allow more accurate measurements or arterial stiffening.  While these suffer from poor 
temporal resolution this is offset by a simultaneous acquisition of the flow information at multiple 
sites therefore reducing the effect of interscan r-r variability on wave arrival time, and also allows 
multiple regions of interest to be applied along a vessels length irrespective of its geometry with 
these multiple sampling points improving the accuracy of the timing of the transit of the pulse wave 
throughout the vessel.(303,304) 
 
We have shown that while the cardiac metrics remained stable a significant deterioration in the six-
minute walk test occurred.  Our finding of a significant correlation between baseline FEV1 and 
pulmonary pulsatility is interesting.    The finding of a significant correlation between FEV1 and 
decline in exercise capacity is consistent with prior work in the ECLIPSE multinational study.(297) 
A previous study using echocardiography found that pulmonary pulsatility significantly correlated 
with NYHA status, so a concordance with exercise capacity would fit with this.(186) In addition, in 
COPD increased pulmonary arterial diameters (typically seen with reduced pulsatility) have been 
demonstrated to be associated with reduced six minute walk test, increased incidence of acute 
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exacerbations and increased prevalence of pulmonary hypertension.(126,127,273) Given the 
findings of our current study and these prior studies, further work is warranted to better examine 
the implications of pulmonary pulsatility in exercise capacity. 
 
The main limitation of the current study other than those mentioned above is the small sample size 
that returned for the final study visit.  This was largely due to the time constraints of the PhD 
meaning that those recruited after the end of the second year could not be brought back for a 
repeat visit.  This reduces the effect size between study visits that can be detected and also 
increases the risk of both type I and type II errors when conducting multiple analyses within a small 
cohort. 
 
7.4 CONCLUSION 
In this chapter we have seen that there was no significant interval change in right ventricular mass 
or function.  As a result we are unable to examine the longitudinal effects of pulmonary PWV on 
ventricular remodeling other than to say that if it is present it is likely small and beyond the power 
of this study to detect it. 
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CHAPTER 8:  Discussion and Further Work  
 
We have seen in Chapter 1 that there are four broad prevailing mechanisms potentially 
linking COPD with the markedly elevated cardiovascular risk profile in those suffering this 
condition.  This thesis was designed and centered on the role of pulmonary hypertension in 
COPD, and more specifically, the role of pulmonary arterial stiffening.  This was based on 
extensive evidence of a relatively common prevalence of this complication, its occurrence 
early in COPD and links to poorer outcome.  A technique for the measurement of pulse 
wave velocity in the pulmonary arteries was developed and its reproducibility was 
assessed.  This technique was then applied in a COPD cohort and age and sex matched 
healthy cohort.  We observed the expected stiffening of the pulmonary arteries in the COPD 
cohort, but contrary to the original hypothesis and expectations, found that it did not 
correlate either with baseline or follow-up right ventricular mass.  In fact the pattern of 
ventricular remodeling was instead that of an underfilled state rather than a pressure 
overloaded state, with the left ventricle demonstrating similar remodeling to the right.   
 
Future work in this area needs to focus on two aspects.  First, what is the cause for this 
underfilling?  We have previously discussed the competing theories for the underfilling of 
the ventricles of increased intra-thoracic pressure impeding venous return versus 
myocardial stiffening with impaired relaxation.  These questions could potentially be 
answered using a combination of cross-sectional/volumetric quantification of the SVC and 
IVC for evidence of compression/collapse, and advanced cardiac imaging techniques of 
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feature-tracking/tagging of the myocardium to examine systolic and diastolic strain and 
relaxation rates to examine for myocardial stiffening.   
 
The second question to be examined is, what are the clinical implications of this 
underfilling, and does this explain the disproportionate cardiovascular risk profile of this 
group of patients?  While utilisation of existing echo databases can give some insight into 
this, looking at historical ventricular volumes and associated mortality risk in those with 
COPD.  Prospective longitudinal follow-up of a large cohort of COPD patients to determine 
causative deterministics of reduced ventricular volumes on cardiovascular morbidity or 
mortality will be ultimately required.    
 
In the current study we found that pulmonary PWV could indeed pick up differences 
between populations but its repeatability needs further improvement and to date, this 
technique has still not been validated against the gold standard of invasive PWV 
measurement. Thus further work is needed exploring the potential utility of both faster 
acquisition sequences using non-Cartesian k-space sampling and 4D acquisition 
techniques.  Assessment of this in a population due to undergo right heart catheterisation 
would be ideal as it would allow acquisition of an invasive PWV without necessitating any 
additional procedures to then compare against these competing techniques. 
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APPENDIX A:  MRI STUDY PROTOCOLS  
 
Localisers. 
To repeat localisers with the patient in the isocentre. 
Further localisers: VLA, HLA, SAX 
HASTE: Axial and coronal, free breathing  
Cine imaging using trueFISP.  Matrix 256 x 80% 
All images to be slice thickness of 8 mm, 25% distance factor. 
Field of view altered to minimum, according to patient's size in all scans. 
Segments altered according to heart rate:  
<70 beats per minute, 14 segments, 70 to 80 beats per minute, 12 segments, 80 
to 100 beats per minute, 11 segments. 
Number of phases for image construction=30. 
 
4 chamber view. 
2 chamber view. 
Complete ventricular short axis coverage. 
First slice planned at mitral valve annulus, perpendicular to inter-
ventricular septum passing through the atrioventricular grooves. 
Ensure also covers from tricuspid valve to apex of right ventricle, not 
just left ventricle. 
 
TAGGING: (3 short axis + 1 long axis 4C) 
Sequence is Grid, 3 slices using single breath hold sequence 
Segments 7-11 depending on heart rate (TR 35-50ms) IPAT factor 2 unless 
poor signal to noise 
3 short axis planned in mid-systole from the 4/3 chambers.   
Mid-slice to be planned at mid-point between mitral valve tips and apex.   
Basal slice should be below the tips of the mitral valve and does not include any 
left ventricular outflow tract. 
Distance factor altered to apical slice below papillary muscles in diastole, 
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distance factor approximately 100 to 200%. 
1 long-axis (4C view) 
Cine imaging using trueFISP.  Matrix 256 x 80% 
All images to be slice thickness of 8 mm. 
Field of view altered to minimum, according to patient's size in all scans. 
Segments altered according to heart rate:  
<70 beats per minute, 14 segments, 70 to 80 beats per minute, 12 segments, 80 
to 100 beats per minute, 11 segments. 
Number of phases for image construction=30. 
 
RVOT cine 
RVOT orthogonal view 
RV free wall 
 
Main PA short axis (planned from RVOT and ortho view above valve leaflet 
tips) 
 
High temporal resolution phase contrast images: 
 
Main PA using position from the main PA cine sequence 
- High temporal resolution 
- Repeat same sequence with 5ms delay 
 
Basal ventricular short axis through the tricuspid and mitral valve 
 
Free breathing. Venc 150cm/s. Document HR. 
Sagittal oblique to include ascending aorta, aortic arch and descending aorta 
If artefact switch to FLASH/gradient echo 
High temporal resolution aortic cine at PA bifurcation. 
Simultaneous BP and document pulse pressure. 
Aorta flow measured at level of pulmonary artery bifurcation 
Venc 150cm/s. 
Aorta flow measured at diaphragm just below level of the heart. 
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FLASH rest perfusion. 
Check perfusion scan without contrast for optimised field of view/artefact. 
Smallest field of view without any wrap. 
Contrast to be injected at 0.04mmol/kg, 5 ml per second, followed by a 20 ml 
flush. Injection to commence after giving breathe IN instruction. 
Inject, then breathe out.  Acquisition starts. 
3 short axis slices depending on heart rate: 
Matrix 224 x 80%, parallel imaging factor x 2 
<70 beats per minute 40 acquisitions 
70-90 beats per minute 50 acquisitions 
>90 beats per minute 60 acquisitions. 
NB If HR > 110 may default to 2 beat trigger- reduce matrix to 192 
The patient is instructed to breathe quietly, when they can no longer hold their 
breath. 
Repeat ventricular short axis coverage. 
First slice planned at mitral valve annulus, perpendicular to inter-ventricular 
septum passing through the atrioventricular grooves. Ensure also covers 
tricuspid valve.  
Repeat Aorta flow - measured at pulmonary artery bifurcation, descending 
aorta. Copy slice position 14. Venc 150cm/s. 
Repeat Aorta flow measured at diaphragm just below level of the heart. 
Delayed contrast imaging inversion recovery flash sequence. 
TI scout copying mid sax image position.  
Complete short axis coverage copy in image positions from SAX cines. 
Use phase-sensitive sequence. 
Capture RR interval.  Set TR ~100 msec less than RR interval. 
Alter TI by 10 msec approximately every 1 to 2 slices. 
If slice shows doubtful enhancement, repeat slice, and swap phase encoding 
direction.   Also plan modified 2- chamber through inferior insertion point and 
anterior insertion point of RV to septum if LGE seen here 
4 chamber, 2 chamber, 3 chamber, SAX stack. 
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Appendix B: Patient Information Sheet 
 
 
 
 
 
 
PARTICIPANT INFORMATION SHEET 
 
 
Title: The role of pulmonary arterial stiffness on right ventricular 
remodeling in COPD. 
 
Chief Investigator: Prof Graeme Houston 
Prinicipal Investigator: Dr Jonathan Weir-McCall 
Department of Clinical Radiology 
Diagnostic Group 
 
We invite you to participate in a study looking at blood vessel stiffness within the blood 
vessels supplying the lungs.  This study forms the core part of Dr Weir-McCall’s PhD 
research.  Before you decide whether or not you wish to participate, we are providing 
you with the following information.  Please read it carefully and do not hesitate to ask 
any questions you may have.  We will provide you with any further information you may 
ask for now and later.  You may also wish to discuss taking part in the study with friends 
or relatives before deciding whether to take part.   If you agree to take part, your GP will 
be informed of your participation as long as you are happy for this to be done. 
                                             
Thank you for reading this. 
 
 
What is the purpose of this study? 
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Objectives: To investigate the ability of MRI to assess the heart and blood vessels supplying the lung 
(pulmonary arteries) in patients with smoking induced lung disease (chronic obstructive pulmonary 
disease), and to improve the accuracy of this assessment.  
Design: We will use MRI to compare the heart muscle and the blood flow within the blood vessels which 
supply the lungs in patients with and without lung disease.  30 healthy volunteers and 90 participants with 
lung disease will be scanned at baseline with a second scan at 1 year.   
Expected outcomes: The pulmonary arteries will be stiffer in patients with COPD.  Injected contrast will 
improve visualisation of the heart muscle and therefore improve the accuracy of MRI assessment.  
Anticipated healthcare outcomes: Increased knowledge about the blood vessels in COPD could allow 
earlier detection of heart disease and provide new avenues of treatment for this difficult to treat disease.   
 
Do I have to take part in this study? 
It is up to you to decide whether or not to take part.  You can refuse to take part and this 
will not affect your treatment in any way.  If you agree to take part but change your mind 
at a later date you can withdraw immediately and do not have to give a reason for doing 
so.  You can do this by contacting Dr Jonathan Weir-McCall.  Should you withdraw from 
the study, all identifiable data collected would be withdrawn and destroyed. Data which 
is not identifiable to the research team may be retained.  Please keep this information 
sheet.  If you have any questions or doubts, please contact us. 
 
Why have I been chosen? 
You have been chosen to take part in this study as you have been previously diagnosed 
with COPD, which we are interested in investigating further to discover its effects on 
blood vessel stiffness.  
 
 
What will happen to me if I take part? 
If after reading through this information sheet you are happy to take part in the study 
please return a reply slip indicating whether or not you would be interested in taking part 
in the study. If you are interested, the researcher will contact you to discuss the study 
further and invite you to attend a screening visit, after which, if both you and the 
researchers are happy to progress, you will be asked to attend two further visits with a 1 
year gap between these. All visits will be held at Ninewells Hospital. 
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Visit 1: At this visit we will talk through the project, answer any questions you might 
have and obtain your written permission to take part in this study.  After this we will take 
a thorough medical history, and do a simple assessment of the heart using ultrasound 
(also called an echocardiogram).  This visit is to make sure you are happy to take part in 
the study, and to make sure there are no conditions that might mean we cannot include 
you in the study. 
 
Visit 2:  This will be shortly after Visit 1. This will take about half a day, and will occur at 
Ninewells Hospital.  This will involve a lung function test, an exercise test (how far you 
can walk in 6 minutes), blood tests and a MRI exam of the heart (which is the crucial 
part of the study).  Some of the blood taken will be stored and used for future analysis 
as long as you are happy for this to occur. 
 
Visit 3: This will occur 1 year after Visit 2, and will involve exactly the same tests. This 
is to see how the heart adapts over time, and whether any of the blood tests, or the 
stiffness of the arteries to the lungs, helps us predict this. 
 
If further information about your condition is revealed it will be passed to the doctor who 
looks after your COPD. 
 
The data held on the Study Database will be analysed by statistics to assess the factors 
affecting blood vessel stiffness and how this affects cardiovascular disease. 
 
Reasonable travel expenses will be reimbursed, should you need to travel to take part 
in the study. 
 
What will the MRI scan involve 
The MRI scan will be performed at the Clinical Research Centre at Ninewells Hospital.  
Each examination takes approximately 60-75 minutes, and involves lying on a table that 
slides into the scanner.   Prior to the scan, we will place a cannula into a vein in your 
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arm, this is to allow an injection of contrast during the scan to help acquire some of the 
images.  The cannula insertion is often experienced as a sharp scratch as it goes into 
the vein after which the pain settles.  Occasionally this will leave a bruise at this site.   
We will also take some blood from the cannula at the same time as this.  As this is a 
study of your heart we will monitor your heart rate during the procedure, and this would 
require us to attach three small leads to your chest along with an MRI coil which is 
placed over the chest that collects the images. We will discuss this in detail with you 
beforehand. This equipment does not hurt you or cause you pain in anyway. 
 
 
Volunteer with an MRI coil on their chest about to go into the MRI scanner  
 
During the scan you will be asked to remain very still, and as the process can be noisy 
you will be given ear protection in the form of headphones. The headphones will also 
allow you to listen to some music during the scan as an aid to relaxation. The scan is 
painless, although it is possible that you might experience a minor amount of discomfort 
such as minor ‘pins and needles’ as a result of lying still on the MRI table. The results of 
your MRI examinations will be confidential. It is unlikely, but possible, that these images 
will reveal an abnormality that you were unaware of. Should this happen, the Consultant 
Radiologist will discuss the findings with you, request your permission to inform your GP 
and recommend whether further investigations are appropriate or not. Thereafter your 
MRI scan will be irreversibly anonymised once the Radiologist has checked it. 
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Some of the scans will involve you having to hold your breath for short periods of time.  
In these instances, full breathing instructions will be provided to you by the 
radiographers during the MRI scan. 
 
Are there any safety implications? 
MRI is recognized as a safe imaging modality and there are no known biological or 
health safety concerns surrounding its use. However you will be asked whether you are 
(or might be) pregnant, and if you are (or think you might be) then we would not include 
you in this study. 
A member of staff will ask you a series of important questions to ensure that you have 
no metallic implants (e.g. pacemaker, internal clips, or other similar devices) inside your 
body before you enter the strong magnetic field. You will also be instructed to remove 
all metal objects such as watches, keys, coins etc, and we will also ask you to change 
into a hospital gown for the duration of the examination. 
The contrast used in the study is widely used in routine clinical MRI scans.  Most people 
experience no side effects from this, but some can experience a slight discomfort at the 
injection site, and a small number of people will have side effects including itchiness, 
headache or nausea. 
 
 
Incidental findings 
Since this research involves MRI scans it is quite possible that it may show up findings 
other than those under investigation.  These are what we call “incidental findings” the 
significance of which is often unclear or, indeed, something that the researchers 
themselves are not qualified to interpret or act upon, if that is the case, expert advice 
will be sought.  It is very important that you understand how “incidental findings” will be 
dealt with in this research and you will be asked to give your specific consent to this in 
the Consent Form that you will sign if you agree to take part. 
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It is normal practice for us to inform your GP of your participation in this study. Further, 
in the event that we find an incidental finding in your images we would wish to provide 
you and your GP with this information in order to plan further medical care. By signing 
the informed consent declaration you agree to us taking this course of action should this 
unlikely situation arise. 
 
It is important that you understand what is intended before you sign the Consent Form 
in which case you may wish to discuss this further with a member of the research team 
or with other independent parties before proceeding. 
 
What if I am harmed by taking part? 
This study is sponsored by the University of Dundee and NHS Tayside.  
If you have a complaint about your participation in the study you should first talk to a 
researcher involved in your care. You can ask to speak to a senior member of the 
research team or the Complaints Officer for NHS Tayside. 
 
In the event that something goes wrong and you are harmed during the study there are 
no special compensation arrangements.  If you are harmed and this is due to 
someone’s negligence then you may have grounds for a legal action for compensation 
against the University of Dundee or NHS Tayside but you may have to pay your legal 
costs.  The normal National Health Service complaints mechanisms will still be available 
to you (if appropriate): 
 
Complaints and Claims Manager 
Complaints and Advice Team 
Level 7, Ninewells Hospital 
Dundee DD1 9SY 
Freephone: 0800 027 5507 
Email: nhstaysidecomplaints@thb.scot.nhs.uk 
 
Will I receive any payment? 
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Reasonable travel costs will be reimbursed, but no extra payments are provided for 
assistance with this study, even if the images or data are used in research that leads to 
an important new MRI development. 
 
What are the advantages of taking part? 
There are no direct benefits to taking part, but the information we obtain will add to our 
understanding of the lungs and heart, and will be be used to optimize the scanner 
performance in support of better clinical practice and future patient studies. If the results 
of the studies are sufficiently interesting to us, we may publish the results in journals or 
present them at conferences. You will not be identified in any of the published 
information. 
 
Insurance Implications 
Some insurance companies consider that participation in medical research such as this 
is a ‘material fact’ which should be mentioned in any proposal for health-related 
insurance, or which could influence their judgment in consideration of claims made 
under existing insurance policies. You should check that participation in this research 
does not affect any policy that you might be thinking about taking out or any existing 
policy. 
 
What confidential data may be collected, and how will it be used? 
We will need to record certain personal details such as your name, gender, height, 
weight, medical number (CHI), and date of birth in addition to the MR images that we 
acquire. NHS Tayside MRI Radiologists,Radiographers and Clinical Scientists will have 
controlled access to this information.    Your data will be allocated a study identifier, and 
will be anonymised for subsequent research analysis.  It is standard procedure for your 
resulting MR images to be stored securely for a period of at least 5 years, and we will 
request informed consent from you to use the images anonymously during this time for 
research, education, technical development and quality control at NHS Tayside, 
University of Dundee or at other collaborative NHS or University institutions within the 
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United Kingdom. External collaborators will be required to sign a code of conduct to 
guarantee that any data received will be kept fully confidential and secure. 
Your MR images will only be used for the above purposes if approved by a Data Access 
Committee made up of local scientists, clinicians, and managers together with input 
from the regional ethics committee 
In addition to the above, we will also ask you to inform us whether you have recently 
participated in or are currently involved in other research prior to this study. 
 
Examples of how your anonymised images might be used in the future 
Research: Your anonymised images could be scientifically reviewed and then compared 
to images from people who have a health condition. The results of this work might be 
published in a scientific journal, but your identity would never be disclosed. 
Education: Your anonymised images could be used in visual presentations for student 
teaching or for presenting work at scientific meetings. Again, your identity would never 
be disclosed. 
Technical Development: Your anonymised images could be used to demonstrate that a 
new piece of MRI equipment or computer software is working well. This might require us 
to send the images to a UK collaborator, but your identity would never be disclosed. 
Quality Control: Your anonymised images could be compared with older or newer 
images taken on the same or other MRI scanners to ensure that optimal imaging 
standards are maintained. 
 
Will my GP be informed? 
It is normal practice for us to inform your GP of your participation in this study as long as 
you are happy for this to occur. Further, in the event that we find an incidental finding in 
your images we would wish to provide you and your GP with this information in order to 
plan further medical care. By signing the informed consent declaration you agree to us 
taking this course of action should this unlikely situation arise. 
 
Your rights: 
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Participation in this study is entirely voluntary and you are free to refuse to take part or 
withdraw from the study at any time without having to give any reason.  
 
Who has reviewed the study? 
The East of Scotland Research Ethics Committee which has responsibility for 
scrutinising all proposals for human research in Tayside has examined this proposal 
and has raised no objections from the point of view of medical ethics.  The study is 
sponsored and overseen by the University of Dundee and NHS Tayside in collaboration. 
It is a requirement that your records in this research, together with any relevant medical 
records, be made available for scrutiny by monitors from NHS Tayside and the 
University of Dundee, whose role is to check that research is properly conducted and 
the interests of those taking part are adequately protected. All information will be strictly 
confidential, anonymised and coded, and will be stored electronically on a database that 
will only be accessible by the current investigators. The information will be kept for 5 
years after which it will be destroyed. 
 
 
Contact for further information? 
For further information or help regarding this study please contact:  
 
Principal Investigator:  
Dr Jonathan Weir-McCall 
Clinical Radiology 
Ninewells Hospital 
Dundee 
DD1 9SY 
Tel: 01382 660111 Bleep. 3188 
 
Chief Investigator: 
Prof Graeme Houston 
Clinical Radiology 
Ninewells Hospital 
Dundee 
DD1 9SY 
Tel: 01382 632651 
 
Thank you for taking the time to consider taking part in this study. 
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Appendix C: Consent Form 
 
 
 
 
 
Title of Study:  The role of pulmonary arterial stiffness on right 
ventricular remodeling in COPD. 
 
Name of CI:  Prof. Graeme Houston 
Name of PI:  Dr Jonathan Weir-McCall 
Please initial box 
 
1. I confirm that I have read and understood the information sheet dated …. (Version …) 
for the above study.  I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason, without any medical care or legal rights being affected. 
 
 
3. I agree that I will not be informed of any incidental findings such as set out in the 
Information Sheet unless the researcher decides that such findings may have an 
important bearing on my future medical care. 
 
 
4. I understand that relevant sections of my medical notes and data collected during 
the study may be looked at by individuals from NHS Tayside, University of Dundee 
or other collaborative EU Healthcare or University Organisations where it is 
relevant to my taking part in this research. I give permission for these individuals 
to have access to my records. 
 
 
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5. I consent to my images being used anonymously for purposes  research, 
education, technical development and quality control at NHS Tayside, University 
of Dundee or at other collaborative NHS or University institutions within the 
United Kingdom 
 
 
6. I agree to my blood samples being stored for future research use.  I agree to the 
use of this for future biomarker and genomic research. 
 
7. I agree to my GP being informed of my participation in the study.  
8. I agree to take part in the above study.  
 
 
______________________  _______________________  ________________ 
Name of participant   Date     Signature 
 
______________________  ______________________  _________________ 
Name of person taking consent Date     Signature 
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Appendix D: Case Report Forms 
 
PARTICIPANT ID:  
 
 
 
 
 
The role of pulmonary arterial stiffness on right ventricular 
remodeling in COPD. 
___________ 
 
The trial is sponsored by  
NHS Tayside  
 
 
 
 
 
 
Principal Investigator: Graeme Houston 
Clinical Radiology 
Ninewells Hospital 
Dundee DD1 9SY 
Tel: 01382 632651 
Email: ghouston@nhs.net 
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GENERAL GUIDELINES FOR THE CASE REPORT FORM COMPLETION 
 
 
 
All clinical data collected during the study has to be documented in this case report form. 
 
Please use a black ball-point pen for filling in the case report form. 
 
Incorrect entries should be deleted with a single line. The original entry must be kept legible. 
All changes and/or corrections made to the case report form must be initialled and dated by 
the investigator or by another responsible person of the respective study centre. 
 
Please answer all questions and write clearly. 
 
Identification of patients throughout the study is done by patient number only. 
 
Please enter only one digit in one box. Data should be entered at the right hand margin. If not 
enough digits are available to fill all fields, please prefix the number by recording “0”. 
 
Please enter complete dates wherever possible. If day or month of a date should be 
unknown, please enter “NK” in the respective fields. e.g.: NK/MAY/2004 
 
Times should be entered using the 24-hour clock. Please enter times from 00:00 to 23:59. Do 
not use 24:00. 
 
If a question is not applicable, please record “NA” for “not applicable”. 
 
If an examination was not done, please record “ND” for “not done”. 
 
If a result is zero, please enter “0”. 
 
If a page has not been used, please enter the patient number and cross out the page.  
 
Comments should be as short as possible. Please do not enter comments outside the 
predefined areas (Final Comment Page). 
 
The case report form has to be signed by the investigator. If a premature termination of the 
trial occurs in a patient, the case report form should be completed up to this day and the 
termination form (page XX) must be filled in. 
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Date of Visit   
   D    D    M   M    M    Y    Y    Y    Y 
Date of Birth   Age  yrs 
   D    D    M   M    M    Y    Y    Y    Y 
Sex Male Female 
Consent obtained Yes No  Date of Consent  
    D    D    M   M    M    Y    Y    Y    Y 
__________________________________________________________________________________________________ 
 
INCLUSION CRITERIA YES    NO 
Male and female aged 40-85 inclusive 
COPD GOLD grade 2-4 
FEV1 <80% predicted and FEV1/FVC ratio <70% 
Smoking history ≥10 pack years 
No exacerbation in the past 2 months 
 
EXCLUSION CRITERIA YES    NO 
History of significant cardiac condition 
Previous cardiac or thoracic operation  
History of other primary or obstructive lung disease 
Connective tissue disease or systemic vasculitis.  
Moderate or severe LV systolic dysfunction (EF <40%)   
Currently participating in an interventional clinical trial  
Pregnancy 
Inability to provide informed consent  
 
 If any of the shaded boxes is ticked, patient is not eligible for the study 
 
MRI ELIGIBILITY 
Does the subject currently have  YES    NO 
eGFR <30mls/min 
Claustrophobia 
Any metal implants or pacemaker 
Patient eligible for MRI 
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OTHER MEDICAL HISTORY 
 
Give brief details of all significant illnesses or operations with dates 
 
Body System Normal Abnormal Details 
Cardiovascular    
Respiratory    
Gastrointestinal    
Genitourinary    
Endocrine/Metabolic    
CNS    
Dermatological    
HEENT    
Psychiatric    
Locomotor    
Haematological    
Other    
 
Any illnesses which would compromise the patient's safety or ability to complete the study  Yes  No 
 
CONCOMITANT MEDICATION PRESENT Yes  No 
 
 If yes, please complete concomitant medication page 
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CONCOMITANT MEDICATION  
Any Concomitant Medication Reported Yes No    
 
Drug Name  
(Trade Name preferred) 
Dose Unit Route  Freq.  Indication Start Da  
(DD-MMM-Y  
  
 
 
 
 
1.         
2.         
3.         
4.         
5.         
6.         
7.         
8.         
9.         
10.         
11.         
Route of Administration: 1=Oral, 2=Subcutaneous, 3=Intramuscular, 4=Intravenous, 5=Rectal, 6=Topical, 
7=Inhaled, 8=Other 
Frequency: 1=1/day, 2=2/day, 3=3/day, 4=4/day, 5=prn, 6=Other 
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CONCOMITANT MEDICATION CONTINUED 
Repeat Page Number        
 
Drug Name  
(Trade Name preferred) 
Dose Unit Route  Freq.  Indication Start Da  
(DD-MMM-Y  
  
 
 
 
 
1.         
2.         
3.         
4.         
5.         
6.         
7.         
8.         
9.         
10.         
11.         
Route of Administration: 1=Oral, 2=Subcutaneous, 3=Intramuscular, 4=Intravenous, 5=Rectal, 6=Topical, 
7=Inhaled, 8=Other 
Frequency: 1=1/day, 2=2/day, 3=3/day, 4=4/day, 5=prn, 6=Other 
Pulmonary arterial stiffness in COPD Page 200 of 225 
Screening visit  PARTICIPANT I.D.  
 200 
 
 
COPD INFORMATION  
 
Date of diagnosis    
 
Smoking status 
Never Smoked   
Ex Smoker  
Current Smoker  
If Current or Ex Smoker, please indicate the average amount/ day: 
Cigarettes  
Cigars  
Pipes  
 
If Ex-Smoker, Date stopped  
    D    D    M   M    M    Y    Y    Y    Y 
Number of years smoked  
 
 
Screening PFTs Yes No Date   
 
FEV1/FVC   . 
FEV1 (% predicited) . 
 
Symptom severity 
 
 mMRC dyspnea grade:  
 
 
Grade Description of Breathlessness 
0 I only get breathless with strenuous exercise. 
1 I get short of breath when hurrying on level ground or walking up a slight hill. 
2 On level ground, I walk slower than people of the same age because of breathlessness, or have to stop for breath when walking at my own pace. 
3 I stop for breath after walking about 100 yards or after a few minutes on level ground. 
4 I am too breathless to leave the house or I am breathless when dressing. 
 
 
  
Pulmonary arterial stiffness in COPD Page 201 of 225 
Screening visit  PARTICIPANT I.D.  
 201 
Exacerbations 
 
COPD exacerbation in the last year   Yes No 
 Requiring antibiotics/steroids   Yes No 
 Requiring hospital admission   Yes No 
 Date of most recent exacerbation    
 
 
 
Combined COPD assessment:  
 
 
Score:  
 
 
 
 
 
 
 
VITAL SIGNS 
 
Blood Pressure: Systolic  mmHg Diastolic  mmHg Pulse  per minute 
 Height    cm. Weight   . kg BMI    . 
 Measured after 5 minutes rest, sitting, on the dominant arm 
_________________________________________________________________________________________ 
Echo 
LVIDd . mm 
LVIDs . mm 
LVFS . % 
LVEF . % 
RAP . % 
TRV . m/s 
Pulmonary PAT . ms 
_________________________________________________________________________________________ 
ELIGIBILITY 
Is the Patient eligible to participate in the study Yes No 
If no, please comment:_______________________________________ _______________________________ 
 
_________________________________________________________________________________________ 
 
 
 
 
 
BLOOD TESTS 
Date of Blood Samples taken  
   D    D    M   M    M    Y    Y    Y    Y 
 
eGFR Yes No 
 Result . ml/min/m2 
 
Samples stored Yes No  By: ____________________________________ 
Date Sample stored  
   D    D    M   M    M    Y    Y    Y    Y 
________________________________________________________________________ 
 
Practice 6MWT 
 
Pre  SpO2________   Pre walk dyspnoea ________   Pre walk fatigue________ 
 
Pre- BP 1 _______/_______ HR_______         
 
6 MWT distance:  ________m 
 
Post  SpO2________   Post walk dyspnoea________   Post walk fatigue ________ 
 
Post- BP 1 _______/_______ HR_______         
 
________________________________________________________________________ 
 
 
 
COMMENTS 
Any Comments Present? Yes No 
 
Page No Field Comment 
   
   
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
VISIT 2 
 
Date agreed for second visit? Yes   
   No   
 
 
Date of next visit   
 
 
INVESTIGATOR STATEMENT 
 
I hereby certify that all information entered by myself or my team is, to the best of my 
knowledge, correct. 
 
 
 
Signature: _____________________________________ Date:
 ______________ 
 
 
 
Main Visits: 
Participant ID:  
 
 
 
 
 
The role of pulmonary arterial stiffness on right ventricular 
remodeling in COPD. 
VISIT 2 
___________ 
 
The trial is sponsored by  
NHS Tayside  
 
 
 
 
 
 
Principal Investigator: Graeme Houston 
Clinical Radiology 
Ninewells Hospital 
Dundee DD1 9SY 
Tel: 01382 632651 
Email: ghouston@nhs.net 
 
 
 
GENERAL GUIDELINES FOR THE CASE REPORT FORM COMPLETION 
 
 
 
All clinical data collected during the study has to be documented in this case report form. 
 
Please use a black ball-point pen for filling in the case report form. 
 
Incorrect entries should be deleted with a single line. The original entry must be kept legible. 
All changes and/or corrections made to the case report form must be initialled and dated by 
the investigator or by another responsible person of the respective study centre. 
 
Please answer all questions and write clearly. 
 
Identification of patients throughout the study is done by patient number only. 
 
Please enter only one digit in one box. Data should be entered at the right hand margin. If not 
enough digits are available to fill all fields, please prefix the number by recording “0”. 
 
Please enter complete dates wherever possible. If day or month of a date should be 
unknown, please enter “NK” in the respective fields. e.g.: NK/MAY/2004 
 
Times should be entered using the 24-hour clock. Please enter times from 00:00 to 23:59. Do 
not use 24:00. 
 
If a question is not applicable, please record “NA” for “not applicable”. 
 
If an examination was not done, please record “ND” for “not done”. 
 
If a result is zero, please enter “0”. 
 
If a page has not been used, please enter the patient number and cross out the page.  
 
Comments should be as short as possible. Please do not enter comments outside the 
predefined areas (Final Comment Page). 
 
The case report form has to be signed by the investigator. If a premature termination of the 
trial occurs in a patient, the case report form should be completed up to this day and the 
termination form (page XX) must be filled in. 
 
 
 
Date of Visit   
   D    D    M   M    M    Y    Y    Y    Y 
Date of Birth   Age  yrs 
   D    D    M   M    M    Y    Y    Y    Y 
Sex Male Female 
Consent obtained Yes No  Date of Consent  
    D    D    M   M    M    Y    Y    Y    Y 
 
__________________________________________________________________________________________________ 
 
INCLUSION CRITERIA YES    NO 
Male and female aged 40-85 inclusive 
COPD GOLD grade 2-4 
FEV1 <80% predicted and FEV1/FVC ratio <70% 
Smoking history ≥10 pack years 
No exacerbation in the past 2 months 
 
EXCLUSION CRITERIA YES    NO 
History of significant cardiac condition 
Previous cardiac or thoracic operation  
History of other primary or obstructive lung disease 
Connective tissue disease or systemic vasculitis.  
Moderate or severe LV systolic dysfunction (EF <40%)   
Currently participating in an interventional clinical trial  
Pregnancy 
Inability to provide informed consent  
 
 If any of the shaded boxes is ticked, patient is not eligible for the study 
 
MRI ELIGIBILITY 
Does the subject currently have  YES    NO 
eGFR <30mls/min 
Claustrophobia 
Any metal implants or pacemaker 
Patient eligible for MRI 
 
 
 
 
  
 
 
 
ADVERSE EVENTS REMINDER 
Did any Adverse Events occur since the last visit Yes No 
 If yes, please fill in the Adverse Events Page 
 
 
CONCOMITANT MEDICATIONS REMINDER 
Where there any changes to Concomitant Medication since the last visit Yes No 
 If yes, please fill in the Concomitant Medications Page 
 
 
_________________________________________________________________________________________ 
ELIGIBILITY 
Is the Patient eligible to participate in the study Yes No 
If no, please comment:_______________________________________ _______________________________ 
 
_________________________________________________________________________________________ 
 
 
ADVERSE EVENTS 
Any Adverse Events Reported Yes No    
Adverse Event Serious 
1=Yes 
2=No 
Start Date 
(DD-MMM-YYYY) 
Stop Date 
(DD-MMM-YYYY) 
Ongoing 
1=Yes 
2=No 
Sev   
  
 
 
 
1.  
 
 
   
  
2.  
 
 
   
  
3.  
 
 
   
  
4.  
 
 
   
  
5.  
 
 
   
  
6.  
 
 
   
  
Severity: 1=Mild, 2=Moderate, 3=Severe 
Relationship: 1=None, 2=Possible, 3=Probable, 4=Likely, 5=Unknown 
Action taken: 1=None, 2=Medication, 3=Treatment, 4=Other 
Outcome: 1=Not Yet Recovered , 2=Resolved without sequelae, 3=Resolved with sequelae, 4=Worsened, 
5=Death 
 If Outcome is Resolved with sequelae, Worsened or Death, please complete a Serious Adverse 
Event/ Serious Adverse Reaction Notification Form 
  
 
 
CONCOMITANT MEDICATION CONTINUED 
Repeat Page Number        
 
Drug Name  
(Trade Name preferred) 
Dose Unit Route  Freq.  Indication Start Da  
(DD-MMM-Y  
  
 
 
 
 
1.         
2.         
3.         
4.         
5.         
6.         
7.         
8.         
9.         
10.         
11.         
Route of Administration: 1=Oral, 2=Subcutaneous, 3=Intramuscular, 4=Intravenous, 5=Rectal, 6=Topical, 
7=Inhaled, 8=Other 
Frequency: 1=1/day, 2=2/day, 3=3/day, 4=4/day, 5=prn, 6=Other 
 
STUDY PFTs 
 
pirometry 1 % Pred 2 % Pred 3 % Pred Highest Highest % pred 
VC         
EV1         
 FVC         
EF         
EV1 FVC         
 
 
MEF 2575         
 
IOS        Keep print outs in patients’ folders  
   
Body Plethysmography      Keep print outs in patients’ folders 
 
  
 
 
6 MWT 
 
Pre SpO2 ________   Pre walk dyspnoea  ________   Pre walk fatigue
 ________ 
 
Pre- 
BP 1 _______/_______ HR_______        BP 2 ______/______ HR________       BP 
3______/_______HR_______  Average BP 1 _______/_______ HR_______         
 
 
6 MWT distance:  ________m 
 
Post SpO2 ________   Post walk dyspnoea  ________   Post walk fatigue
 ________ 
 
Post- 
BP 1 _______/_______ HR_______        BP 2 ______/______ HR________       BP 3______/_______HR_______  Average 
BP 1 _______/_______ HR_______         
 
 
 
 
 
COPD INFORMATION  
 
St George’s COPD questionnaire completed: Yes No 
 
 
VITAL SIGNS 
 
Blood Pressure: Systolic  mmHg Diastolic  mmHg Pulse  per minute 
 Height    cm. Weight   .  kg BMI    .  
 Measured after 5 minutes rest, sitting, on the dominant arm 
 
 
 
BLOOD TESTS 
Date of Blood Samples taken  
   D    D    M   M    M    Y    Y    Y    Y 
 
eGFR Yes No 
 Result .  ml/min/m2 
 
Samples stored Yes No  By: ____________________________________ 
Date Sample stored  
   D    D    M   M    M    Y    Y    Y    Y 
 
 
 
 
 
MRI 
 
Date of MRI   
   D    D    M   M    M    Y    Y    Y    Y 
 
Safety checks for MRI performed Yes No 
Patient eligible for MRI  Yes No 
If no, please comment:______________________________________________________________________ 
________________________________________________________________________________________ 
 
 
MRI RESULTS 
 
Blood Pressure: 
PWV1 measurement: Systolic    mmHg Diastolic    mmHg  
 
 
PWV2 measurement:  Systolic    mmHg Diastolic    mmHg  
 
 
CARDIAC FUNCTION 
 
 Results 
LV EF (%)  
LVEDV (ml)  
LVESV (ml)  
LVSV (ml)  
Cardiac output (CO) 
(min/ml) 
 
Left ventricular mass 
(LVM) (g) 
 
RVEF (%)  
RVEDV (ml/m^2)  
RVESV (ml/m^2)  
RVSV (ml/m^2)  
RVM (g/m^2)  
 
  
 
 
Pulmonary Pulse Wave Velocity: 
 
PWV .  m/s 
 
Pulsatility .  % 
 
 
Aortic Pulse Wave Velocity: 
 
PWV .  m/s 
 
Compliance .  cm Hg 
 
Delayed Gadolinium YES  NO  
 A AS  S  I  IL AL 
If Yes, Segmental Enhancement:  Basal   
Mid  
 A S I  L 
Apical  
 
A=Anterior, AS=Anteroseptal, S=Septal, I=Inferior, L=Lateral 
 
 
Subendocardial  YES  NO  
Maximal Wall Thickness Enhancement:   
 
 
 
Endocardial  YES  NO  
 
Focal  YES  NO  
 
 
Generalised  YES  NO  
 
 
 
 
0 = nil 
1 < 50% 
2 > 50% 
 
 
 
COMMENTS 
Any Comments Present? Yes No 
 
Page No Field Comment 
   
   
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
VISIT COMPLETION 
 
 
Did the patient complete the visit as planned Yes   
   No   Please state reason below 
 
 
Date of last study procedure   
    D    D    M   M    M    Y    Y    Y    Y 
 
____________________________________________________________________________________
_____ 
 
If the visit was not completed as planned, please state the reason for study termination: 
 
Patient withdrawal of consent  
Investigator’s discretion   
Intercurrent illness  Please document under Adverse Events  
Changes in the patient's condition   
Noncompliance with study procedures  
Termination of the clinical trial  
Other   Please describe 
________________________________________ 
 
____________________________________________________________________________________
_____ 
 
____________________________________________________________________________________
_____ 
 
 
 
 
INVESTIGATOR STATEMENT 
 
 
 
I hereby certify that all information entered by myself or my team is, to the best of my 
knowledge, correct. 
 
 
 
Signature: _____________________________________ Date:______________ 
 
 
 
 
Appendix E: Ethics Approval 
 
 
 
 
 
 
 
 
 
 
